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CHAPTER I 
 
INTRODUCTION 
 
Schizophrenia 
 
 Clinical features and symptom domains 
 Schizophrenia is a debilitating neuropsychiatric disease affecting approximately 
one percent of the worldwide population irrespective of gender or race; and currently 
ranks as the seventh most costly medical illness to our society, making it one of the most 
important public health concerns in modern medicine (Freedman, 2003). While current 
treatments considerably reduce the suffering of the patient, approximately two-thirds of 
those who are diagnosed with schizophrenia require public assistance from governmental 
social security systems within a few years of onset (Ho et al., 1997). Traditionally, 
schizophrenia is defined by three distinct symptom clusters, including positive symptoms, 
negative symptoms, and deficits in cognition (American Psychiatric Association, 2013). 
Positive symptoms include auditory hallucinations, delusions (often involving paranoid 
beliefs that external forces are conspiring against the patient), disorganized speech or 
abnormal language, and disorganized behavior (American Psychiatric Association, 2013). 
 The negative symptoms of schizophrenia are characterized as a diminution or 
absence of mental functions that are normally present in healthy humans.  Examples 
include alogia, which is a decrease in the fluency of ideas and language; affective 
blunting or a reduction in the intensity of an individual’s emotional responses; avolition 
that is a decrease in the ability to initiate and pursue goal-directed activity; and 
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anhedonia, which involves a reduced ability to seek out and experience pleasurable 
activities (Andreasen, 2000; Sarkar et al., 2015). Recent epidemiological studies in 
schizophrenia patient populations have reported that the negative symptoms persist 
longer than positive symptoms and are more resistant to treatment (Boonstra et al., 2012; 
Chang et al., 2011). Moreover, the severity of negative symptoms in individuals with 
schizophrenia has been shown to be a better predictor of concurrent and future socio-
occupational functioning and potential conversion to psychosis in patients with at risk 
mental states (Rabinowitz et al., 2012; Kurtz et al., 2005; Milev et al., 2005; Lencz et al., 
2004; Valmaggia et al., 2013). 
 Cognitive dysfunction in patients with schizophrenia may present as attentional 
impairment, deficits in working and episodic memory functions, and disruptions in 
executive function, and have been extensively described in the CATIE trials (Clinical 
Antipsychotic Trials of Intervention Effectiveness) (Keefe et al., 2006) and through the 
MATRICS (Measurement and Treatment Research to Improve Cognition in 
Schizophrenia) initiative (Buchanan et al., 2007).  Many of these cognitive domains are 
impaired prior to the emergence of the positive symptoms and detectable at the time of 
the first psychotic episode (Bilder et al., 2000; Davidson et al., 1999). In recent years, 
interest in the cognitive deficits  has dramatically increased with reports that they are 
consistently more reliable predictors of functional outcomes (Green et al., 2000).  With 
this in mind, there has been a push towards developing novel antipsychotic agents that 
exhibit a broader range of efficacy across the three major symptom clusters, including the 
cognitive deficits as well as the negative symptoms as mentioned earlier. 
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 As shown in Figure 1, the time course for the disease progression of 
schizophrenia is often associated with various prodromal symptoms and behaviors, 
including cognitive deficits (McGlashan, 1996; Gottesman & Erlenmeyer-Kimling, 
2001), followed by the onset of the positive and negative symptoms in late adolescence 
or early twenties (Hafner et al., 1994; Heilbronner et al., 2016; Lewis & Lieberman, 
2000; Talonen et al., 2016). Since the initial characterization and description of 
schizophrenia, patients with the disease have, in large part, been treated as a homogenous 
population, with little work done to differentiate stages of progression. There is emerging 
evidence, however, to support a phenotypic progression throughout the life of a patient 
with schizophrenia thought to be due in part to changes in neural circuitry and/or 
responses to lifelong antipsychotic therapies (see Figure 1). For example, meta-analyses 
report decreases in the integrity of grey and white matter (Chan et al., 2011; Mathalon et 
al., 2001) and faster rates of glutamate signaling decline in patients with schizophrenia, 
compared to healthy aging individuals (Marsman et al., 2013). Additionally, structural 
magnetic resonance imaging (MRI) studies report a significant reduction in brain tissue 
volume in patients with schizophrenia that has subsequently been shown to be 
progressive in several longitudinal studies (Borgwardt et al., 2008; Cahn et al., 2002; 
DeLisi, 2008; Heilbronner et al., 2016; Hulshoff Pol & Kahn, 2008; Pantelis et al., 2003; 
van Haren et al., 2008). This may be due to reduced neuropil, suggesting changes in 
synaptic, dendritic, and axonal organization, and is observed most prominently in the 
prefrontal cortex (PFC) (Harrison, 1999). For these reasons, one of the prevailing 
hypotheses regarding the underlying pathophysiology of schizophrenia suggests that 
these structural changes result in subsequent progression of abnormalities in the normal 
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functional connections between different brain regions, particularly the PFC (Cho et al., 
2006; Cole et al., 2011; Van Snellenberg et al., 2006). For example, functional MRI 
studies examining patients in the early stages of the illness have shown patterns of 
hyperconnectivity between the PFC and hippocampal with other brain regions, which 
appear to diminish with the progression of the illness (Marsman et al., 2013; Schobel et 
al., 2013; Sun et al., 2013). Therefore, it is reasonable to suggest that early stages of the 
disease are associated with a shift in the excitation:inhibition balance in critical PFC 
circuits, consistent with models of disinhibition (Uhlhaas, 2013). Thus, stratifying 
patients based on their stage of illness will be of utmost importance when designing 
animal models of the disease, assessing novel therapeutics, and carrying out future 
clinical trials. 
 Clinically available typical (eg, haloperidol) and atypical (eg, clozapine, 
risperidone) antipsychotic medications reliably treat the positive symptoms, but have 
little or no effect on the negative symptoms or cognitive impairments (Keefe et al., 2007; 
Swartz et al., 2008), and will be discussed at length in future sections. While the etiology 
of schizophrenia is unknown, there is mounting evidence that the pathophysiology of the 
illness is linked to disruptions in normal signaling of several different neurotransmitter 
systems, including dopaminergic, glutamatergic, GABAergic, serotonergic and 
cholinergic systems (Carlsson, 1977; Guan et al., 1999; Krystal et al., 2002; Lewis & 
Moghaddam, 2006; Scarr et al., 2007). As background for my thesis work, I will focus on 
the delicate interplay between the dopaminergic and glutamatergic systems, and how 
selective modulators of muscarinic acetylcholine receptors affect each at length in this 
chapter. 
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Figure 1. Time course of schizophrenia disease progression. The diagram above 
depicts the clinical signs and symptoms observed in patients from the premorbid stage of 
the illness through the chronic stages.  Accompanying these symptoms are proposed 
pathological processes that coincide with developmental events throughout the life of a 
patient with schizophrenia. Adapted from (Lewis & Lieberman, 2000). 
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Dopamine hypothesis 
 
 Aberrant dopamine (DA) signaling has been implicated in schizophrenia for over 
50 years and is the principal explanatory model of antipsychotic drug action. This 
hypothesis theorizes there is an excessive amount of dopaminergic signaling in 
subcortical structures of the brain which leads to over activation of DA D2 receptors.  
The advent of antipsychotic agents that increased the metabolism of DA when 
administered to animals suggested a vital role for dopamine signaling in psychosis 
(Carlsson & Lindqvist, 1963).  Furthermore, another antipsychotic agent, reserpine, was 
found to prevent the reuptake of DA leading to decreased dopaminergic signaling 
(Carlsson et al., 1957). Conversely, drugs that act to increase synaptic DA levels in the 
brain can recapitulate psychotic symptoms in animals and humans (Lieberman et al., 
1987). The role of DA in relation to antipsychotic agents became clear with the finding 
that effectiveness in the clinic was directly related to the drug’s ability to inhibit DA 
receptors (Creese et al., 1996; Seeman & Lee, 1975). 
 It was not until the 1980s that investigation began into regional specificity of 
dysfunctional DA signaling and the distinct subtypes of dopamine receptors involved. 
These studies originated as a result of clinical findings from post-mortem and 
cerebrospinal fluid (CSF) experiments that revealed conflicting data for a homogenous 
DA excess theory in schizophrenia (Bird et al., 1977; Crow et al., 1979; Widerlov, 1988). 
Specifically, these early post-mortem studies indicated patients with schizophrenia had 
increases in striatal DA levels that were accompanied by increases in DA D2 receptor 
density (Mackay et al., 1982; Owen et al., 1978). More recent studies have suggested an 
increase in the capacity to produce DA in the terminals of substantia nigra neurons in 
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patients with schizophrenia, as measured by an increase in the rate-limiting enzyme 
tyrosine hydroxylase (Howes et al., 2013).   
The development of in vivo quantification techniques, such as Positron Emission 
Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), 
allows for measurement of DA synthesis, DA release, and the availability of postsynaptic 
DA receptors (Kim et al., 2013).  Taking advantage of these techniques, studies have 
shown that patients diagnosed with schizophrenia show an increase in the uptake of [18F] 
DOPA, an L-DOPA PET tracer, in the striatum, which indirectly indicates an increase in 
striatal dopamine signaling (Egerton et al., 2010). Additionally, studies examining 
cortical blood flow in drug-naïve patients with schizophrenia reveal a significant 
reduction in perfusion in lateral, orbital and medial prefrontal cortices (Andreasen et al., 
1997). Taken together, these data point towards regional brain dysfunction in 
schizophrenia that constitutes hyperdopaminergic signaling in subcortical regions and 
hypodopaminergic signaling in cortical regions. 
Two important components of the dopaminergic system are the mesolimbic and 
mesocortical pathways. Two key parts of the these two DA pathways have been 
implicated in the pathophysiology of schizophrenia, including the dopaminergic neurons 
projecting from the ventral tegmental area (VTA) to the nucleus accumbens (NAS), and 
the dopaminergic neurons  of VTA neurons projecting to the PFC (Figure 2). Preclinical 
animal studies that lesioned prefrontal cortical DA neurons resulted in increased release 
of DA and increased expression of DA D2 receptor in the nucleus accumbens (Pycock et 
al., 1980). Conversely, local infusion of DA agonists directly to the PFC results in 
decreased DA metabolite levels in the striatum (Scatton et al., 1982). These data provide 
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direct evidence for cortical dopaminergic control of subcortical DA signaling.  
Furthermore, examples of human and animal frontal lobe lesions result in strikingly 
similar phenotypes to those characterized as negative symptoms in schizophrenia 
(Mesulam, 1986; O'Driscoll & Leach, 1998), and longitudinal studies of plasma 
homovanillic acid (HVA) levels in patients receiving antipsychotic treatment relate 
directly to efficacy on the positive symptoms (Pickar et al., 1986). 
The DA hypothesis of schizophrenia has evolved since its inception nearly 60 
years ago from a theory of global dopaminergic dysregulation to one of regional specific 
dysfunction.  It is now clear that subcortical hyperdopaminergic signaling in mesolimbic 
projections leads to overstimulation of DA D2 receptors and is responsible, in large part, 
for the positive symptoms associated with the disease.  In contrast, hypoactive 
mesocortical dopaminergic projections lead to hypostimulation of cortical DA dopamine 
D1 receptors (D1) receptors and is heavily implicated in both the negative symptoms and 
cognitive deficits observed in schizophrenia. Moreover, postmortem studies of patients 
with schizophrenia have revealed regions of PFC pyramidal cell dendritic atrophy 
thought to result in decreased cortical DA levels and possible changes in DA D1 receptors 
(Arnsten et al., 2016).  It is also clear that these two pathways are strongly linked, as a 
deficiency in mesocortical DA signaling results in disinhibition of mesolimbic 
dopaminergic activity, which has led to a revised DA hypothesis for the pathophysiology 
of schizophrenia (Davis et al., 1991; Deutch, 1992). To date, alterations in DA function 
are the most understood and directly linked to manifestations of the symptoms of 
schizophrenia, but much work needs to be done to understand the interplay between the 
DA system and glutamatergic and GABAergic systems. It is likely that disruptions in 
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normal signaling in these systems could lead to or be associated with aberrant cortical 
and subcortical DA control.  
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Figure 2.  Mesocortical and mesolimbic circuitry in the rat brain. It is hypothesized 
that hyperdopaminergic signaling in the mesolimbic circuit accounts for the positive 
symptoms of schizophrenia, while a hypodopaminergic state in the mesocortical circuit 
leads to negative symptoms and cognitive deficits. This may also be referred to as the 
hypofrontality model of schizophrenia.   Figure adapted from (Russo & Nestler, 2013). 
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NMDA receptor hypofunction hypothesis 
 Within the mammalian central nervous system, glutamate is the primary 
excitatory neurotransmitter and is responsible for the generation of fast excitatory 
synaptic responses at most central nervous system (CNS) synapses (Dingledine et al., 
1999). Ionotropic glutamate receptors, including the N-methyl-D-aspartate (NMDA) 
receptor subtype, are a well characterized family of glutamate receptor cation channels 
that are responsible for mediating fast synaptic responses at glutamatergic synapses 
(Javitt, 2010). The NMDA receptor is normally composed of two obligatory NR1 
subunits and two NR2A-D subunits, though a related gene family, termed NR3A or 
NR3B, may also be present and exert an inhibitory effect on receptor activity. Functional 
heterotetramers maintain a voltage-sensitive block through extracellular Mg
2+
, which 
prevent cation flow at resting membrane potentials. NMDA receptors also require one of 
two co-agonists to allow for channel opening, either glycine or D-serine (Kleckner & 
Dingledine, 1988). Upon depolarization, and in the presence of co-agonist, the Mg
2+
 
block is dislodged and a voltage-dependent flow of Na
+
 and Ca
2+
 enter the cell (Cull-
Candy et al., 2001; Paoletti & Neyton, 2007). NMDA receptor activation, in particular 
through induction of synaptic plasticity, is known to be a requisite component of long and 
short-term memory, memory consolidation, spatial memory, episodic memory, and 
contextual fear memory (Tsien et al., 1996; Zhao et al., 2005). It is clear that with such 
vital roles in normal brain function, perturbation of this system may have strong 
implications for many neuropsychiatric diseases. 
There is growing evidence that modulation of NMDA receptors is involved in the 
pathophysiology of the psychotic symptoms and cognitive impairments of many 
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neuropsychiatric disorders such as schizophrenia (Konradi & Heckers, 2003). This 
hypothesis stemmed from observations that non-competitive NMDA receptor 
antagonists, such as phencyclidine (PCP) and ketamine, produce symptoms in humans 
that mimic the positive symptoms (delusions, hallucinations, thought disorders), negative 
symptoms (alogia and anhedonia), and cognitive deficits (attention and working memory) 
observed in schizophrenia (Krystal et al., 1994). Moreover, in many clinical cases, there 
are not sufficient assessments available to distinguish patients on PCP from those with 
acute functional mental illness (Yesavage & Freman, 1978). Additionally, administration 
of either PCP or ketamine results in the precipitation of symptoms in patients that were 
previously stabilized on antipsychotic medication (Bakker & Amini, 1961; Ban et al., 
1961; Cohen et al., 1962; Davies & Beech, 1960; Lahti et al., 1995; Luby et al., 1959). 
However, the precise mechanism of action for PCP-induced brain disruptions was not 
determined until the pioneering work by David Lodge and colleagues, which linked the 
blockade of NMDA receptors directly with the behaviors observed following PCP 
administration (Lodge & Anis, 1982). 
 Previous reports indicate that blocking NMDA receptors in vivo leads to 
excessive release of glutamate (Adams & Moghaddam, 1998; Moghaddam et al., 1997) 
and acetylcholine (ACh) (Giovannini et al., 1994; Hasegawa et al., 1993; Kim et al., 
1999) in the cerebral cortex. In animal studies, prolonged exposure to glutamate and ACh 
has been associated with irreversible morphological changes in cortical neuron 
populations (Olney & Farber, 1995). In rats, prolonged exposure to high doses of NMDA 
receptor antagonists result in irreversible damage and neuron death in many cortical and 
limbic regions of the brain (Corso et al., 1997). It is postulated that excessive release of 
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excitatory neurotransmitters could lead to overstimulation of postsynaptic neurons, which 
causes these morphological changes, and may account for the cognitive and behavioral 
disturbances observed when NMDA receptor antagonists are administered (Olney & 
Farber, 1995).  
 
Figure 3. NMDA receptor. Adapted from (Waxham, 2004). NMDA receptors have been 
implicated in the etiology, or as a result, of the schizophrenia disease state.  The 
schematic shows a functional NMDA receptor with binding sites for agonists, co-
agonists, and antagonists. Also depicted are the permeable cations and possible 
glycosylation and phosphorylation sites.   
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Electron microscopy studies carried out on post-mortem tissue from patients with 
schizophrenia report consistent pathological abnormalities compared to healthy human 
controls. Frontal and limbic cortices exhibit dystrophic changes that include pronounced 
swelling in dendrites with reduced number or absent microtubule, dense and degenerating 
presynaptic endings, and pathological changes in myelinated fibers (Uranova, 1988). 
Other reports indicate a 30% reduction in the size of spines in the basal ganglia (Roberts 
et al., 1996). In cortical tissue, Golgi staining revealed decreases in neuropil, dendritic 
complexity of pyramidal neurons, and spine density (McGlashan & Hoffman, 2000; 
Selemon et al., 1995). Many, if not all, of the pathological changes observed in human 
tissue can be recapitulated in mouse models of NMDA receptor hypofunction.  In mice 
lacking sufficient levels of the co-agonist D-serine, reductions in the complexity, total 
length, and spine density of pyramidal cells has been observed, along with decreases in 
neuropil and cortical volume (Balu et al., 2012). In mice expressing only 10% of normal 
NMDA receptor levels, dendritic spine number and expression of Disrupted in 
Schizophrenia-1 (DISC1), a protein involved in embryonic and adult neurogenesis, is 
reduced in an age-dependent manner. Interestingly, sub-chronic administration of an 
NMDA receptor antagonist produces similar synaptic reductions in spine density and 
DISC1 (Ramsey et al., 2011). These findings, among others, provide significant validity 
to the role of NMDA receptor hypofunction in morphological changes observed in 
patients with schizophrenia. 
 It is well established that NMDA receptor hypofunction leads to excessive 
neurotransmitter release at glutamatergic synapses through disinhibition of pyramidal 
cells. Early studies in the CA1 region of the hippocampus revealed that GABAergic 
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interneurons were 10-fold more sensitive to NMDA receptor antagonists than pyramidal 
cells in the same region (Grunze et al., 1996). Additional studies utilizing ex vivo 
electrophysiology showed that NMDA receptors provide excitatory drive on GABAergic 
interneurons in the olfactory bulb, posterior cingulate and retrosplenial cortex (Li et al., 
2002; Zhang et al., 2008). Thus, administration of NMDA receptor antagonists, or under 
expression of NMDA receptors, results in disinhibition of glutamatergic neurons through 
loss of recurrent inhibition provided by GABAergic neurons. In accordance with these 
findings, deficits in GABAergic signaling have been reported in the cortex and limbic 
system of patients with schizophrenia (Schwarcz et al., 2001). Immunohistochemical 
studies of recurrent inhibitory interneurons revealed that a subset containing parvalbumin 
(PV) are particularly vulnerable to disruption in schizophrenia (Beasley & Reynolds, 
1997). Pre-clinical studies examining the effect of NMDA receptor antagonists in mouse 
cortical tissue reveal similar reductions in PV expression (Behrens et al., 2007; Zhang et 
al., 2008). Taken together, these findings indicate a vital role for NMDA receptors on 
GABAergic interneurons and provide a viable mechanism for many of the 
neurochemical, electrophysiological, and behavioral changes observed in models of the 
disease, and in the disease itself. 
 Genetic models of NMDA receptor hypofunction have been developed to further 
elucidate the role of aberrant glutamatergic signaling in animal models of disease. One of 
the first models described was the NR1 knockdown model of NMDA receptor 
hypofunction (Mohn et al., 1999). Since complete deletion of Grin1, the gene encoding 
the obligatory NR1 subunit of the NMDA receptor, results in lethal respiratory failure 
(Forrest et al., 1994; Li et al., 1994), this model employs only a partial loss-of-function, 
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or hypomorphic, mutation. This is achieved by targeted insertion of a 2 kilobase pair 
segment of foreign DNA, a neomycin selectable marker (neo), into the Grin1 gene near 
the 3’ end. The presence of this foreign DNA causes premature termination in the 
majority of transcripts at the polyadenylation sequence of neo, resulting in a reduction in 
the amount of full-length mRNA transcript encoding the NR1 subunit. Splicing removes 
a portion of the neo sequence, resulting in sufficient quantities of functional NR1 
subunits to allow for NMDA receptor formation, though at a greatly reduced level 
(Figure 4). As a consequence, there are sufficient functional NMDA receptors expressed 
to support survival of the animal, but with only 10-20%  of wildtype controls in critical 
brain regions implicated in schizophrenia, as measured in radioligand binding studies 
utilizing [
3
H] MK-801 (Duncan et al., 2002; Mohn et al., 1999) (Figure 4).  
 NR1 knockdown (KD) mice exhibit abnormal behaviors consistent with acute 
NMDA receptor antagonist administration in several assays used to evaluate new 
antipsychotic medications. For example, NR1 KD mice show increases in spontaneous 
locomotor activity and stereotypic behavior, and decreases in habituation to novel 
environments, sensorimotor gating, sociability, and performance in spatial and non-
spatial working memory tasks (see Table 1). Many of these phenotypes are only observed 
in global NR1 KD animals, though there is a growing body of literature characterizing 
the effects of cell type-specific ablation, as well as deletion of NR2 subunits (Belforte et 
al., 2010; Rampon et al., 2000; Tsien et al., 1996; von Engelhardt et al., 2008; Zhao et al., 
2005). Consistent with MK-801 and PCP-treated mice, currently available typical and 
atypical antipsychotics can attenuate some of the behavioral deficits observed in NR1 KD 
mice, such as increased locomotor activity (Duncan et al., 2006; Mohn et al., 1999; 
 17  
 
Ramsey et al., 2008). While this adds to the validity of the model, these findings would 
suggest an interaction between antipsychotic agents and neurotransmitter systems that are 
known to regulate locomotor activity in rodents, namely the dopaminergic system. 
However, initial characterization of the dopaminergic system in NR1 KD mice would 
suggest a lack of excessive signaling, as observed by unchanged dopamine D1 and D2 
receptor expression level, analogous behavioral responses to dopaminergic agonists or 
amphetamine, and similar levels of amphetamine-induced dopamine efflux compared to 
wildtype animals (Mohn et al., 1999; Ramsey et al., 2008). As such, there is a disconnect 
between the observed effects with current antipsychotics and the construct validity of the 
NR1 KD model when assessing changes in locomotor activity. One proposed explanation 
suggests that the observed locomotor abnormalities in NR1 KD mice may reflect a deficit 
in cognition rather than excessive dopamine signaling (Nilsson et al., 2001). With this in 
mind, it will be important to evaluate novel therapeutics in NR1 KD mice using assays 
that require intact signaling in brain regions known to be associated with the cognitive 
deficits and negative symptoms of schizophrenia.   
Unlike acute pharmacological models of NMDA receptor hypofunction, NR1 KD 
mice demonstrate deficits in several models predictive of antipsychotic-like activity 
without non-competitive NMDA receptor antagonists present.  This may be critical, as 
will be discussed in future chapters, since novel mechanisms for alleviating NMDA 
receptor hypofunction may rely on potentiating NMDA current. Also of importance, NR1 
KD mice experience NMDA receptor hypofunction during critical developmental stages 
that may be relevant to schizophrenia disease populations, something that most acute or 
chronic pharmacological models do not account for. Taken together, the NR1 KD mouse 
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model of NMDA receptor hypofunction represents an innovative approach for assessing 
modulation of the glutamatergic system using novel therapeutic mechanisms.  
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Figure 4. Creation of NR1 KD mouse model of global NMDAR hypofunction. (A) 
Grin1 is transcribed and alternately spliced, resulting in NR1 subunits that are produced 
in excess of NR2 subunits.  In this case, expression of NR2 subunit is the limiting factor 
for production of functional NMDA receptors. (B) In NR1 KD mice, the presence of neo 
results in a high occurrence of truncated transcripts, though proper splicing does allow for 
the production of functional NR1 transcripts, though at a much lower level than in 
wildtypes. NR1 subunit expression is no longer in excess of NR2 subunits, and becomes 
the limiting factor in functional NMDA receptor expression. (C) Hypothetical illustration 
depicting relative levels of NMDA receptor expression, where darker shades represent 
higher levels of the receptor. (D) Initial findings reported by (Mohn et al., 1999) using 
radioligand binding to quantify maximal binding (Bmax) of MK-801. (adapted from 
(Ramsey, 2009)). 
 
 
   
 
Phenotype Knockdown Location Reference 
↓ Radial arm maze performance Global NR1 KD (Dzirasa et al., 2009) 
↓ Attentional modulation of evoked 
potentials Global NR1 KD (Bickel et al., 2007) 
↓ Social interaction Global NR1 KD 
(Duncan et al., 2004; Halene et al., 
2009; Mohn et al., 1999) 
↓ Y-maze performance 
50% in hippocampal and cortical 
interneurons (Belforte et al., 2010) 
↓ Social recognition 
50% in hippocampal and cortical 
interneurons (Belforte et al., 2010) 
↓ Morris water maze performance Hippocampal and forebrain NR2B 
(Rampon et al., 2000; Tsien et al., 1996; 
von Engelhardt et al., 2008) 
↓ Novel object recognition Hippocampal NR1 deletion 
(Rampon et al., 2000; Tsien et al., 1996; 
von Engelhardt et al., 2008) 
↓ Radial arm maze performance NR1 in CA1 and dentate gyrus (Niewoehner et al., 2007) 
↓ Contextual fear memory performance Cortical NR2B deletion (Zhao et al., 2005) 
↑ Spontaneous locomotor activity Global NR1 KD (Mohn et al., 1999) 
↓ Sensorimotor gating (PPI) Global NR1 KD 
(Duncan et al., 2006; Duncan et al., 
2004; Fradley et al., 2005) 
↓ Auditory ERP gating Global NR1 KD (Halene et al., 2009) 
↓ Visual ERP gating Global NR1 KD (Halene et al., 2009) 
 
Table 1. Effects of global and cell type-specific knockdown or knockout of NMDA receptor subunits in mouse 
models of schizophrenia. 
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Current antipsychotic therapies 
 
 
First-generation, also referred to typical, antipsychotics, target the DA D2 
receptor with high affinity where they act as antagonists to block excessive DA signaling. 
While these treatments are very effective at treating the psychotic symptoms of the 
disease, they have high rates of extrapyramidal side effects such as tardive dyskinesia due 
to excessive inhibition of DA receptors in the basal ganglia, and do not address 
disturbances observed in the negative symptoms or cognitive deficits of patients with 
schizophrenia (Gerlach et al., 1975; Miyamoto et al., 2005). In addition, 30% of all 
patients with schizophrenia remain treatment resistant to typical antipsychotics, such as 
haloperidol and chlorpromazine, and up to 50% only have a partial response 
(Fleischhacker, 1995; Kane, 1989).  These medications also possess some affinity for 
muscarinic, histaminergic, and noradrenergic receptors, which could contribute to 
overlapping adverse effects, such as cognitive deficits and sedation (Hill et al., 2010). 
The development of second-generation, or atypical, antipsychotics promised to 
improve therapeutic effects and decrease the side effects associated with typical 
antipsychotics. However, all atypical antipsychotics still share DA D2 receptor 
antagonism properties, albeit with much lower binding affinity.  In addition to DA D2 
receptor activity, atypical antipsychotics exhibit a diverse pharmacology with appreciable 
binding affinities towards dopaminergic, serotonergic, histaminergic, muscarinic, and 
adrenergic receptors, along with activity at many transporters found in the CNS (Kapur et 
al., 2002; Meltzer, 1989; Schotte et al., 1996; Schotte et al., 1993). Clozapine, marketed 
under the name Clozaril
®
, remains the gold-standard antipsychotic for treatment-resistant 
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patients, though the clinical superiority remains unclear for treatment of the psychotic 
symptoms (Leucht et al., 1999; Markowitz et al., 1999). Clozapine also carries a 
significant risk of adverse side effects, most notably agranulocytosis, which requires the 
patient to undergo frequent monitoring of leukocyte levels (Honigfeld et al., 1998). The 
risk for adverse side effects spurred the development of additional atypical 
antipsychotics, such as risperidone (Risperdal
®
), olanzapine (Zyprexa
®
), quetiapine 
(Seroquel
®
), and ziprasidone (Geodon
®
) (Lieberman et al., 2005). These do not carry the 
risk of agranulocytosis, but pose problems in that they increase the risk of causing weight 
gain and disturbances in glucose and lipid metabolism (Bak et al., 2014). 
As stated previously, clozapine carries a significant side effect profile risk that 
may preclude use in some individuals. The risk for serious and sometimes life threatening 
side effects makes clozapine a poor candidate for a first-line drug in many patients.  
Treatment with clozapine often begins only after a lack of adequate response with other 
typical or atypical antipsychotics or in cases where severe side effects are observed with 
other medications. Clozapine is the only antipsychotic to consistently show efficacy in 
patients with treatment refractory schizophrenia, making it the only option for some 
patients (Chakos et al., 2001; Kane et al., 1988). That being said, patients who are stably 
controlled on other antipsychotics may see additional benefits when taking clozapine, 
such as return to full time employment, which make the risk of severe side effects 
justifiable. In some cases, highly dysfunctional patients (those suffering from behavioral 
outbursts or those with suicidal intent, etc.) may only respond to clozapine (Buchanan et 
al., 1998).  
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The effects that atypical antipsychotics have on the negative symptoms and 
cognitive deficits have been controversial and inconsistent (Keefe et al., 1999; Meltzer & 
McGurk, 1999; Worrel et al., 2000).  The improvements reported in the negative 
symptom domain are usually moderate to small compared to typical antipsychotic or 
placebo control groups, and often times the impact on specific components are not stated 
(Goff & Evins, 1998; Leucht et al., 1999; Marder et al., 1997). One theory for the 
observed decrease in negative symptoms points solely to the decrease in extrapyramidal 
side effects or other symptoms that were typically observed in patients prescribed typical 
antipsychotics (Carpenter et al., 1995; Marder & Meibach, 1994; Meltzer, 1995; 
Remington & Kapur, 2000). Likewise, it is unclear whether efficacy of atypical 
antipsychotics on cognitive performance is linked to improvement of positive symptoms 
(Buckley, 2001). Several studies have reported modest improvements in cognition in 
patients taking atypical antipsychotics, when compared to typical antipsychotic controls. 
These improvements include efficacy on tests of verbal fluency, fine motor function, and 
executive function, with improvements in learning and memory (Keefe et al., 1999; 
Meltzer & McGurk, 1999; Worrel et al., 2000). Taken together, it is clear there is a large 
unmet medical need for therapies that address all three symptom domains of 
schizophrenia without the high risk of dose-limiting side effects. 
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Table 2. Summary of current antipsychotic mechanisms and their functional 
outcomes in patients. Adapted from (Miyamoto et al., 2012). 
 
Mechanisms 
Potential clinical 
efficacy 
Potential consequences 
D2 receptor antagonism ↓ positive symptoms Extrapyramidal side effects 
    ↑ Negative symptoms 
    ↑ Cognitive symptoms 
D2 receptor partial agonism ↓ positive symptoms ↓ Extrapyramidal side effects 
 ↓ negative symptoms Behavioral activation 
 ↓ cognitive symptoms  
↑ DA and NE release in the PFC ↓ negative symptoms Behavioral activation 
  ↓ cognitive symptoms   
  ↓ depressive symptoms   
ACh release in the PFC ↓ cognitive symptoms   
5-HT2A antagonism ↓ negative symptoms ↓ Extrapyramidal side effects 
5-HT1A partial agonism ↓ negative symptoms   
  ↓ cognitive symptoms   
  ↓ anxiety symptoms   
  ↓ depressive symptoms   
Muscarinic receptor antagonism ↓ EPS ↑ Anticholinergic symptoms 
Muscarinic receptor agonism ↓ positive symptoms   
  ↓ cognitive symptoms   
Glutamate modulation ↓ positive symptoms   
  ↓ negative symptoms   
  ↓ cognitive symptoms   
  ↓ illness progression   
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Novel approaches to treating schizophrenia 
Muscarinic Acetylcholine Receptor (mAChR) Targets  
The inability of current antipsychotics to address the positive, negative, and cognitive 
symptoms associated with schizophrenia concurrently, and with few side effects, has led 
to research into novel therapeutic mechanisms. One such target that has garnered interest 
in the last 20 years is the muscarinic acetylcholine receptor (mAChR) system, which has 
several lines of evidence implicating it in the etiology of schizophrenia and other 
psychiatric illnesses. The mAChRs are G-protein coupled receptors (GPCRs) for the 
neurotransmitter acetylcholine (ACh) and consist of five different subtypes, termed M1-
M5 (Bonner et al., 1987). Each of the five mAChR subtypes is a seven-transmembrane 
(TM) protein that can be further divided into two major functional classes based on G-
protein coupling. The M1, M3, and M5 receptor subtypes couple to Gαq proteins, resulting 
in the activation of phospholipase Cβ and the subsequent release of calcium from 
intracellular stores and stimulation of protein kinase C and resultant intracellular 
signaling pathways. The M2 and M4 receptor subtypes couple predominantly to Gαi/o 
proteins to inhibit adenylate cyclase, causing a decrease in intracellular cAMP levels and 
overall decrease in cellular excitability. The M1, M4 and M5 receptor subtypes are 
predominantly expressed in the CNS, while the M2 and M3 receptor subtypes are widely 
distributed in both the CNS and peripheral tissues (Caulfield & Birdsall, 1998; Wess et 
al., 2007). There is significant sequence homology at the orthosteric ACh binding site 
across all of the subtypes of mAChR, which has made the development of subtype-
selective ligands for muscarinic receptors difficult. 
 
26 
 
 
 
 
Figure 5. Muscarinic Acetylcholine Receptor Subtypes.  The mAChR M1, M3, and M5 
subtypes are Gq coupled and activation leads to increased neuronal excitability through 
increases in intracellular calcium and activation of MAPK and PLC. M2 and M4 subtypes 
are Gi/Go coupled and activation leads to inhibition of adenylyl cyclase and decreased 
excitation of the cell.  Figure from (Jones et al., 2012).  
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Previous work has shown that mAChRs are vital for modulation of multiple 
functions in the CNS, including cognition and motor control.  Clinical literature indicates 
that impairment of cholinergic transmission contributes to the cognitive deficits in 
Alzheimer’s disease and other neurologic disorders (Auld et al., 2002; Winkler et al., 
1998). Additionally, multiple clinical studies indicate agents that enhance cholinergic 
transmission, including acetylcholinesterase (AChE) inhibitors, are clinically efficacious 
in reducing the loss of cognitive function in patients with Alzheimer’s disease and other 
memory disorders (Davis et al., 1992; Langmead et al., 2008; Rogers et al., 1998). 
However, the efficacy of these drugs in enhancing cognition  is  limited,  in  part  because  
AChE  inhibitors  increase  transmission  at  all  cholinergic synapses, resulting in dose-
limiting central and peripheral adverse effects. The most prominent adverse effects of 
AChE inhibitors are mediated by activation of peripheral M2 and M3 mAChRs and 
include bradycardia, gastrointestinal distress, excessive salivation, and sweating 
(Bymaster et al., 2002; Langmead et al., 2008; Wess et al., 2007). To better understand 
the role of each receptor subtype in the potential adverse side effects, and more 
importantly the reported efficacy, a more refined characterization of regional localization 
has been undertaken. Neuroanatomical studies using subtype-selective antibodies for the 
different mAChRs have established distinct patterns of expression for the different 
mAChR subtypes within the CNS (Levey et al., 1994; Levey et al., 1995; Levey et al., 
1995; Levey et al., 1991). Additionally, the recent development and characterization of 
knockout (KO) mice for each of the mAChR subtypes has proven invaluable in 
understanding the central and peripheral functions of each subtype (Wess et al., 2007). 
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The M1 mAChR is the predominant subtype expressed in the CNS, and is most 
densely located in the striatum, postsynaptically on the cell bodies of dendrites of 
hippocampal pyramidal neurons and granule cells, and in all layers of the cortex (Levey 
et al., 1995; Levey et al., 1991; Marino et al., 1998; Rouse et al., 1998). Importantly, M1 
mAChR activation has been shown to potentiate NMDA currents in the hippocampus and 
forebrain of rodents (Marino et al., 1998), and it is postulated that selectively activating 
M1 mAChRs may alleviate some of the positive symptoms and cognitive deficits 
observed in schizophrenia through this mechanism (Marino et al., 1998; Tsai & Coyle, 
2002). In addition, recent studies have shown that activation of M1 mAChRs in wildtype 
animals increases the synaptic excitation of pyramidal cells in the medial PFC (mPFC), 
resulting in enhanced performance in mPFC-mediated behavioral paradigms, specifically 
the attentional set shift task (Shirey et al., 2009).  Conversely, M1-KO mice exhibited 
deficits in hippocampal and mPFC-mediated behavioral tasks, as observed in 
consolidation of contextual conditioned freezing and in radial arm maze, respectively 
(Anagnostaras et al., 2003). M1-KO mice also have significant increases in spontaneous 
locomotor activity and enhanced amphetamine-induced hyperactivity associated with a 
twofold increase in DA efflux in the striatum, suggesting a role for M1 mAChRs in 
modulating the dopaminergic system (Gerber et al., 2001; Miyakawa et al., 2001). 
 The M4 mAChRs are widely distributed across several brain regions, including 
the cortex and hippocampus, with the densest expression occurring in the striatum 
(Hersch & Levey, 1995; Levey et al., 1991; Rouse et al., 1998). M4 mAChRs can be 
expressed presynaptically, where they function as autoreceptors on striatal cholinergic 
interneurons or in midbrain projection neurons (Tzavara et al., 2004; Zhang et al., 2002), 
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and postsynaptically as modulatory receptors in the striatum, cortex, and hippocampus 
(Levey et al., 1991; Zang & Creese, 1997). M4-KO mice show significantly higher basal 
locomotor activity and increased psychostimulant-induced DA efflux in the nucleus 
accumbens (Gomeza et al., 1999; Tzavara et al., 2004). Interestingly, targeted KO of M4 
in DA D1 receptors results in a similar psychostimulant response on DA efflux, 
suggesting a crucial role for M4 in modulating dopaminergic circuitry related to 
schizophrenia (Jeon et al., 2010).  
The M1 and M4 mAChRs emerged as potential targets for treating some of the 
symptoms associated with Alzheimer’s disease and schizophrenia following the initial 
characterization of the M1/M4-preferring orthosteric agonist, xanomeline. In clinical 
studies, xanomeline produced a dose-dependent reduction in Alzheimer’s disease-related 
behavioral disturbances, including vocal outbursts, suspiciousness, delusions, agitation, 
and hallucinations (Bodick et al., 1997a; Bodick et al., 1997b). Interestingly, xanomeline 
also improved blunted affect, something that few clinically available medications 
achieve. These aspects of Alzheimer’s disease share remarkable similarities to those 
observed in schizophrenia, and the surprising efficacy observed raised the possibility that 
xanomeline might provide a novel approach for the treatment of schizophrenia. For these 
reasons, a subsequent 4-week, double-blind, placebo-controlled outcome trial was 
performed in subjects with schizophrenia (n=20) to evaluate the potential antipsychotic 
efficacy of xanomeline. In these studies, xanomeline treatment resulted in marked 
improvements in patients with schizophrenia when compared with the placebo group, as 
measured by the Brief Psychiatric Rating Scale (BPRS), Positive and Negative Syndrome 
Scale (PANSS), and Clinical Global Impression (Shekhar et al., 2008). Unlike tradition 
30 
 
 
 
antipsychotic medications, xanomeline showed efficacy in improving multiple domains 
of cognition, including visuospatial learning, verbal learning, attention/vigilance, speed 
of processing, and working memory, indicating efficacy in some aspects of cognition 
(Shekhar et al., 2008). Also of importance, xanomeline elicited its effects on the BPRS 
within one week of initiation, and continued improvement in the BPRS and PANSS were 
observed for the duration of the study. 
In preclinical studies predictive of antipsychotic-like activity, xanomeline 
recapitulated many of the effects observed with atypical antipsychotics such as clozapine 
(Jones et al., 2005; Perry et al., 2001). Specifically, pretreatment with xanomeline 
reversed apomorphine and scopolamine-induced deficits in prepulse inhibition (PPI) of 
the acoustic startle reflex, a model of sensory information processing deficits, and 
increased extracellular levels of dopamine and c-fos expression in prefrontal cortex and 
nucleus accumbens, respectively. Xanomeline also attenuated amphetamine-induced 
increases in locomotor activity and increased dopamine turnover in the prefrontal cortex 
of rats, with similar efficacy to that observed in the clozapine and haloperidol control 
groups (Stanhope et al., 2001). This novel mechanism for modulating psychotic 
symptoms was further supported by studies reporting decreases in DA cell firing in the 
VTA, inhibition of conditioned avoidance responding, and reductions in apomorphine-
induced climbing. Importantly, xanomeline did not induce catalepsy like other typical 
antipsychotics such as haloperidol, and the beneficial effects could be blocked by 
administration of the muscarinic receptor antagonist scopolamine (Shannon et al., 2000). 
In non-human primates, xanomeline produced functional dopamine antagonism and did 
not induce extrapyramidal side effects, as demonstrated by blockade of amphetamine and 
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apomorphine-induced motor unrest and stereotypies, mimicking observations in rodent 
models (Andersen et al., 2003). These findings demonstrate that xanomeline has a 
pharmacologic profile similar to currently available typical and atypical antipsychotics, 
indicating xanomeline could provide a novel approach for the treatment of psychotic 
symptoms in patients with Alzheimer’s disease and schizophrenia. 
Unfortunately, adverse effects were prevalent in patients who participated in the 
initial clinical trials with xanomeline, as well as in preclinical animal models receiving 
elevated doses of xanomeline (Andersen et al., 2003; Bodick et al., 1997a). These 
included gastrointestinal cramping, salivation, and vomiting, and were thought to be due 
to the nonselective nature of xanomeline, which resulted in activation of peripheral M2 
and M3 mAChRs.  Although these side effects did not lead to any mandatory 
discontinuation, there was voluntary attrition and these dose limitations prevented 
xanomeline from long-term clinical use. These studies, however, provided important 
clinical validation of the potential of mAChR agonists as novel therapeutic agents for 
treatment of psychosis as well as cognitive disturbances in schizophrenia patients. These 
findings also raised the question of whether activation of M1, M4, or both receptor 
subtypes is critical for the observed clinical effects, and highlight the need for the 
development of selective ligands to address this question. 
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Figure 6.  Synaptic Localization of M1-M5 mAChR.  M1, M3, and M5 are found 
exclusively on the postsynaptic neuron.  M4 is found on both pre and postsynaptic 
neurons and M2 is exclusively found on presynaptic neurons. Figure adapted from (Jones 
et al., 2012). 
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Allosteric mAChR modulators 
 Over the last decade, a novel approach has been undertaken in the discovery of 
mAChR ligands that selectively activate a particular receptor subtype by actions at sites 
that are topographically distinct and less highly conserved than the orthosteric binding 
site of ACh, termed allosteric sites (Conn et al., 2009). The use of allosteric activators has 
been well validated during the development of benzodiazepines, which are allosteric 
activators of GABAA receptors and provide a safe, effective treatment approach for 
anxiety disorders without inducing adverse effects of direct-acting GABAA receptor 
agonists (Ehlert et al., 1983). Allosteric activators of mAChRs possess high subtype 
selectivity and can show different modes of action. Allosteric agonists can activate the 
receptor subtype directly and do not require the presence of ACh. Alternatively, positive 
allosteric modulators (PAMs) do not directly activate the receptor, but bind to an 
allosteric site distinct from the ACh-binding site and potentiate the effects of endogenous 
ACh. One potential advantage of the use of mAChR PAMs is that these ligands have no 
intrinsic activity and can only exert their effects in the presence of ACh at a given 
synapse, thereby maintaining some level of activity dependence of endogenous receptor 
activation. To date, these novel agonists and allosteric activators of the different mAChR 
subtypes have shown robust efficacy in preclinical models of antipsychotic-like activity 
and/or enhancement of cognitive function, and possess suitable physiochemical 
properties for optimization as potential clinical candidates. 
Development of selective mAChR ligands 
 Sizeable advances have been made in the development of potent and selective 
allosteric modulators of mAChRs by our group at the Vanderbilt Center for Neuroscience 
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Drug Discovery as well as in others that allow for further investigation into the role of M1 
and M4 in the preclinical and clinical efficacy observed with xanomeline (Bridges et al., 
2010; Conn et al., 2009). Recently, several systemically active, M1 allosteric agonists and 
PAMs are proving to be useful tools for the study of selective activation of M1 mAChRs 
in vitro and in animal models predictive of antipsychotic-like activity and enhancement 
of cognition. To date, several M1 allosteric agonists have been described, including 
TBPB, 77-LH-28-1, AC260584, VU0186470 and VU0357017. TBPB is a potent 
(EC50=280 nM) and selective (>30 μM vs M2–M5) M1 allosteric agonist in cell-based 
systems (Jones et al., 2008). M1 mAChR activation by TBPB potentiated NMDAR 
currents in CA1 hippocampal pyramidal cells, a physiological response that is linked to 
the facilitation of learning and memory. Functional anatomical studies with TBPB 
revealed a Fos expression pattern that was consistent with what is observed with the 
atypical antipsychotic clozapine, with increased numbers of Fos-containing cells in the 
mPFC and nucleus accumbens but not the dorsal striatum. Additionally, TBPB reversed 
amphetamine-induced hyperlocomotion in a dose dependent manner within a dose range 
that did not induce side effects associated with the non-selective stimulation of peripheral 
mAChRs, as measured using a modified Irwin test battery or catalepsy, preclinical 
measures of extrapyramidal motor symptoms (Jones et al., 2008). 
 Studies describing the discovery of BQCA (benzyl quinolone carboxylic acid) 
represented a breakthrough in the development of selective M1 PAMs. BQCA does not 
bind at the orthosteric ACh-binding site, but increases the affinity of the M1 mAChR for 
ACh, as represented by a 129-fold leftward shift of the ACh concentration response curve 
(Ma et al., 2009). In ex vivo slice electrophysiology studies, BQCA increased inward 
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currents in mPFC pyramidal cells and spontaneous excitatory postsynaptic currents in 
response to the non-selective mAChR agonist carbachol, and these effects were not 
observed in M1-KO mice (Shirey et al., 2009). BQCA also has pharmacokinetic 
properties that make it suitable for in vivo experiments.  As such, behavioral studies 
revealed efficacy in a mPFC-dependent discrimination reversal learning task in a 
transgenic mouse model of Alzheimer’s disease (Shirey et al., 2009).  In addition, reports 
indicate efficacy in reversing scopolamine-induced deficits in the acquisition of 
contextual fear conditioning, improved novel object recognition, improving cognition on 
a top-down processing task, and altered sleep architecture by enhancing wakefulness and 
decreasing delta sleep (Chambon et al., 2012; Gould et al., 2015; Ma et al., 2009). Similar 
to the effects observed with TBPB, xanomeline, and clozapine, BQCA increased Fos 
expression in the forebrain and dose dependently reversed amphetamine-induced hyper-
locomotion in mice (Ma et al., 2009).  
A more recently discovered selective M1 PAM, VU0453595, has been evaluated 
in models of NMDA receptor hypofunction in mice (Ghoshal et al., 2016). In these 
studies, VU0453595 bath application potentiated M1-mediated muscarinic long term 
depression (LTD) in the prefrontal cortex, a response that is dependent on M1 activation. 
Interestingly, repeated PCP treatment in mice during adolescence resulted in a deficit in 
muscarinic LTD; however, bath application of VU0453595 reversed this response.  When 
assessed in vivo, VU0453595 reversed chronic PCP-induced deficits in performance in 
PFC-dependent behavioral assays, suggesting a role for M1 mAChRs in the cognitive 
deficits and negative symptoms associated with schizophrenia (Ghoshal et al., 2016).  
36 
 
 
 
Collectively, these data demonstrate that selective activation of M1 by both M1 
allosteric agonists and PAMs is sufficient to reproduce some of the effects of xanomeline 
and clinically available antipsychotics in animal models that are predictive of 
antipsychotic-like activity and cognitive enhancement. These studies also support the 
idea that M1 activation may play a critical role in hippocampal- and mPFC-dependent 
cognitive functions and suggest that M1 allosteric activators may serve as an important 
approach for the treatment of the prefrontal cortical deficits observed in patients with 
schizophrenia.  
To investigate the relationship between M1 PAM potency and behavioral efficacy, 
tool compounds with nanomolar potency that retain suitable physiochemical properties 
for in vivo dosing need to be developed. To address this, the M1 PAM tool compound, 
VU6004256, has been reported. VU6004256 is a potent potentiator of mouse M1 (EC50 = 
155 nM, 88% ACh Max) and is ~20-fold more potent than VU0453595.   In addition, 
VU6004256 displays mouse brain:plasma partitioning (Kp) coefficient of 4.84 and an 
unbound brain:plasma coefficient (Kp,uu) of 2.6.   In addition to selectivity for M1 (M2-5 
EC50s >30 µM), VU6004256 also displayed no off-target pharmacology at over 68 
GPCRs, ion channels and transporters in an ancillary pharmacology radioligand binding 
panel (% inhibition @ 10 µM <50%).   Therefore, VU6004256 represents a more potent 
and centrally penetrant M1 PAM compared to VU0453595 to explore efficacy in 
behavioral models of schizophrenia (Chapter V).  
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Figure 7. Summary of previously described M1 and M4 orthosteric and allosteric 
activators. 
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 There have also been breakthroughs in the last decade in the development of M4-
selective ligands, as represented by LY2033298, VU0010010, VU0152100, and 
VU0467154. One of the first M4 PAMs described was LY2033298, a highly selective 
compound with suitable properties for in vivo dosing and no detectable activity at any of 
the other mAChR subtypes (Chan et al., 2008). Interestingly, LY2033298 had no effects 
in preclinical studies when administered alone, but was able to potentiate the effects of a 
sub-threshold dose of the non-selective mAChR agonist oxotremorine to reverse 
dopamine receptor agonist-induced disruptions in prepulse inhibition and the inhibition of 
conditioned avoidance responding (Chan et al., 2008; Leach et al., 2010). In addition, 
neurochemical studies using in vivo microdialysis revealed LY2033298 potentiated 
oxotremorine-stimulated DA release in the PFC but not nucleus accumbens, and had no 
measurable effect when administered alone (Chan et al., 2008). It was hypothesized that 
species differences resulting in decreased potency at rat M4 vs. human M4 receptors was 
responsible for a lack of in vivo efficacy when administered alone, highlighting the need 
for more potent tool compounds to more accurately predict efficacy in the clinic.  
Nonetheless, in combination with an ACh agonist, LY2033298 demonstrated efficacy in 
animal models predictive of antipsychotic-like activity and provided support for further 
development of other selective M4 PAMs. 
 Following closely on the heels of the reports of LY2033298, Shirey et al. (Shirey 
et al., 2008) reported the chemical and pharmacological characterization of the M4 PAM 
VU10010, which has an EC50 of 400 nM for potentiation of ACh effects at the rat M4 and 
a 47-fold leftward shift in the functional ACh response curve (>30 μM vs M1–M3, M5). 
Interestingly, VU10010 was shown to be an allosteric potentiator that increased both the 
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efficiency of the coupling of the M4 mAChR to G-proteins and the affinity of the M4 
mAChR for ACh (Shirey et al., 2008). Unfortunately, VU10010 had unsuitable 
physiochemical properties for in vivo studies. Further optimization of this chemical series 
resulted in the discovery of VU0152099 and VU0152100.  Both of these M4 PAMs 
retained high mAChR subtype selectivity for M4 relative to the other mAChRs (>30 μM 
vs M1–M3, and M5) and further functional selectivity in a screen of 15 other GPCRs that 
are highly expressed in the brain (Brady et al., 2008). These novel M4 PAMs are highly 
centrally penetrant, unlike VU10010, with pharmacokinetic properties ideal for studies in 
animal models of psychosis and cognition. Consequently, behavioral studies utilizing 
these compounds revealed efficacy in a preclinical model predictive of antipsychotic-like 
activity as represented by a robust reversal of amphetamine-induced hyper-locomotion 
(Brady et al., 2008). VU0152100 also reversed amphetamine-induced disruptions in the 
acquisition of contextual fear conditioning in rats, suggesting behavioral efficacy in 
preclinical models used to assess cognition (Byun et al., 2014). Interestingly, these more 
optimized compounds exhibited effects in vivo when administered alone, suggesting there 
is sufficient ACh present in the synapse for an M4 PAM to elicit a pharmacologically 
relevant responses under normal conditions. 
  To date, the most potent M4 PAM described is VU0467154 (5-amino-3,4-
dimethyl-N-(4-((trifluoromethyl)sulfonyl)benzyl)thieno[2,3-c]pyridazine-6-
carboxamide). VU0467154 is a potent potentiator of rat M4 (EC50 = 17.7 nM, 68% ACh 
Max), shows no activity at any of the other mAChRs at concentrations greater than 30 
µM, and has little to no ancillary off-target pharmacology when assessed in a Ricerca 
lead profiling screen (Bubser et al., 2014).  VU0467154 also exhibits a favorable 
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pharmacokinetic profile for in vivo studies in rodents (t1/2 = 5.7 h; CLp = 7.8 mL/min/kg; 
F = 61%; Kp,uu =0 .41), though its utility is limited to that of a tool compound due to 
differences in potency at human M4 that preclude its development for use in clinical 
populations (human M4 EC50 = 627 nM). In behavioral studies, VU0467154 dose-
dependently reversed both MK-801- and amphetamine-induced increases in locomotor 
activity in wildtype, but not M4 KO mice. In addition, dose-dependent reversals of MK-
801-induced disruptions in a touch screen operant task were observed with VU0467154 
co-administration to wildtype, but not M4 KO mice. VU0467154 also demonstrated 
efficacy in reversing MK-801-induced disruptions in acquisition of contextual fear 
conditioning, but perhaps more interesting was the enhancement of acquisition of this 
task in wildtype animals when VU0467154 was administered alone (Bubser et al., 2014).  
Collectively, these studies indicate that the observed antipsychotic-like and cognition 
enhancing activity of VU0467154 are mediated through an M4-dependent mechanism 
Using polysomnography and quantitative electroencephalographic (EEG) 
recordings, VU0467154 was shown to induce state-dependent alterations in sleep 
architecture and arousal in a manner similar to atypical antipsychotics, including delayed 
Rapid Eye Movement (REM) sleep onset, increased cumulative duration of total and 
Non-Rapid Eye Movement (NREM) sleep, and increased arousal during waking periods 
(Gould et al., 2016). Additionally, in acute MK-801 models of NMDAR hypofunction, 
both VU0467154 and clozapine reduced elevations in high frequency gamma power, 
consistent with and antipsychotic-like mechanism of action (Gould et al., 2016; Hiyoshi 
et al., 2014). In summary, selective positive allosteric modulation of M4 muscarinic 
receptors by VU0467154 reverses the behavioral, cognitive, and sleep deficits in an acute 
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model of NMDAR hypofunction, which provides strong evidence for the broader 
therapeutic utility for M4 PAMs in the treatment of complex symptoms observed in 
patients with schizophrenia. 
 
Outline of current studies 
 Thus, in Chapter II, we performed studies to assess the ability of selective M4 
PAMs to modulate mesolimbic circuitry and behaviors that are predictive of 
antipsychotic-like activity. Specifically, we examined the effects of two novel M4 PAMs, 
VU0152100 and VU0467154, to reverse amphetamine-induced hyperlocomotor activity.  
Next, we evaluated changes in cerebral blood volume (CBV) in rats in specific regions of 
interest following dosing with amphetamine, or a combination of amphetamine and the 
M4 PAM VU0152100. We then assessed changes in amphetamine-evoked dopamine 
efflux in the nucleus accumbens (NAS) and caudate putamen (CP), and how co-
administration of VU0152100 affected this response. In these studies, we hypothesized 
that the antipsychotic-like efficacy observed with M4 PAMs could be due to modulation 
of mesolimbic dopamine release.  
 In Chapter III, we performed studies to elucidate the role of M4 mAChRs in 
cortical circuits thought to be disrupted in schizophrenia. To achieve this, whole-cell 
patch-clamp experiments were utilized to measure changes in hallucinogen-evoked 
changes in excitatory signal in the PFC, and the ability of the M4 PAM, VU0467154, to 
mediate this response. To determine if M4 mAChRs could be exerting this effect through 
modulation of thalamocortical circuitry, an optogenetic whole-cell electrophysiology 
study was carried out. To further support these findings, in situ hybridization studies were 
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performed to confirm M4 mAChR expression on thalamocortical neurons. Next, we 
determined the effect of pretreatment with an M4 PAM on hallucinogen-induced head-
twitch response in mice, a behavior known to be regulated by thalamocortical glutamate 
release.  Then, we measured performance in an operant-based spatial alternation task, 
which is thought to require thalamocortical signaling, following dosing with an NMDA 
receptor antagonist in the presence or absence of an M4 PAM. We hypothesized that 
deficits in glutamatergic signaling in the PFC induced by NMDA receptor antagonists or 
hallucinogens could be normalized by M4 PAMs. Additionally, we postulated that the 
actions of M4 PAMs could be working through modulation of thalamocortical circuitry, 
and regulation of this circuit could, in part, result in improvements in PFC-mediated 
behavior.  Finally, we assessed whether M4 potentiation would result in reversal of 
electrophysiological deficits in a genetic model of NMDAR hypofunction. 
 In Chapter IV, we examined the effects of repeated dosing with the M4 PAM 
VU0467154 on learning a touchscreen-based visual pairwise discrimination task. To 
determine if the effects of M4 PAM administration were due to acquisition or 
consolidation of new learning, studies were carried out in which animals were treated 
with an M4 PAM before or directly following training in the discrimination task.  To 
ensure repeated dosing with an M4 PAM would not lead to tolerance of the antipsychotic-
like or cognitive enhancing effects, or changes in pharmacokinetic disposition, behavioral 
studies were performed followed by tissue collection. We hypothesized that repeated 
dosing with an M4 PAM would lead to cognitive enhancement, at least in part through 
actions during memory consolidation during sleep, and that the antipsychotic-like profile 
would remain intact following this repeated dosing paradigm. 
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 In Chapter V, we sought to examine the role of M1 PAMs in modulating PFC-
mediated cognition in a mouse model of NMDA receptor hypofunction. To achieve this, 
we observed changes in muscarinic-long term depression (LTD) in the PFC of NR1 
deficient mice, followed by the effects of the M1 PAM VU6004256.  Next, we evaluated 
changes in layer V PFC pyramidal cell firing rate in NR1 KD animals before and after M1 
PAM administration. To determine if M1 PAMs would be efficacious in behavior models 
reliant on PFC signaling, studies were conducted in WT and NR1 KD animals evaluating 
performance in novel object recognition and cue-mediated conditioned freezing behavior.  
Finally, the effects of two M1 PAMs, VU6004256 and VU0453595, were observed in 
spontaneous locomotor behavior in WT and NR1 KD mice. We hypothesized that M1 
PAM administration would normalize electrophysiological deficits that are related to 
abnormal behavior in a genetic animal model of NMDA receptor hypofunction. 
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CHAPTER II 
 
SELECTIVE POTENTIATION OF M4 MUSCARINIC ACETYLCHOLINE 
RECEPTORS MODULATES MESOLIMBIC DOPAMINERGIC CIRCUITRY IN 
MODELS PREDICTIVE OF ANTIPSYCHOTIC-LIKE ACTIVITY 
 
Introduction 
 Patients diagnosed with schizophrenia suffer from a host of debilitating 
symptoms, including positive symptoms, negative symptoms, and deficits in cognition 
(American Psychiatric Association, 2013; Nuechterlein et al., 2004). Unfortunately, all 
clinically available typical and atypical antipsychotics are primarily efficacious in 
treating the positive symptoms, with little effect on the negative symptoms or cognitive 
deficits (Swartz et al., 2008). Current antipsychotic medications are also plagued with 
only partial patient responsiveness, treatment resistance, delayed onset of action, and a 
long list of dose-limiting side effects, including extrapyramidal motor effects and 
metabolic disorders (Bak et al., 2014; Lieberman et al., 2003; Parsons et al., 2009). As a 
result, there remains a large unmet medical need to develop novel treatment strategies 
that address all three symptoms domains without the complexities present with current 
antipsychotic medications. 
 As discussed in Chapter I, there is growing evidence to suggest selective 
activators or potentiators of mAChRs may present a new treatment approach for the 
treatment of the psychotic symptoms and cognitive deficits observed in schizophrenia 
and Alzheimer’s disease patients. Much of this interested stemmed from preclinical and 
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clinical findings with the M1/M4-preferring mAChR orthosteric agonist, xanomeline. In a 
large multicenter clinical trial, xanomeline produced modest, although statistically 
insignificant, effects on cognitive function; however, strikingly robust efficacy was 
observed in treating the psychotic symptoms in Alzheimer’s disease patients (Bodick et 
al., 1997a; Bodick et al., 1997b). In particular, xanomeline induced dose-dependent 
reductions in suspiciousness, delusions, hallucinations, and other behavioral disturbances 
and psychotic symptoms that are highly analogous to those observed in schizophrenia. 
Based on these initial findings, a double blind, placebo-controlled clinical study was 
performed to determine if xanomeline also had antipsychotic efficacy in patients with 
schizophrenia (Shekhar et al., 2008). Interestingly, xanomeline produced robust 
improvements in both positive and negative symptoms in this population and also 
improved cognitive performance, particularly in measures of verbal learning and short-
term memory. While xanomeline ultimately failed to progress in the clinic due to off 
target activation of peripherally expressed M2 and M3 receptors, it did shine light on the 
potential of muscarinic system modulation for the treatment of several symptom domains 
in schizophrenia.    
One potential mechanism for the efficacy observed in treating the positive 
symptoms may be through modulation of mesolimbic circuitry. In support of this 
hypothesis, anatomical studies in rodents indicate that M4 mAChRs are abundantly 
expressed in several key regions of the mesocorticolimbic dopaminergic circuitry, 
including the VTA, NAS and mPFC. In particular, M4 mAChRs are reported to be 
localized on both cholinergic interneurons and medium spiny GABAergic neurons within 
the NAS and dorsal striatum (Hersch & Levey, 1995; Zhang et al., 2002), presynaptically 
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on glutamatergic terminals in multiple cortical regions and presynaptically on cholinergic 
terminals from midbrain CH5/6 cholinergic projections providing monosynpatic 
activation of dopamine neurons in the VTA (Garzon & Pickel, 2000; Levey, 1993; 
Levey, 1996; Oakman et al., 1999; Sugaya et al., 1997; Volpicelli & Levey, 2004; 
Westerink et al., 1998; Westerink et al., 1996). In line with this expression pattern, M4 
KO mice show elevated extracellular levels of dopamine in the NAS  compared with 
wildtype controls (Tzavara et al., 2004). Moreover, M4 KO mice also show increased 
sensitivity to psychostimulants which result in elevated levels of extracellular dopamine 
release in the NAS. While the direct mechanism responsible for this change is unclear, 
evidence indicates that one important site of regulation may be the M4 inhibitory 
autoreceptor feedback on cholinergic terminals in the VTA.  Consistent with this 
hypothesis, loss of M4 mAChR control on Ch5/Ch6 cholinergic projections results in 
increased extracellular levels of ACh in the VTA in M4 KO mice, leading to enhanced 
activation of midbrain dopamine neurons (Tzavara et al., 2004). This disinhibition of the 
mesolimbic dopamine neurotransmission observed in M4 KO mice also provides a likely 
mechanism for the exacerbated behavioral response to psychostimulants in these animals 
(Gomeza et al., 1999; Gomeza et al., 2001).  Taken together, these findings indicate that 
the absence of M4 mAChR function in the M4 KO mice results in a state of 
hyperexcitability of the mesolimbic dopaminergic circuitry, a state thought to underlying 
symptoms associated with schizophrenia, and suggest that activation of M4 mAChRs may 
reduce mesolimbic and mesostriatal dopaminergic neurotransmission.  
Thus, using behavioral, neurochemical, and imaging approaches, the following 
studies were performed to assess the ability of selective M4 PAMs to modulate 
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dopaminergic circuitry involved in schizophrenia. To complete these studies, two distinct 
M4 PAMs were used, VU0467154 and VU0152100.  As discussed in Chapter I, 
VU0152100 represented the first highly selective, potent M4 PAM with pharmacokinetic 
properties suitable for in vivo studies (Byun et al., 2014). VU0467154 is a closely related 
analog with more optimized potency and pharmacokinetic properties that allows for 
insight into the role of M4 receptors in modulating mesolimbic circuitry, as well as in 
more complex electrophysiological and behavioral paradigms (Chapters III and IV). 
 
 
Methods 
Animal Care and Housing 
All in vivo studies were carried out using adult male Sprague–Dawley rats (Harlan, 
Indianapolis, IN), age-matched adult male wild-type C57BL/6 mice (Taconic Farms, 
Hudson, NY), and adult male M4 KO mice with a C57BL/6 background (Dr. Jürgen 
Wess, National Institute of Diabetes and Digestive and Kidney Disorders, Bethesda, 
MD). Animals were group-housed under a 12/12 h light-dark cycle (lights on at 6 AM) 
with food and water available ad libitum unless stated elsewhere. All animal experiments 
were approved by the Vanderbilt University Animal Care and Use Committee, and 
experimental procedures conformed to guidelines established by the National Research 
Council Guide for the Care and Use of Laboratory Animals. All efforts were made to 
minimize animal suffering and the number of animals used. 
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Chemicals and Biological Materials 
Chemicals for the synthesis of VU0467154 and VU0152100 were obtained from 
Sigma-Aldrich or made in-house. Large scale syntheses were conducted at NAEJA 
Pharmaceutical (Edmonton, Canada) using chemical methods developed at Vanderbilt 
University. 
 
Drugs 
D-Amphetamine hemisulfate was obtained from Sigma-Aldrich. VU0467154 and 
VU0152100 were prepared as a microsuspension in vehicle (10% Tween 80 in sterile 
water) and administered IP in a volume of 2 mL/kg (rats) or 10 mL/kg (mice). For oral 
(PO) dosing in rats, VU0467154 was administered in a volume of 10 mL/kg. 
Amphetamine was dissolved in sterile water. In rats, amphetamine was administered 
subcutaneously (SC) at 1 mL/kg. In mice, drugs were administered in a volume of 10 
mL/kg. 
 
Locomotor Activity Studies in Rats 
Open field activity was tested using a SmartFrame Open Field System (Kinder 
Scientific, San Diego, CA) with a 16 × 16 array of infrared photobeams located 2.5 cm 
above the floor of the chamber as previously described (Jones et al., 2008). To establish 
the dose–response relationship for amphetamine on locomotor activity, rats were 
habituated for 60 min in the open field and then injected with vehicle (sterile water SC) 
or dose of amphetamine (0.1–1 mg/kg, SC), and locomotor activity was recorded for an 
additional 60 min. To determine the effects of VU0467154 on reversing amphetamine-
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induced hyperlocomotion, rats were habituated in the open field for 30 min, followed by 
administration of vehicle (10% Tween 80 in sterile water) or a dose of VU0467154 (1–
56.6 mg/kg, IP or PO). After an additional 30 min, vehicle (sterile water) or amphetamine 
(0.75 mg/kg SC) was injected, and locomotor activity was recorded for another 60 min. 
The time course of drug-induced changes in ambulation is expressed as mean number of 
beam breaks per 5 min bin over the 120 min session. Total locomotor activity was 
calculated as the total number of beam breaks from the time of amphetamine 
administration [t = 60 min] to the end of the experiment [t = 120 min]. Total activity and 
time course data (means ± SEM) were analyzed by one-way and two-way ANOVA, 
respectively, and post hoc comparisons were made by Dunnett’s test using GraphPad 
Prism. 
 
Locomotor Activity Studies in Mice 
Open field activity was tested in wild-type and M4 KO mice, 8–10 weeks old, 
using an open field system (OFA-510, MedAssociates, St. Albans, VT) with three 16 × 
16 arrays of infrared photobeams. The following paradigm was used to assess drug 
effects on amphetamine-induced locomotor activity: Wild-type and M4 KO mice animals 
were habituated for 90 min in the open field before being injected with vehicle or 
VU0467154; 30 min later, vehicle or amphetamine were administered, and locomotor 
activity was recorded for an additional 120 min. To assess the dose–response relationship 
for amphetamine-induced hyperlocomotion, mice were administered vehicle (10% Tween 
80 in sterile water, IP) followed 30 min later by an injection of vehicle (sterile water SC) 
or a dose of amphetamine (1–3 mg/kg SC). The effects of VU0467154 on amphetamine-
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induced hyperlocomotion were examined by pretreating mice with vehicle (10% Tween 
80 in sterile water IP) or a dose of VU0467154 (0.3–30 mg/kg IP) followed 30 min later 
by an injection of vehicle (sterile water SC) or amphetamine (1.8 mg/kg SC). 
 
In Vivo Microdialysis and Locomotor Activity 
Guide cannulae (BioAnalytical Systems, West Lafayette, IN) were implanted into 
the NAS (AP +1.5 mm bregma, ML −1.5 mm, DV −7.8 mm) or CP (AP 1.0 mm, ML 
−2.5 mm, DV −5.5 mm). After recovery for 4–7 days, microdialysis probes (2 mm 
membrane length) were inserted the night before the experiment using methods 
previously reported by (Perry et al., 2001). The following day, rats were placed into open 
field chambers as used for the amphetamine-induced hyperlocomotion studies. Probes 
were perfused with aCSF (150 mM NaCl, 3 mM KCl, 1.7 mM CaCl2, and 0.9 mM 
MgCl2) and dialysate samples were collected in 15-min fractions onto a 96-well plate 
using a refrigerated fraction collector (EFC-82, Eicom). Following a 2-h equilibration, 
four baseline samples were collected, followed by a 30-min pre-treatment with either 
vehicle or VU0152100 (56.6 mg/kg, i.p.). Then all rats were injected with either vehicle 
or amphetamine (1 mg/kg, s.c.) and dialysate samples were collected for another 120 min. 
At the end of the study, probes were perfused with methyl blue to verify placement. 
Dialysates were analyzed using an Eicom ECD-700 HPLC system. Dopamine and its two 
major metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid 
(HVA) were separated at a flow rate of 400 μl/min using a mobile phase consisting of 
0.1 M citrate-acetate buffer/methanol (80 : 20), 220 mg/l sodium octanesulfonic acid, and 
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5 mg/l EDTA and quantitated by electrochemical detection. Chromatograms were 
analyzed using PowerChrom (eDAQ, Denistone East, NSW, Australia). Only animals 
with accurate probe placement that showed three consecutive stable baseline values 
(within ⩽20%) were included in the statistical analysis. 
 
Pharmacologic Magnetic Resonance Imaging (phMRI) 
Isoflurane-anesthetized rats, with preimplanted jugular catheters, underwent 
endotracheal intubation (14 G catheter), insertion of i.p. catheters (size P50, Braintree 
Scientific, Braintree, MA), and mechanical ventilation (Kent Scientific, Litchfield, CT; 
O2:N2O 1 : 2; 2% isoflurane). For scanning, isoflurane was set to 0.88% and 
pancuronium bromide administered (1 mg/kg, i.p.; BoundTree Medical, Dublin, OH). 
Heart rate, respiration, and rectal temperature were continuously measured and 
temperature maintained through a thermocoupled heating unit (SAM-PC; SA 
Instruments, Encinitas, CA). End-tidal CO2 was continuously monitored (Invivo 
Research, Orlando, FL). PhMRI data were acquired with a Doty Litz 38-mm transmit-
receive radio frequency coil using a 9.4 T Varian magnet controlled by a Varian Inova 
console (Agilent, Palo Alto, CA). High-resolution fast spin-echo (fse) structural images 
were collected (repetition time (TR) 2550 ms; effective echo time (TEeff) 40 ms; number 
of excitations (NEX) 2; 128 × 128 matrix; 35 × 35 mm2 field of view; 11 contiguous 
slices, 1.5 mm thick). Pre-contrast reference images and post-contrast functional images 
were acquired (fse: TR 2600 ms; TEeff 36 ms; NEX 2; 64 × 64 matrix). To measure 
cerebral blood volume (CBV), Molday iron oxide nanoparticles (30 nm; 20 mg/kg, i.v.; 
BioPAL, Worcester, MA) were injected. For amphetamine interaction experiments, rats 
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were pre-treated for 15 min with vehicle or 56.6 mg/kg VU0152100 (i.p.), then a 15-min 
baseline was collected, after which rats were administered with vehicle or a 1 mg/kg 
amphetamine (i.p.) followed by 45 min of continuous acquisition. In a separate study to 
assess the effects of VU0152100 alone on fractional CBV changes, an initial 15-min 
baseline was collected, followed by administration of vehicle or VU0152100 
(56.6 mg/kg, i.p.), and 45 min of continuous image acquisition. 
phMRI data were processed using in-house MATLAB code (MathWorks, Natick, 
MA) and Analysis of Functional NeuroImages (AFNI; afni.nimh.nih.gov). All masked, 
motion-corrected (AFNI 2dreg) images were coregistered to the template anatomical 
images in AFNI. Fractional CBV changes were calculated on a voxel-wise basis for each 
subject using the equation: ΔCBV(t)=(ln S(t)−ln So)/(ln So−ln Spre), where S(t) is the 
measured signal at time t, So is the post-contrast baseline signal, and Spre is the pre-
contrast baseline (Mandeville et al, 1998). Regions of interest (ROIs), pre-defined on the 
template based on a rat brain atlas (Paxinos and Watson, 2007), were applied to all 
subjects. Mean CBV values (left and right hemispheres averaged) were calculated for 
each subject at the 15- to 25-min interval after the vehicle or amphetamine challenge or at 
the 15- to 25-min interval after vehicle or VU0152100 alone. Group-averaged maps were 
colorized according to the voxel CBV value. 
 
Functional Connectivity Analysis 
The strength of functional connections between brain regions was quantified by 
computing the Pearson linear correlation coefficient between the integral of the CBV 
response to amphetamine for each ROI pair for the vehicle/amphetamine and 
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VU0152100/amphetamine groups (Schwarz et al, 2007b). Correlation coefficients, r, 
were converted to z-scores using Fisher's transformation 
(z=ln[(1+r)/(1−r)]/[2*(1/(N−3))0.5]) and thresholded at |Z|>2 (in-house MATLAB code). 
Permutation analysis (Holmes et al, 1996) was used to identify the correlations that were 
significantly different (Δz, p<0.05) between vehicle/amphetamine and 
VU0152100/amphetamine groups (in-house MATLAB code). 
 
Results 
VU0467154 Reverses Amphetamine-Induced Hyperlocomotion in Rats after IP and 
PO Dosing 
The M1/M4-preferring agonist xanomeline has previously been reported to have an 
APD-like profile, including reversal of amphetamine-induced hyperlocomotion 
(Stanhope et al., 2001). To confirm and extend these findings using a more potent 
M4 PAM, we assessed the ability of VU0467154 to counteract the motor stimulant effects 
of amphetamine. We first evaluated the dose–response relationship for amphetamine in 
inducing hyperlocomotion in rats to select an optimal dose for subsequent reversal studies 
with VU0467154 (Figure 8). Amphetamine produced a dose- and time-dependent 
increase in locomotor activity (Fdose(5,1008) = 96.37, p < 0.001; Ftime(23,1008) = 58.99, p < 0.001; 
and Fdose×time(115,1008) = 6.64,p < 0.001), significant at doses of 0.3–1 mg/kg (F5,47 = 29.47, p < 
0.001). VU0467154 produced a robust dose-dependent reversal of amphetamine-induced 
hyperlocomotion after IP (Fdose(6,1032) = 40.97, p < 0.001; Ftime(23,1032) = 42.78, p < 0.001; and 
Fdose×time(138,1032) = 2.66, p < 0.001) and PO (Fdose(6,1176) = 45.54, p < 0.001; Ftime(23,1176) = 
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65.09, p < 0.001; and Fdose×time(138,1176)= 2.55, p < 0.001) routes of administration (Figure 9). 
Total locomotor activity was significantly reversed with doses of 10–56.6 mg/kg IP 
(F6,49 = 9.51, p < 0.001) and 3–56.6 mg/kg PO (F6,55 = 11.10, p < 0.001). 
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Figure 8. Amphetamine (AMPH) dose-dependently increases open field locomotor 
activity. The time course of locomotor activity is shown on the left and total locomotor 
activity during the 60 min period following amphetamine administration on the right. 
Data are means ± SEM of 6–8 animals per group. * p < 0.05, ** p < 0.01, *** p < 0.001 
vs vehicle (ANOVA followed by Dunnett’s test). 
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Figure 9. VU0467154 reverses amphetamine-induced hyperlocomotion in rats. 
Systemic (IP [A] or PO [B]) administration of VU0467154 dose-dependently reverses 
amphetamine-induced hyperlocomotion. The time course of locomotor activity is shown 
on the left and total locomotor activity during the 60 min period following amphetamine 
administration on the right. Data are means ± SEM of 6–8 animals per group. * p < 0.05, 
** p < 0.01, *** p < 0.001 vs vehicle (A) or vs vehicle + amphetamine (B and C) 
(ANOVA followed by Dunnett’s test). 
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VU0467154 Reverses Amphetamine-Induced Hyperlocomotion in Wild-type but Not 
in M4 KO Mice 
We first determined the dose–response relationship for the effects of amphetamine on 
locomotion in wild-type and M4 KO mice to allow selection of an optimal dose for 
subsequent reversal studies with VU0467154 across both genotypes (Figure 10). 
Amphetamine produced a dose- and time-dependent increase in locomotor activity in 
both wild-type and M4 KO mice (Fdose(7,3696) = 337.8, p < 0.001; Ftime(47,3696) = 31.77, p < 
0.001; and Fdose×time(329,3696) = 9.99, p < 0.001). The effect of amphetamine treatment on 
locomotor activity was significant at a dose of 1.8 mg/kg in M4 KO mice and at a dose of 
3 mg/kg in both genotypes; however, there was no significant main effect of genotype on 
the amphetamine response (Fdose(3,77) = 85.81, p < 0.001; Fgenotype(1,77) = 1.08, ns; 
and Fdose×genotype(3,77) = 1.02, ns; Figure 10). VU0467154 (0.3–30 mg/kg) produced a robust 
reversal of the amphetamine-induced hyperlocomotion in wild-type mice (Fdose(5.2550) = 
68.42, p < 0.001;Ftime(47,2550) = 68.73, p < 0.001; and Fdose×time(235,2555) = 2.91, p < 0.001), 
significant at doses of 3–30 mg/kg (F5,59 = 9.13, p < 0.001; Figure 11A). In contrast, 
VU0467154 had no effect on the time course of amphetamine-induced hyperlocomotion 
in M4 KO mice (Ftreatment(2,1296) = 0.86, ns; Ftime(47,1296) = 15.33, p < 0.001; and Fdose×time(94,1296) = 
0.47, ns), nor did it reduce the total number of beam breaks compared with the animals 
treated with vehicle plus amphetamine (F(2,29) = 0.87, ns; Figure 11B). 
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Figure 10. Amphetamine-induced hyperlocomotion in WT and M4 KO mice. 
Amphetamine (AMPH) dose-dependently increases open field locomotor activity in wild-
type (WT) and M4 KO mice. The time course of locomotor activity is shown on the left 
and total locomotor activity during the 120 min period following amphetamine 
administration on the right. Data are means ± SEM of 9–13 wild-type mice and 10–11 
M4 KO mice per group. *** p < 0.001 vs wild-type vehicle + vehicle (A); 
###p < 0.001 vs 
M4 KO vehicle + vehicle (A); (ANOVA followed by Bonferroni’s test). 
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Figure 11. VU0467154 reverses amphetamine-induced hyperlocomotion in wild-
type, but not M4 KO mice. (A) In wild-type mice, administration of VU0467154 dose-
dependently reverses amphetamine-induced hyperlocomotion. (B) VU0467154 does not 
reverse amphetamine-induced hyperlocomotion in M4 KO mice. The time course of 
locomotor activity is shown on the left and total locomotor activity during the 120 min 
period following amphetamine administration on the right. Data are means ± SEM of 9–
13 wild-type mice and 10–11 M4 KO mice per group. 
++p < 0.01, +++p < 0.001 vs wild-
type vehicle + amphetamine (ANOVA followed by Bonferroni’s test). 
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phMRI Quantification of VU0152100-Mediated Suppression of Amphetamine-
Induced Regional Brain Activation and Functional Connectivity Pattern 
In order to more comprehensively assess the specific brain regions underlying the effects 
of VU0152100 in reversing the amphetamine-induced changes in behavior, phMRI was 
used to examine the effects of a behaviorally relevant dose of VU0152100 (56.6 mg/kg, 
i.p.) on amphetamine-evoked (1 mg/kg, i.p.) alterations in CBV. As shown in the group-
averaged CBV maps (Figure 12A) and time courses (Figure 12B), amphetamine robustly 
increased CBV in the NAS and CP, areas of high dopamine transporter expression, as 
well as in extrastriatal areas, including the thalamus, hippocampus, and retrosplenial 
cortex. Pre-treatment with VU0152100 (56.6 mg/kg, i.p.) significantly blunted 
amphetamine-evoked increases in CBV in the medial thalamus (F2, 31=15.7, p<0.0001), 
hippocampus (F2, 31=11.7, p<0.001), CP (F2, 31=10.3, p<0.001), NAS (F2, 
31=9.31, p<0.001), and retrosplenial cortex (F2, 31=3.8, p<0.05) (Figure 12B). There were 
no significant CBV changes in response to amphetamine alone or in combination with 
VU0152100 (F2, 31=0.94, NS) in the PFC (Figure 12B); however, the lack of observed 
amphetamine effects may have been due in part to the anesthetized preparation and/or the 
exclusion of the two most anterior brain slices (1.5 mm in thickness) in the analysis to 
avoid partial volume effects as these slices also include the frontal pole and olfactory 
cortex, respectively. There were also no significant CBV responses detected in groups 
treated with vehicle/vehicle (Figure 12) or VU0152100 alone (data not shown). 
Functional connectivity analysis of the above phMRI data revealed multiple inter-
regional correlations in neural activation elicited by amphetamine in rats, while pre-
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treatment with VU0152100 (56.6 mg/kg, i.p.) modified the amphetamine-induced 
correlation pattern; fewer significant inter-regional correlations were found in the group 
pre-treated with VU0152100 before amphetamine (data not shown). Permutation analysis 
identified significant differences between the two treatment groups (the statistical 
threshold was set at p<0.05 and reported as z-scores), including retrosplenium-
hippocampus (Δz=3.4499), NAS-motor cortex (Δz=3.3348), retrosplenium-motor cortex 
(Δz=3.2268), and NAS-medial thalamus (Δz=3.1553) (Figure 12C). Other ROI pairs with 
significant differences included the NAS-CP (Δz=3.0555), motor cortex with 
hippocampus (Δz=2.8753), and visual cortex (Δz=2.7884); PFC-sensory cortex 
(Δz=2.3990); and substantia nigra-amygdala (Δz=2.3409). 
The effects of VU0152100 on peripheral cardiovascular parameters, including 
blood pressure and heart rate, were assessed since changes might confound hemodynamic 
readouts of brain function (Ferrari et al., 2012). Compared with vehicle treatment, 
VU0152100 (56.6 mg/kg, i.p.) did not change arterial blood pressure (F(treatment)1, 
72=9.28, p<0.01, F(time)7, 72=1.44, NS, and F(interaction)7, 72=3.83, NS) or heart rate 
(F(treatment)1, 72=7.58, p<0.05, F(time)7, 72=7.41, NS, and F(interaction)7, 72=2.47, NS) in 
awake, freely moving animals (Figure 13). 
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Figure 12. VU0152100 modulates amphetamine-induced cerebral blood volume 
responses. (a) Amphetamine (1 mg/kg, i.p.) elicited CBV increases, reflecting neural 
activity, while pre-treatment with VU0152100 (56.6 mg/g, i.p.) suppressed this effect in 
multiple brain areas. (b) Regional CBV time courses for amphetamine and reversal by 
VU0152100 are shown for the retrosplenial cortex, medial thalamus, hippocampus, NAS, 
CP, and PFC; note that amphetamine by itself and in combination with VU0152100 did 
not alter CBV in the PFC. Data are means±SEM of 10–11 animals per group. Functional 
connectivity analysis of the phMRI data revealed fewer inter-regional correlations in the 
VU0152100/amphetamine group and the significant ROI–ROI correlation differences 
between the vehicle/amphetamine group and the VU0152100/amphetamine group 
(thresholded at p<0.05) are depicted in panel (c). Cells are colored according to the 
corresponding z-statistic. Abbreviations of regions of interest (number indicates slice): 
Amyg, amygdala; CP, caudate-putamen; Cg, cingulate; Hipp, hippocampus; MT, medial 
thalamus; M, motor cortex; NAS, nucleus accumbens; PFC, prefrontal cortex; Pir, 
piriform cortex; Rs, retrosplenial cortex; S, sensory cortex; SN, substantia nigra; V, 
visual cortex.  
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Figure 13. VU0152100 does not cause cardiovascular side effects. VU0152100 
(56.6 mg/kg, i.p.) does not alter blood pressure and (d) heart rate in awake animals. 
Although two-way ANOVA revealed a significant treatment effect on blood pressure and 
heart rate there were we no significant differences between vehicle- and VU0152100-
treated rats at any time point (Bonferroni test).  
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VU0152100 Reverses Amphetamine-Induced Increases in Dopamine Release in the 
NAS and CP 
The finding that VU0152100 reverses effects of amphetamine in multiple 
behavioral models and on CBV in multiple brain regions raises the possibility that this 
M4 PAM may act in part by reducing effects of amphetamine on extracellular dopamine 
levels in brain regions associated with antipsychotic efficacy. The effects of VU0152100 
in reversing amphetamine-induced increases in extracellular dopamine levels in the NAS 
and CP were assessed using in vivo microdialysis in rats at a dose of 56.6 mg/kg (i.p.), 
which produced maximum efficacy in blocking amphetamine-induced hyperlocomotion 
and disruption of PPI. As shown in Figures 14A and B, VU0152100 reversed 
amphetamine-induced hyperlocomotion (F(treatment)3, 312=30.6, p<0.001, F(time)12, 
312=17.5, p<0.0001, and F(interaction)36, 312=34.8, p<0.001; Figure 4b: F(treatment)3, 
351=27.1, p<0.001, F(time)12, 351=20.0, p<0.0001, and F(interaction)36, 351=30.7, p<0.001). 
When administered alone, VU0152100 had no effect on basal dopamine release in either 
the NAS or CP (Figure 14C and D). However, when given in combination with 
amphetamine, VU0152100 significantly reduced amphetamine-evoked dopamine release 
in both the NAS and CP (Figure XC for NAS: F(treatment)3, 297=19.9, p<0.001, F(time)12, 
297=23.3, p<0.001, and F(interaction)36, 297=30.2,p<0.001; Figure XD for the CP: 
(F(treatment)3, 351=18.8, p<0.001, F(time)12, 351=27.3, p<0.001, and F(interaction)36, 
351=32.4, p<0.001). In the NAS, VU0152100 alone increased extracellular levels of the 
dopamine metabolites DOPAC (Figure 15A: F((treatment)3, 296=16.3, p<0.001, F(time)12, 
296=3.87, NS, and F(interaction)36, 296=21.2, p<0.001) and HVA (Figure 15C: 
F(treatment)3, 296=17.9, p<0.001, F(time)12, 296=2.86, NS, and F(interaction)36, 
65 
 
 
 
296=17.3,p<0.001). In the CP, amphetamine alone or in combination with VU0152100 
reduced DOPAC (Figure 15B: F(treatment)3, 334=16.4, p<0.001, F(time)12, 
334=11.8, p<0.001, and F(interaction)36, 334=17.7, p<0.001) and HVA (Figure 15D: 
F(treatment)3, 331=13.9, p<0.001, F(time)12, 331=9.98, p<0.001, and F(interaction)36, 
331=24.0, p<0.001). 
 
  
66 
 
 
 
 
Figure 14. Effects of VU0152100 on locomotor activity and dopamine efflux in the 
nucleus accumbens and caudate-putamen. Pre-treatment with VU0152100 
(56.6 mg/kg, i.p.) reverses amphetamine-induced (1 mg/kg, s.c.) hyperlocomotion (a, b) 
and reduces the amphetamine-elicited increase in extracellular dopamine levels in the 
nucleus accumbens and caudate-putamen (c, d). Data are mean±SEM of 6–8 rats per 
group; *p<0.05, **p<0.01 vs vehicle/vehicle; #p<0.05, ##p<0.01 vs 
vehicle/amphetamine (Dunnett’s test). 
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Figure 15. Effects of VU0152100 on extracellular dopamine metabolites. Effects of 
VU0152100 (56.6 mg/kg, ip) and amphetamine (1 mg/kg, sc), alone or in combination on 
extracellular levels of the dopamine metabolites DOPAC (A and B) and HVA (C and D) 
in the nucleus accumbens (A and C) and caudate-putamen (B and D). Data are mean ± 
S.E.M. of 6 - 8 rats/group; * p<0.05, ** p<0.01 vs. vehicle/vehicle; # p< 0.01 vs. 
vehicle/amphetamine (Dunnett’s test).  
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Discussion 
In recent years, selective activators of mAChRs have emerged as a new approach 
for the treatment of psychotic symptoms and cognitive disturbances associated with 
various neuropsychiatric disorders. In these studies, the selective M4 PAMs VU0152100 
and VU0467154 displayed dose-dependent efficacy in behavioral models that predict 
antipsychotic-like activity. In contrast to orthosteric mAChR agonists, VU0152100 and 
VU0467154 did not produce adverse effects associated with non-selective activation of 
peripheral mAChR subtypes (data not shown) or impairments in locomotor activity when 
administered alone. phMRI studies also indicated that VU0152100 reduces amphetamine-
induced activation of the NAS and CP, as well as certain cortical, thalamic, and 
hippocampal areas. Functional connectivity analyses of the phMRI data revealed that 
VU0152100 modulated the activity of neural circuits that included the NAS, retrosplenial 
and motor cortices, hippocampus and thalamus. Finally, the behavioral effects of 
VU0152100 were accompanied by reversal of amphetamine-induced increases in 
extracellular DA levels in the NAS and CP, suggesting that the antipsychotic-like activity 
is mediated, in part, through modulation of mesolimbic and mesostriatal dopamine 
signaling. 
The present findings suggest that VU0152100 and VU0467154 reverse 
amphetamine-induced behavioral and neurochemical changes directly through 
potentiation of M4 mAChRs. Although the observed effects could also be due to a drug–
drug interaction between the M4 PAM and amphetamine, this seems unlikely since drug-
naive rats were used in acute dosing paradigms that would not allow sufficient time for 
induction of metabolizing enzymes responsible for degrading amphetamine to occur 
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(Fahmi & Ripp, 2010). Moreover, we have previously reported a lack of VU0152100 and 
VU0467154 interaction with a host of GPCRs, transporters, ion channels, and enzymes 
found in the periphery and CNS which would be relevant for the observed behavioral 
responses (Brady et al., 2008; Bubser et al., 2014).  
Our finding that VU0152100 attenuates amphetamine-induced increases in 
extracellular DA in the NAS and CP is consistent with previous studies and suggests that 
the in vivo antipsychotic-like effects of M4 PAMs are at least partially mediated by 
reduction of DA release. In particular, DA release in the nucleus accumbens and striatum 
can be induced by administration of muscarinic agonists, but is absent in M4 KO mice, 
suggesting that M4 negatively regulates dopaminergic tone in these regions (Threlfell et 
al., 2010). Currently, the mechanism by which M4 activation regulates mesolimbic and 
mesostriatal dopaminergic transmission remains unclear. M4 has been postulated to act as 
an inhibitory autoreceptor on terminals of cholinergic neurons originating in the 
pedunculopontine and laterodorsal tegmental nuclei that excite dopaminergic neurons in 
the ventral tegmental area (Holmstrand & Sesack, 2011; Yeomans, 2012). In this case, 
M4 activation in the VTA would result in attenuation of dopaminergic signaling in the 
mesolimbic pathway. In addition, the observed effects on dopamine signaling could also 
be the result of M4 activation on cholinergic interneurons in the NAS, which have been 
shown to enhance phasic DA release under normal conditions (Cachope et al., 2012). 
There is also recent evidence suggesting that activation of M4 receptors results in 
increased activity in D1-containing striatal projection neurons through a mechanism of 
action involving enhanced Ca
2+
 currents though Cav1-channels (Hernandez-Flores et al., 
2015). This, in turn, would result in enhanced GABAergic signaling to the VTA, leading 
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to reductions in DA release in the striatum. Conflicting reports suggest that M4 activation 
in the NAS results in direct inhibitory control of DA D1 receptor signaling, resulting in 
decreases in inhibitory control of VTA signaling (Onali & Olianas, 2002). 
There is emerging evidence implicating interactions between M4 receptors and the 
endocannabinoid system, namely through a CB2-dependent mechanism (Foster et al., 
2016). These studies showed that activation of M4 receptors on striatal spiny projection 
neurons resulted in dopaminergic regulation resulting in a sustained depression of striatal 
dopamine release. Furthermore, both the M4-mediated sustained inhibition of dopamine 
release and the antipsychotic-like efficacy of M4 activators were dependent on functional 
signaling through CB2 cannabinoid receptors. These findings highlight a novel 
mechanism by which striatal cholinergic and cannabinoid signaling leads to sustained 
reductions in dopaminergic transmission, resulting in behavioral effects predictive of 
antipsychotic-like activity. 
Consistent with the behavioral and neurochemistry results, VU0152100 
suppressed amphetamine-induced increases in CBV in the NAS and CP as well as the 
medial thalamus, hippocampus, and retrosplenial cortex. It has been previously reported 
that changes in blood volume can reflect changes in neural activity, specifically in 
response to psychoactive compounds (Chen et al., 1997; Hackler et al., 2010; Kim & 
Ogawa, 2012; Schwarz et al., 2004).  The effects of VU0152100 on brain activity in 
multiple regions suggest that actions in areas outside of the basal ganglia may also 
contribute to the in vivo antipsychotic-like effects of VU0152100. These findings are 
consistent with previous evidence that cortical projections modulate DA function in the 
striatum (Desole et al., 1992; Tzavara et al., 2004). We characterized the regional 
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correlation patterns in response amplitude to VU0152100 using a well-established 
functional connectivity analyses approach (Schwarz et al., 2007; Schwarz et al., 2007). 
Pre-treatment with VU0152100 attenuated several strong connectivity patterns of the 
NAS and retrosplenial cortex with other brain areas after amphetamine challenge. These 
included correlated activity between NAS and hippocampus, motor cortex, and CP and 
the retrosplenial cortex with motor cortex and hippocampus. Importantly, the low 
isoflurane (0.88%) necessary for proper maintenance anesthesia to prevent movement-
related artifacts did not result in negative CBV changes to amphetamine. Also, the 
observed changes in hemodynamics cannot be attributed to changes in blood pressure or 
heart rate, as VU0152100 administration had no effect on either at any specific time 
point. Although additional studies are needed to further investigate the underlying 
mechanisms of the observed functional changes by VU0152100, these data suggest M4 
potentiation can directly and indirectly modulate dopaminergic signaling in multiple 
brain regions implicated in schizophrenia. 
 It is important to note that while M4-mediated decreases in DA release may 
contribute to the in vivo effects of VU0152100, the phMRI findings would suggest other 
mechanisms are also likely contribute to the antipsychotic-like actions of M4 PAMs. 
Previous studies have reported the ability of xanomeline to reverse the behavioral effects 
of both amphetamine and the direct dopamine receptor agonist apomorphine and that 
these effects are eliminated in M4 KO mice (Dencker et al., 2011; Jones et al., 2005; 
Stanhope et al., 2001). The ability of M4 activation to inhibit responses to a direct acting 
dopamine receptor agonist suggests that M4 activation must also act at a level 
downstream of DA release to induce its overall in vivo effects. With this in mind, it is 
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worth noting that M4 receptors are expressed at multiple levels in basal ganglia and 
forebrain regions, and future studies utilizing VU0152100 or VU0467154 are essential to 
elucidate other actions of M4 PAMs that may contribute to the overall in vivo effects. 
These studies, taken together with a growing body of research discussed 
previously, suggest that M4 PAMs reduce dopaminergic signaling and have a range of 
efficacy in rodent models predictive of antipsychotic-like activity. Importantly, these 
findings support a role for M4 in the antipsychotic-like efficacy observed with the M1/M4-
preferring ligand, xanomeline, and point to modulation of other brain circuits and 
neurotransmitter systems implicated in the cognitive deficits and negative symptoms 
observed in schizophrenia. Studies described in Chapters III-V will address these 
questions in relation to modulation with both M1 and M4 PAMs. 
 
Sections of this chapter have been reprinted from the following: 
Byun, N.E., Grannan, M., Bubser, M., Barry, R.L., Thompson, A., Rosanelli, J., Gowrishankar, R., Kelm, N.D., Damon, S., Bridges, 
T.M., Melancon, B.J., Tarr, J.C., Brogan, J.T., Avison, M.J., Deutch, A.Y., Wess, J., Wood, M.R., Lindsley, C.W., Gore, J.C., Conn, 
P.J., and Jones, C.K. (2014) Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric 
modulator VU0152100. Neuropsychopharmacology. 39(7): 1578-93. 
 
Bubser, M., Bridges, T.M., Dencker, D., Gould, R.W., Grannan, M., Noetzel, M.J., Lamsal, A., Niswender, C.M., Daniels, J.S., 
Poslusney, M.S., Melancon, B.J., Tarr, J.C., Byers, F.W., Wess, J., Duggan, M.E., Dunlop, J., Wood, M.W., Brandon, N.J., Wood, 
M.R., Lindsley, C.W., Conn, P.J., and Jones, C.K. (2014) Selective activation of M4 muscarinic acetylcholine receptors reverses MK-
801-induced behavioral impairments and enhances associative learning in rodents. ACS Chem Neurosci. 5(10): 920-42. 
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CHAPTER III 
 
SELECTIVE POTENTIATION OF M4 MUSCARINIC ACETYLCHOLINE 
RECEPTORS MODULATES ELECTROPHYSIOLOGICAL AND 
BEHAVIORAL EFFECTS IN PHARMACOLOGIC AND GENETIC MODELS 
OF NMDAR HYPOFUNCTION 
 
 
Introduction 
 
Previous studies suggest that acute psychotic episodes in patients diagnosed with 
schizophrenia are associated with increased activity in several key brain regions, 
including the PFC (Cleghorn et al., 1989; Ebmeier et al., 1995; Hermle et al., 1992; 
Kaplan et al., 1993; Vollenweider et al., 1997a; Vollenweider et al., 1997b). In support of 
this, recent clinical findings have demonstrated that acute treatment with the NMDAR 
antagonist ketamine in healthy humans can induce a state of mPFC disinhibition, or 
hyperconnectivity, that is also observed in early course schizophrenic patients (Anticevic 
et al., 2015). In animal studies, acute pharmacologic challenge with either NMDAR 
antagonists or hallucinogens induces increases in spontaneous activity at glutamatergic 
synapses in layer V mPFC in brain slices and in vivo (Jackson et al., 2004; Aghajanian 
& Marek, 1999). One mechanism for this increase in spontaneous activity at mPFC 
glutamatergic synapses is through direct activation of 5-HT2A receptors located 
presynaptically on glutamatergic thalamocortical terminals in the mPFC.  Upon activation 
74 
 
 
 
of these 5-HT2A receptors, there is a dramatic increase the frequency of spontaneous 
excitatory postsynaptic currents (EPSCs) measured in layer V pyramidal cells of the 
mPFC (Aghajanian & Marek, 1997; Aghajanian & Marek, 1999; Marek et al., 2001; 
Marek et al., 2000). Previous studies have demonstrated that atypical antipsychotics, 
including clozapine and olanzapine, inhibit this effect and reduce spontaneous EPSCs in 
the mPFC by direct antagonist activity at 5-HT2A receptors on thalamocortical terminals. 
Based on the postulated role of altered glutamatergic transmission in the 
pathophysiology of schizophrenia, this has been suggested to be important for the 
unique clinical profile of atypical antipsychotic agents (Deutch et al., 1991). More 
recently, novel ligands with antipsychotic-like activity, such as metabotropic glutamate 
receptor subtypes 2 and 3 (mGlu2 and mGlu3) agonists and mGlu2 potentiators, have been 
shown to dramatically reduce increases in spontaneous EPSCs induced by 5-HT2A 
receptor activation in mPFC pyramidal cells. Additional studies showed this inhibition of 
glutamate signaling was dependent on activation of presynaptic mGlu2 receptors 
expressed on thalamocortical nerve terminals (Jackson et al., 2004; Aghajanian & 
Marek, 1999). Importantly, administration of these ligands also resulted in a reduction of 
hyperactive glutamatergic signaling in vivo, suggesting modulation of this circuit is 
critical for mPFC function (Lorrain et al., 2003; Lorrain et al., 2003; Moghaddam & 
Adams, 1998). 
In the following studies, we performed experiments to elucidate the role of M4 
mAChRs in cortical circuits thought to be disrupted in schizophrenia. To do this we 
utilized a range of electrophysiological techniques, both ex vivo and in vivo, along with 
behavioral assays known to be dependent on cortical glutamatergic signaling. 
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Additionally, the effects of VU0467154 were assessed in a genetic model of NMDAR 
hypofunction (introduced in Chapter I and discussed in great detail in Chapter V) to 
confirm a role for M4 modulation in glutamatergic signaling in a model of constitutive, 
global NMDAR deficient mice. 
  
 
 
Methods 
 
Animals 
All animal studies were approved by the Vanderbilt University Medical Center 
Institutional Animal Care and Use Committee and were conducted in accordance with the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals. All in 
vivo electrophysiology studies were carried out using adult male Sprague–Dawley rats 
(Harlan, Indianapolis, IN).  Ex vivo electrophysiology studies used age-matched male WT 
and M4 KO mice (P25-30) with a C57BL/6 background (Dr. Jürgen Wess, National 
Institute of Diabetes and Digestive and Kidney Disorders, Bethesda, MD). Animals were 
group-housed under a 12/12 h light-dark cycle (lights on at 6 AM) with food and water 
available ad libitum.  
 
Compounds 
 5-amino-3,4-dimethyl-N-(4-((trifluoromethyl)sulfonyl)benzyl)thieno[2,3-
c]pyridazine-6-carboxamide (VU0467154) was synthesized in house as previously 
described (Bubser et al., 2014).  For in vivo studies, VU0467154 was dissolved in a 10% 
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tween 80 vehicle and injected intraperitoneal (i.p.).  Ex vivo electrophysiology studies 
used VU0467154 dissolved in a dimethyl sulfoxide (DMSO) stock, then diluted to 3 µM 
in artificial cerebrospinal fluid (aCSF). 
 
Whole-Cell Patch-Clamp Recordings 
Whole-cell patch-clamp recordings were performed using 300 μm coronal slices 
prepared from P25-P30 day old WT and M4 KO mice with a K-gluconate-based 
intracellular solution as described previously (Shirey J. Neuro). Spontaneous EPSCs were 
recorded from pyramidal cells in layer V prelimbic mPFC while clamped at -70 mV. The 
interevent intervals of sEPSCs from 2 min episodes during baseline and drug application 
were used to generate cumulative probability plots. The interevent intervals from each 
experiment were then expressed as frequency and the mean values from the 2 min 
episodes were grouped and compared. Inward current data analysis was performed using 
Clampfit  and Minianalysis software.   
 
Stereotaxic Injections  
Viral-mediated gene transfer of channelrhodopson-2 (ChR2) in the midline nuclei 
of the thalamus (mThal) was accomplished in male C57bl/6j mice (4-5 weeks of age). 
Anesthesia was obtained via dexmetometidine-ketamine (0.5-80 mg/kg, i.p.), after which 
mThal was targeted at ML: ± 0.3, AP: -1.2, DV: -3.0, relative to bregma with a 
stereotaxic instrument and software (Leica Angle Two). Bilateral injections of AAV5-
CaMKII-ChR2-EYFP (250-400 nL; UNC Viral Vector Core) were delivered at 100 
nL/min. Atipamazole (1.0 mg/kg, s.c.) and ketoprofen (10 mg/kg, s.c.) were administered 
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to reverse anesthesia and relieve pain. Mice were sacrificed for ex vivo electrophysiology 
3-4 weeks post-surgery.  
 
Whole-cell Optogenetic Electrophysiology 
Mice were anaesthetized with isoflurane and decapitated. The brains were rapidly 
removed and placed in cold sucrose-based slicing solution (in mM): 183 sucrose, 20 
NaCl, 0.5 KCl, 2.0 CaCl2, 1.0 MgCl2, 1.2 NaH2PO4, 10 glucose, and 26 NaHCO3. 
Hemisected coronal slices (250 µM) were prepared using a Leica VT 1200S vibratome 
and immediately transferred for 10 minutes to a heated (37 ± 1 °C) bath containing N-
methyl-D-glucamine (NMDG)-based recovery solution (in mM): 93 NMDG, 20 HEPES, 
2.5 KCl, 0.5 CaCl2, 10 MgCl2, 1.2 NaH2PO4, 25 glucose, 30 NaHCO3, 5 Na-ascorbate, 
and 3 Na-pyruvate. Slices then recovered for at least 60 min at room temperature (23 ± 1 
°C) in a holding chamber containing artificial cerebrospinal fluid (aCSF) (in mM): 119 
NaCl, 2.5 KCl, 2.5 CaCl2, 1.3 MgCl2, 1 NaH2PO4, 11 glucose, and 26 NaHCO3. Once 
placed in the recording chamber, slices were continuously perfused with aCSF at a rate of 
2 ml/min at 30 ± 2°C. Picrotoxin (50 μM) was added to the recording aCSF to block 
GABAARs. All solutions were continuously oxygenated with 95% O2 / 5% CO2. 
Whole-cell voltage-clamp recordings were obtained using IR-DIC video microscopy. 
Recordings were made with 3.0–4.0 MΩ glass electrodes pulled on a P-1000 
Flaming/Brown puller (Sutter Instruments) filled with (in mM): 120 CsMeSO4, 15 CsCl, 
8 NaCl, 10 HEPES, 0.2 EGTA, 10 TEA-Cl, 4 MgATP, 0.3 Na3GTP, 0.1 spermine, and 5 
QX-314. For optogenetic experiments, ChR2-driven optical excitatory postsynaptic 
currents (op-EPSCs) were elicited by 1-2 ms illumination with 470 nm light. Recordings 
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were acquired using a Multiclamp 700B (Molecular Devices) amplifier, filtered at 2 kHz 
and digitized at 10 kHz. The monosynaptic component of the op-EPSC was defined to be 
the peak current obtained in the 4-8 ms window following stimulation. The light intensity 
was adjusted to obtain op-EPSCs with a magnitude of 150–400 pA. Cells were voltage 
clamped at -70 mV and op-EPSCs were evoked at 0.1 Hz. Data acquisition and analysis 
were performed using pClamp 10.4 software (Axon Instruments). Membrane properties 
were monitored continuously throughout the duration of experiments, and changes in 
series resistance were less than 20 % across each experiment. op-EPSCs were binned by 
minute and subsequently normalized to the average value of the 5-minute baseline. The 
coefficient of variation (CV) of 30 responses was determined by dividing the standard 
deviation the mean. 
 
RNAScope 
Animals received 125 nl deposits of cholera toxin B-Alexa 555 into the medial 
prefrontal cortex (N=4); injections involved the prelimbic cortex (area 32) and the 
dorsally contiguous anterior cingulate cortex (area 24b).  7-10 days later animals were 
overdosed with isoflurane, the brains removed and blocked, and tissue stored at -80°C 
until assayed.  Coronal sections were cut at 14um through the frontal cortex and thalamus 
and collected on Superfrost slides.  Chrm4 transcripts were labelled using the Advanced 
Cell Diagnostics (Newark, CA) RNAscope fluorescent assay kit (ACD Manual Cat. No. 
320293) with the following modifications.  The sections were fixed in 4% 
paraformaldehyde in phosphate buffer at 4°C for 15 minutes, after which there were 
dehydrated for 1 min each in 50%, 50%, 70%, 100% and 100% ethanol.  Sections were 
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treated with 2 drops of RNAscope Pretreat 4 for 15 minutes at room temperature and 
rinsed in PBS. For the hybridization step, 50 µL Chrm4 probe set/section was added, and 
1 drop/section of the AMP used.   
 
(±) DOI Head Twitch 
On test day, the animals were taken to the testing room and allowed to habituate 
for up to 60 minutes. Animals received an intraperitoneal (IP) injection of 1-(2,5-
dimethoxy-4-iodophenyl)-2-aminopropane (DOI, Sigma) directly before testing. Animals 
were dosed with the M4 PAM VU0467154 or vehicle 60 minutes prior to DOI dose.  The 
mGlu2 PAM BINA was used as a positive control and was dosed 30 minutes prior to 
DOI.   After the injection, each animal was placed in a large glass beaker for 30 minutes. 
A head-twitch response is characterized by a distinct left-to-right or right-to-left rapid 
head movement following DOI treatment. Head twitches were recorded by video 
continuously over the course of 30 minutes in a quiet room. Scoring was completed by 2 
independent, blinded scorers and the data was averaged. 
 
Locomotor Activity Studies in Mice 
Spontaneous locomotor activity was assessed in 8-10 week old wild-type and NR1 KD 
mice.  Animals were placed in an open field system (OFA-510, MedAssociates, St. 
Albans, VT) with three 16 × 16 arrays of infrared photobeams as described previously 
(Byun et al., 2014). Mice were allowed to habituate in their home cage for one hour prior 
to the start of the experiment.  Following the habituation period, mice were injected with 
either vehicle (10% tween 80, i.p.) or a dose of VU0467154 (3 mg/kg or 10 mg/kg, i.p.) 
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and placed directly into the open field chambers.  Spontaneous locomotor activity was 
recorded for 120 minutes.  The time course of drug-induced changes in spontaneous 
locomotor activity is expressed as distance traveled (cm) per 5 minute bin for the 90 
minute session.  Total activity data represent the sum of all 5 minute bins for the 
recording session.  Data are represented as mean ± SEM and were analyzed using two-
way ANOVA with Bonferroni’s post hoc test. 
 
In vivo electrophysiology 
Male Sprague-Dawley rats (300-400g) were anaesthetized with 1-2% isoflurane 
and secured using a stereotaxic device.  Upon completion of craniotomy and dural 
opening, five quartz-platinum/tungsten electrodes were independently driven into the 
mPFC (-3.0 mm AP; +1.0 mm ML; -3.0 mm DV).  Once stable baseline recording was 
achieved, rats were dosed with either VU0467154 (10 mg/kg, IP) or vehicle (10% tween 
80), followed 30 minutes later by dosing with either MK-801 (0.1 mg/kg, SC) or vehicle 
(sterile water).  Continuous recording occurred for 60 minutes following the final 
injection.  Offline sorting was performed to determine cell type. Only cells that produced 
a minimum of 100 spikes in the baseline sample with less than 1% refractory period 
violations (refractory period <1.1 ms) were used for subsequent analysis. Pyramidal cells 
were defined as neurons with firing rate < 5 Hz with sporadic firing patterning. The firing 
rate of each neuron was normalized to the baseline frequency and neurons were grouped 
based on the drug treatment the aniamal received. Changes in firing rate (frequency) were 
determined using Neuroexplorer V4.091 (Nex Technologies, Madison, AL). 
 
81 
 
 
 
Spatial Alternation 
Briefly, mice were initially trained to respond in either left or right nosepoke, with 
the correct nosepoke alternating after each training session for two to three sessions in 
each nosepoke. The response contingencies were then changed such that the mice were 
required to respond alternately on the left and right nosepoke within each training session 
to obtain 33% ensure liquid reinforcer. The beginning of each trial was signaled by the 
illumination of the stimulus light in the nosepoke hole. Correct responses produced a 
liquid reinforcer and initiated a 10-second retention interval, illumination of the house 
light, and extinction of the stimulus light. During the retention interval responses had no 
scheduled consequences. Incorrect responses were followed by a 0.2-second feedback 
tone. After an incorrect trial, the correct nosepoke remained on the same side; i.e., a 
correction procedure was used. The retention interval was held constant for 15 training 
sessions, at which time responding asymptoted at approximately 85% correct. The 
duration of the retention interval was then varied among 2, 4, 8, 16, and 32 seconds in a 
randomized order during each session. All response contingencies remained the same. 
Behavior was allowed to stabilize over the next 15 sessions. Sessions were conducted 5 
days per week and each training session ended after 60 minutes or 100 reinforcers, 
whichever occurred first.  
 
In Vivo Electrophysiology 
The method was a modified version of that described in (Walker et al., 2008).  
Mice anesthetized with isoflurane were secured on a stereotaxic apparatus and a 
craniotomy was performed at AP(+1.7 mm) ML(+0.5 mm).  The electrode bundle was 
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composed of eight 25 μm Formvar-insulated stainless-steel wires for recording single 
units and two 50 μm uninsulated stainless-steel ground wires, one of which served as a 
depth reference electrode.  The bundle length was 2.5 mm, allowing for recording of 
prelimbic mPFC pyramidal cells when the array is fixed to the skull with dental acrylic.  
Mice are allowed to recover 5-7 days before entering the recording arena. All recordings 
took place between 12pm and 4pm.  A wire harness attached to a headstage containing 
unity gain amplifiers was secured to the electrode array and mice were allowed to explore 
the chamber for fifteen minutes prior to the initiation of baseline recording.  Animals 
were placed in a chamber equipped with a Faraday cage and attached to an electric 
commutator which allowed for unrestricted movement during the in vivo recording.   
Neuronal discharges were acquired by the Multichannel Acquisition Processor 
(MAP) system following preamplification (Plexon Inc, Dallas, TX). To detect spiking 
activity, signals were bandpass filtered (154 Hz to 8.8 kHz) and digitized at a rate of 40 
kHz. After establishing a voltage threshold ≥2.5 times background noise, waveforms 
were continuously collected and principal component analysis was used to discriminate 
putative pyramidal neurons from fast-spiking interneurons. All recording sessions lasted 
for 30 minutes.  Baseline firing rate was assessed during the final 5 minutes of the 
baseline collection period (30 minutes into recording), and the effects of vehicle (10% 
tween 80, i.p.) or VU0467154 (10 mg/kg , i.p.) were assessed during the final 5 minutes 
of the drug treatment period (60 minutes following dose).  Data are expressed as mean 
frequency during each period or as a percent of baseline and significance is determined 
using a paired t-test. 
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Statistical Analysis 
All statistical analyses were performed in GraphPad Prism 5 (GraphPad, San 
Diego, CA). The effects of pharmacological application in whole cell electrophysiology 
experiments were compared using unpaired t-test.  DOI-induced head twitch and in vivo 
electrophysiology studies were compared using two-way analysis of variance (ANOVA) 
with Bonferroni post hoc tests unless otherwise mentioned. 
 
Results 
VU0467154 attenuates 5-HT-induced increases in EPSCs in layer V mPFC 
pyramidal cells in WT, but not M4 KO tissue 
In animal studies, acute pharmacologic challenge with either NMDAR antagonists 
or hallucinogens induce increases in spontaneous activity at glutamatergic synapses in 
layer V mPFC in brain slices and in vivo (Aghajanian & Marek, 1999; Jackson et al., 
2004).  One mechanism for this increase in spontaneous activity at mPFC glutamatergic 
synapses is through direct activation of 5-HT2A receptors located presynaptically on 
glutamatergic thalamocortical terminals in the mPFC. Previous reports provide evidence 
for modulating thalamocortical circuitry via activation or potentiation of presynaptic 
receptors expressed on this circuit (Gewirtz & Marek, 2000). To model disruptions in this 
circuit ex vivo, 5-HT application was utilized to elicit changes in glutamatergic signaling. 
Bath application of 5-HT (30 µM) for 10 minutes resulted in a robust increase (153.0 ± 
9.638 percent of baseline; Figure 16D and E) in sEPSCs in WT tissue, resulting in a 
leftward shift in the interevent interval cumulative probability plot consistent with 
previously reported results (Benneyworth, 2007).  Co-application of VU0467154 (3 µM) 
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significantly reduced the response to 5-HT (97.19 ± 17.37 percent of baseline; Figure 16F 
and G) resulting in a rightward shift in the cumulative probability plot towards baseline 
values.  In contrast, 5-HT application alone or in combination with VU0467154 had no 
effect on amplitude of sEPSCs as depicted in the representative cumulative probability 
plot and group means (p > 0.05; Figure 16F and G).   
Identical studies were performed using M4 KO mouse tissue in order to determine 
if the effects of VU0467154 observed in WT tissue were M4-mediated.  Bath application 
of 5-HT (30 µM) still elicited a leftward shift in the interevent interval cumulative 
probability plot and a significant increase in sEPSC frequency compared to baseline 
(161.3 ± 5.663 percent of baseline; Figure 17D and E); however, co-application with 
VU0467154 had no effect on the 5-HT-induced response.  Similar to WT tissue, neither 
5-HT alone or in combination with VU0467154 had a significant effect on sEPSC 
amplitude (Figure 17F and G).  Taken together, these data indicate VU0467154 
modulates glutamatergic signaling in layer V mPFC in an M4-dependent manner. 
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Figure 16. 5-HT-induced increases in sEPSCs can be attenuated with co-application 
of VU0467154 in WT tissue. (A-C) Representative EPSC traces from WT slices in layer 
V mPFC pyramidal cells. (D) Representative cell showing 5-HT bath application (30 
µM) causes a leftward shift in the interevent interval cumulative probability plot (bold 
line).  Co-application with VU0467154 (3 µM) attenuates this response resulting in a 
rightward shift (red dotted line). (E) 5-HT bath application induces robust increase in 
EPSCs, but co-application with VU0467154 reverses this response (n=5-7). (F) 
Representative cell showing no change in amplitude cumulative probability plot 
following 5-HT or 5-HT + VU0467154 co-application. (G) 5-HT or 5-HT + VU0467154 
bath application did not result in a significant change in amplitude of EPSCs compared to 
baseline. (paired two-tail t test; p value <0.05). 
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Figure 17. 5-HT-induced increases in sEPSCs are not attenuated with co-application 
of VU0467154 in M4 KO tissue. (A-C) Representative EPSC traces from M4 KO slices 
in layer V mPFC pyramidal cells. (D) Representative cell showing 5-HT (30 µM) bath 
application induces a significant leftward shift in the interevent interval cumulative 
probability plot in M4 KO tissue (bold line).  VU0467154 (3 µM) co-application had no 
effect on IEI (red dotted line).  (E) 5-HT application resulted in a significant increase in 
sEPSCs, an effect that could not be attenuated with VU0467154 co-application in M4 KO 
tissue (n=5-7). (F,G) 5-HT and 5-HT + VU0467154 co-application had no effect on 
amplitude of sEPSCs as observed in the representative cumulative probability plot and 
averaged group mean. (paired two-tail t test; p value <0.05). 
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VU0467154 attenuates thalamocortical synaptic transmission 
Viral-mediated gene transfer of ChR2-EYFP in the midline thalamic nuclei led to 
robust expression of ChR2-EYFP in the PFC and the medial striatum (Figure 18A). 
Optically-evoked excitatory postsynaptic currents (op-EPSCs) were elicited from layer V 
PFC pyramidal neurons. Application of NBQX blocked op-EPSCs (data not shown), 
confirming AMPAR-mediated glutamatergic transmission. After obtaining a stable 
baseline, VU0467154 (3 µM) was bath applied and a significant reduction in the 
amplitude of the op-EPSC 10-15 minutes after drug application (Figure 18B-C; 82.7 ± 
2.5 % baseline, p < 0.05, one-sample t-test) was observed. Of note, no electrical 
stimulation was applied during these experiments, consistent with the effect of 
VU0467154 on spontaneous neurotransmission. In the PFC, M4 receptors may be 
expressed on pyramidal neurons and/or as presynaptic heteroreceptors on thalamic inputs. 
To begin to address the synaptic locus of VU0467154 action, we analyzed the coefficient 
of variation (CV), which is inversely correlated with presynaptic release probability.  
VU0467154 application increased the CV of the evoked responses (0.181 ± 0.021 vs. 
0.142 ± 0.024 at baseline, p < 0.05, paired t-test, Figure 18E), consistent with the 
interpretation that potentiation of M4 receptors inhibits thalamocortical neurotransmission 
through a presynaptic site of action. 
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Figure 18. VU0467154 attenuates thalamocortical synaptic transmission. (A) Images 
of ChR2-EYFP expression and experimental schematic. ChR2-EYFP was exogenously 
expressed in the midline thalamus and terminal expression was observed in the PFC 3-4 
weeks later. Light stimulation elicited op-EPSCs from neurons in the PFC. (B) Left, 
representative experiment displaying timecourse of op-EPSC amplitude following bath 
application of VU0467154 (3 µM,). Right, representative op-EPSC traces during baseline 
(black) and drug application period (gray). Scale bars denote 5 ms and 100 pA. (C) 
Summarized data displaying timecourse of VU154-mediated op-EPSC inhibition (n = 6 
cells, N = 4 mice). (D) Scatter plot showing average op-EPSC amplitude in final 5 
minutes of VU0467154 application normalized to baseline (gray area panel B,C). (E) 
VU0467154 application increased the coefficient of variation (CV) of the op-EPSC. 
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VU0467154 administration reverses NMDAR antagonist-induced increases in 
pyramidal cell firing rate in layer V mPFC 
Consistent with previous reports, systemic dosing with the NMDAR antagonist 
MK-801 (0.1 mg/kg, i.p., vehicle saline) induced a robust increase in pyramidal cell 
firing rate in layer V mPFC neurons that persisted for 30 minutes following dosing 
(Figure 19).  Pretreatment with VU0467154 (10 mg/kg, i.p, vehicle 10% tween 80, 30 
minute pretreatment time) resulted in a complete blockade of this response.  Dosing with 
VU0467154 (10 mg/kg, i.p, vehicle 10% tween 80, 30 minute pretreatment time) alone 
did not affect firing rate. 
 
VU0467154 Attenuates Excessive Pyramidal Cell Firing in the Prefrontal Cortex of 
NR1 KD Mice.  
In vivo electrophysiology recordings from the prelimbic cortex of awake, 
behaving mice revealed a significant increase in firing rate of pyramidal neurons in NR1 
KD mice (1.70 Hz ± 0.14) compared to wild-type littermate controls (1.040 Hz ± 
0.06)(t129 = 4.49, p < 0.0001; see Figure 29B). Mice received either vehicle or 10 mg/kg 
VU0467154 following 30 minutes of baseline recording (Figure 20A).  Pyramidal cell 
firing rate was reduced in the NR1 KD animals following VU0467154 administration 
(61.08% ± 4.59, t63 = 3.70, p < 0.005; Figure 20D), with no observed effect of vehicle 
dosing (101.7% ± 10.6; Figure 20D). Vehicle administration did not affect firing rate in 
wild-type animals, though VU0467154 treatment did produce a significant reduction 
(107.8% ± 4.75 and 85.5% ± 6.55, respectively, t63= 2.64, p < 0.05; Figure 20G). 
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Comparison of raw firing rates using a paired t-test revealed a strong post-dose decrease 
in NR1 KD mice following VU0467154 administration (t34= 7.68, p < 0.0001; Figure 
20B) with a much smaller decrease in wild-type animals (t33= 2.70, p < 0.05; Figure 
20E).  
 
(±) DOI induced head-twitch response can be reversed by VU0467154 
(±) DOI-induced head-twitch response onset was observed approximately 5 
minutes after (±) DOI administration.  Pretreatment with VU0467154 dose-dependently 
reversed head-twitch response (ANOVA, Dunnett’s test, ** p<0.01, *** p < 0.001 vs. 
vehicle + DOI, F6,38=10.07, Figure 21).  Pretreatment with 56.6 mg/kg of the mGlu2 
PAM BINA resulted in a significant reduction in head-twitch response that is consistent 
with previously reported literature (Benneyworth, 2007) (ANOVA, Dunnett’s test,*** p 
< 0.001 vs. vehicle + DOI, F6,38=10.07).  (±) DOI administration in M4 KO mice  resulted 
in comparable head-twitch responses to those observed in WT littermate controls, but the 
effect of the top dose of 10 mg/kg VU0467154 was absent (unpaired t-test, p = 0.5734, 
t0.5788, 12). 
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Figure 19. NMDAR antagonist systemic administration results in enhanced PFC 
pyramidal neuron firing rate. MK-801 administration results in increased pyramidal 
cell firing rate in layer V mPFC in rat (squares). Pretreatment with VU0467154 
significantly reverses MK-801-induced increases in firing rate. VU0467154 
administration alone had no effect on firing rate. Data are mean±SEM of 6-8 rats per 
treatment group, 40-60 cells.   (vehicle 10% Tween 80, VU0467154 10 mg/kg, IP, 60 min 
pretreatment; 0.1 mg/kg MK-801, SC, 30 min pretreatment, ANOVA, Bonferroni’s test * 
p < 0.05, ** p<0.01, *** p < 0.001 vs. vehicle +vehicle). Below (left), schematic showing 
location of electrode placement location in layer V PrL cortex (black square). Below 
(right), representative neuron graphed in principle component analysis space along with 
representative waveforms.  
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Figure 20. VU0467154 reduces pyramidal cell firing rate in awake, freely moving 
NR1 KD mice. (A) NR1 KD mice exhibit significantly increased firing rate compared to 
WT littermate controls. (B-D) VU0467154 significantly reduced pyramidal cell firing 
rate in NR1 KD mice, but vehicle treatment had no effect. (E-F) VU0467154 also 
reduced pyramidal cell firing rate WT littermate controls. Data in panels D and G 
represent changes in frequency compared to the baseline recording period prior to drug 
administration.  (A, D, and G) t-test, *p < 0.05, ***p < 0.005, ****p < 0.001. (b, C, E, 
and F) Paired t-test, *p < 0.05, ****p < 0.001. A: n=65-66 cells, B-G: n=30-35 cells. 
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Figure 21. (±) DOI induced head-twitch response can be reversed by VU0467154. 
VU0467154 dose-dependently reverses (±) DOI-induced head-twitch response in WT 
mice, but not M4 KO mice. (Right) Time-course of drug effect in WT and M4 KO mice. 
(vehicle 10% Tween 80, VU0467154 & BINA  IP, 60 min pretreatment VU0467154, 30 
min pretreatment BINA; 2.0 mg/kg (±) DOI, IP, ANOVA, Dunnett’s test * p < 0.05, ** 
p<0.01, *** p < 0.001 vs. vehicle +DOI; M4 KO Veh/DOI vs. 10 VU154/DOI n.s, 
Unpaired t-test). 
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VU0467154 administration reverses NMDAR antagonist-induced deficits in an 
operant-based spatial alternation task 
WT mice were trained in an operant-based spatial alternation task. Upon 
acquisition of stable baseline, characterized as 2 consecutive training days above 80%, 
mice were dosed with the following paradigm: vehicle/vehicle (10% tween 80, i.p., 60 
min prior to test; sterile water, i.p., 30 min prior to test), vehicle/MK-801 (10% tween 80, 
i.p., 60 min prior to test; MK-801, 0.3 mg/kg, i.p., 30 min prior to test) or 
VU0467154/MK-801 (VU0467154, 10 mg/kg, i.p., 60 min prior to test; , MK-801, 0.3 
mg/kg, i.p., 30 min prior to test). MK-801 treatment resulted in a significant disruption in 
performance compared to vehicle administration (Figure 22) (42.6 ± 3.5% vs. 85.2 ± 
1.5%, respectively; F(2,29) = 43.76, p < 0.0001). Pretreatment with VU047154 
significantly attenuated the response to MK-801 alone, resulting in performance above 
chance responding (63.1 ± 3.8% vs. 42.6 ± 3.5%, respectively).  
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Figure 22. M4 PAM administration reverses NMDAR-induced deficits in spatial 
alternation performance.  MK-801 (0.3 mg/kg, i.p.) administration significantly 
reduced accuracy in an operant-based spatial alternation task.  Pretreatment with 
VU0467154 (10 mg/kg, i.p.) resulted in a significant attenuation of this deficit. **p < 
0.01, ****p < 0.0001, one-way ANOVA, Bonferroni’s post hoc test.  
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Chrm4 mRNA is found in mediodorsal thalamic projection neurons to the mPFC 
Most but not all cells of the mediodorsal nucleus of the thalamus (MD) expressed 
Chrm4; the cholinergic receptor mRNA was also observed in the thalamic paraventricular 
and intermediodorsal nuclei, and in the paracentral nucleus posteriorly (Figure 23).  
Almost all cells retrogradely labeled from the PFC expressed Chrm4.  Expression levels 
of the cholinergic receptor transcript were subjectively moderate, being roughly 
comparable to the CA1 of the hippocampus and the retrosplenial cortex overlying the 
MD.  
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Figure 23. Chrm4 mRNA is found in mediodorsal thalamic projection neurons to 
the mPFC. Both MD neurons that project to the PFC (retrogradely labeled with CTB, in 
red) and MD neurons that do not innervate the PFC (open nuclei) express Chrm4 (green 
puncta).  Few if any of the thalamocortical neurons do not express the receptor transcript.   
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Discussion 
In Figure 16, we measured spontaneous excitatory postsynaptic currents (sEPSCs) 
in layer V mPFC pyramidal cells using whole-cell voltage clamp electrophysiology.  
Bath application of serotonin (5-HT) in this paradigm results in increased sEPSCs via 
enhanced presynaptic glutamate release from thalamocortical terminals (Aghajanian & 
Marek, 1999).  We hypothesized that M4 modulation on these terminals could potentially 
regulate glutamate release in the cortex, which was observed when VU0467154 was co-
applied with 5-HT.  This response was absent in tissue from M4 knockout animals 
(Figure 17).  These exciting data are consistent with previous reports by our group and 
others demonstrating that the selective mGlu2 PAM BINA and mGlu2/3 agonists also 
blocked increases in the frequency of sEPSCs in layer V pyramidal cells of the PFC 
induced by activation of 5-HT2A receptors on these presynaptic glutamatergic 
thalamocortical terminals in the PFC (Benneyworth et al., 2007). 
 
To confirm a role for M4 on thalamocortical terminals we recorded optically-
evoked excitatory postsynaptic currents (op-EPSCs) from layer V PFC pyramidal 
neurons following viral-mediated gene transfer of ChR2-EYFP in the midline thalamic 
nuclei before and after VU0467154 application (Figure 18), where M4 potentiation lead 
to a significant decrease in peak amplitude. To begin to address the synaptic locus of 
VU0467154 action, we analyzed the coefficient of variation (CV), which is inversely 
correlated with presynaptic release probability.   VU0467154 application increased the 
CV of the evoked responses consistent with the interpretation that potentiation of M4 
receptors inhibits thalamocortical neurotransmission through a presynaptic site of action. 
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Based on our findings in whole cell electrophysiology we hypothesized MK-801 
administration in vivo would result in dramatic changes in mPFC electrophysiological 
properties.  To test this hypothesis we dosed anesthetized rats with MK-801 and observed 
changes in firing rate of putative pyramidal neurons in layer V mPFC (Figure 19).  Pre-
treatment with VU0467154 was able to completely block this NMDAR antagonist-
induced increase in relative firing rate.  These data are consistent with our hypothesis that   
administration results in a disinhibition of the thalmocortical circuit, and likely others, but 
that M4 potentiation is sufficient to dampen the resulting changes in network excitability 
in vivo.  
Here we report deficits in spontaneous pyramidal cell activity in the layer V PFC 
of awake, free-moving NR1 KD mice in comparison with their wild-type littermate 
controls.  These findings revealed substantial increases in cortical pyramidal cell activity 
that are consistent with previous studies performed in rodents after acute administration 
of MK-801 or PCP, and which are known to be associated with deficits in cognitive 
performance and information-processing (Jackson et al., 2004). At present, the 
underlying mechanism(s) for this disinhibition of PFC activity in the NR1 KD mice 
remains unclear. However, based on NMDAR antagonist studies, one possible 
explanation may involve increased PFC activation resulting from disinhibition of 
thalamocortical circuitry, leading to excessive glutamate release and cortical excitability 
(Celada et al., 2013). If disruptions in normal signaling in this circuit are contributing to 
the observed changes in cortical electrophysiology, it is likely that VU0467154 
administration is attenuating this response based on the studies outlined above. However, 
there are additional mechanisms by which and M4 PAM could be eliciting these effects. 
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Previous reports indicate increases in activity in hippocampal-PFC inputs following 
NMDAR antagonist treatment (Jodo, 2013; Jodo et al., 2005; Kamiyama et al., 2011; 
Thomases et al., 2014). This, taken with reports that M4 PAMs can modulate 
hippocampal synaptic transmission (Shirey et al., 2008), suggests modulation of this 
circuit could also contribute to the observed efficacy in NR1 KD mice. Future studies 
will be conducted to directly investigate the potential for M4 PAMs to modulate 
thalamocortical and hippocampal-cortical in NR1 KD mice. 
Previous reports indicate excessive glutamatergic signaling in the prefrontal 
cortex in response to hallucinogen administration manifests as a stereotyped head twitch 
response in mice that is distinct from other stereotypical movements, such as rearing, ear 
scratching, and sniffing (Schreiber et al., 1995).  This is thought to be the result of 
activation of 5-HT2A receptors expressed presynaptically on thalamocortical afferents, 
demonstrated by loss of effect in 5-HT2A knockout mice, in the presence of 5-HT2A 
antagonists, and in thalamocortical lesion models (Gewirtz & Marek, 2000; Willins & 
Meltzer, 1997; Klodzinska et al., 2002).  In light of the in vivo and ex vivo 
electrophysiology data, experiments were designed to examine the effects of an M4 PAM 
in behavioral models of hyperglutamatergic signaling.  As Figure 20 demonstrates, the 5-
HT2A/2C agonist (±) DOI elicits a robust increase in head twitch response following 
systemic administration.  This response can be significantly attenuated with VU0467154 
pretreatment, suggesting M4 modulation is sufficient to affect glutamate signaling.  
Importantly, this response is consistent with previous reports that the mGlu2 PAM BINA 
can attenuate the head twitch response through a presynaptic mechanism (Benneyworth 
et al., 2007).  The effects of VU0467154 are absent in M4 knockout mice confirming the 
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observed behavioral responses are M4-dependent. To further assess the ability of an M4 
PAM to influence behavioral changes in response to hyperglutamatergic signaling in the 
PFC, an operant-based spatial alternation task was performed in WT mice.  Spatial 
learning tasks have been shown to heavily rely on normal signaling in the mPFC, and 
pharmacologic manipulations or lesions that disrupt this activity result in deficits in 
performance (Floresco et al., 1997; Kolb, 1984; Sargolini et al., 1999; Seamans et al., 
1995; Sutherland et al., 1982). 
Taken together, our data offer new evidence to support a broader role for M4 
modulation in the neural circuits mediating the affective and cognitive functions that are 
disrupted in neuropsychiatric disorders such as schizophrenia. 
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CHAPTER IV 
 
ENHANCED ACQUISITION OF A VISUAL TOUCHSCREEN PAIRWISE 
DISCRIMINATION TASK FOLLOWING REPEATED DOSING WITH THE M4 
PAM VU0467154 
 
Introduction 
 
Current antipsychotic medications (APDs) for schizophrenia primarily treat 
positive symptoms (hallucinations, delusions) yet are largely ineffective in treating the 
negative (anhedonia, social withdrawal, apathy) and cognitive symptoms (attention, 
memory, executive function) (Nuechterlein et al., 2004; APA, 2000; Barch & Ceaser, 
2012). Overall functional outcome in patients with schizophrenia has been positively 
linked to cognitive function (Bobes et al., 2007; Green et al., 2004; Green, 1996), 
suggesting that novel treatments to improve cognition may provide greater efficacy 
compared to currently available APDs. Accumulating evidence suggests that modulation 
of the muscarinic cholinergic system represents a potential target for developing novel 
APDs for the treatment of multiple symptom associated with schizophrenia (Jones et al., 
2012). Of the five different subtypes of muscarinic acetylcholine receptors (mAChRs), 
termed M1-M5 (Bonner et al., 1987; 1988), M1 and M4 mAChRs subtypes demonstrate 
substantial promise for antipsychotic-like potential (Jones et al., 2012). In clinical studies, 
the M1/M4-preferring mAChR agonist xanomeline reduced the psychotic symptoms and 
trended to improve cognition in patients with schizophrenia (Shekhar et al., 2008). 
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However, xanomeline, similar to other mAChR agonists, failed in clinical development 
due to dose-limiting adverse side effects attributed to nonspecific activation of peripheral 
mAChRs (McArthur et al., 2010).  
Targeting allosteric binding sites that are topographically distinct and less highly 
conserved than the classic orthosteric binding site represent one pharmacological 
approach for developing highly selective compounds for individual mAChR subtypes 
(Conn et al., 2009). Allosteric modulation does not activate a receptor directly, but can 
potentiate the response of a specific receptor subtype to ACh, thereby enhancing 
activity-dependent signaling (Conn et al., 2009). We have recently identified and 
characterized the antipsychotic-like potential of several positive allosteric modulators 
(PAMs) targeting the M4 mAChR subtype (Bubser et al., 2014; Byun et al., 2014; Brady 
et al., 2008). Selective M4 PAMs produce an APD-like profile in preclinical models of 
positive and cognitive symptoms as well as alter sleep architecture in a manner that may 
be beneficial in patients with schizophrenia (Brady et al., 2008; Bubser et al., 2014; Byun 
et al., 2014; Gould et al., 2016). Specifically, the M4 PAM VU0467154 reverses 
amphetamine and MK-801-induced hyperlocomotion, and MK-801-induced excessive 
increases in high frequency cortical gamma power (Bubser et al., 2014; Gould et al., 
2016). MK-801, an antagonist of the N-methyl-D-aspartate subtype of the glutamate 
receptor (NMDAR), models NMDAR hypofunction, which is hypothesized to underlie 
many of the symptoms in schizophrenia (Coyle et al., 2012; Blot et al., 2013; Anticevic et 
al., 2015). Although the M1 mAChR subtype has long been thought to be important for 
cognition, increasing evidence supports the role of M4 mAChRs for learning and 
memory. Importantly, we recently demonstrated that the M4 PAM VU0467154 blocks 
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MK-801 induced memory impairments and produces cognitive enhancing effects acutely 
when administered alone in conditioned freezing assays (Bubser et al., 2014). However, 
the effects of M4 PAMs on more complex assessments of learning and memory, and 
importantly, effects of repeated dosing remain unknown.  
In the present studies, we examined the effects of repeated dosing with the M4 PAM 
VU0467154 on learning a touchscreen-based visual pairwise discrimination task. We 
examined both rate of learning by comparing daily percent accuracy across 10 
consecutive testing days and acquisition, as defined by the number of days to achieve 
80% accuracy. When dosed prior to each discrimination session, VU0467154 dose-
dependently enhanced rate of learning and acquisition. VU0467154 administered for 10 
consecutive days attenuated MK-801-induced hyperlocomotion to a similar degree as a 
single administration, and plasma and brain concentrations following repeated dosing 
were similar to a single dose administration. Lastly, the cholinergic system has been 
implicated in multiple stages of learning and memory including acquisition or initial 
encoding as well as stabilization or consolidation of memories over longer periods of 
time, often associated with sleep-dependent mechanisms (Gais & Born, 2004; Hasselmo 
& Sarter, 2011). We examined M4 mAChR-mediated effects on acquisition versus 
consolidation by comparing administration of VU0467154 before or immediately after 
cognition sessions. Dosing immediately after cognition sessions produced qualitatively 
similar cognitive enhancing effects as dosing prior to each session, suggesting effects on 
cognition may in part be through consolidation of memory. Together these data further 
support a role for M4 mAChR in learning and memory and in the potential treatment of 
multiple symptom clusters associated with schizophrenia. 
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Methods 
Subjects. All behavioral studies were conducted with adult male wild-type mice (n=132) 
and M4 KO mice (n=17) with the same genetic background (C57BL/6NTac). Mice were 
group-housed 2-5 mice per cage in a temperature and humidity controlled environment 
under a 12/12 h light-dark cycle with water available ad libitum. 8-12 week old mice 
were used for all studies and gradually food restricted and maintained at ~85% free-
feeding weight prior to initiating all cognition studies. Cognition sessions occurred during 
the first 6 hr when the lights were on. All experiments have been carried out in 
accordance with the Guide for the Care and Use of Laboratory Animals as adopted and 
promulgated by the U.S. National Institutes of Health were approved by the Vanderbilt 
University Animal Care and Use Committee. 
 
Touchscreen training. Mice were trained in operant chambers (Lafayette Instruments, 
Lafayette, IN) to respond to stimuli presented on a computer screen by breaking an 
infrared beam in close proximity to the stimuli (e.g. a nosepoke) according to convention 
(for detailed methods see Horner et al., 2013; Bubser et al., 2014; Gould et al., 2015). 
Throughout training and testing, a mask was placed over the touchscreen such that 
responses could only be made in one of two (2x2 inch) windows on the screen. In brief, 
mice were trained over the course of 7-10 days to initiate each trial by emitting a 
response via a nose-poke in a receptable located on the wall opposite the touchscreen, 
turn, and to nose-poke on a stimulus appearing in one of the response windows, and then 
collect a liquid reward (33% diluted Ensure; 30 µl delivered via a peristaltic pump) from 
the same receptacle located on the opposite wall from the touchscreen. Trial availability 
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was signaled by illumination of a light within the receptacle, with a 5 sec inter-trial 
interval. Incorrect responses (nose-poke on a window without a stimulus) were signaled 
by extinguishing the houselight for 5 sec. Once mice reliably tracked and responded on 
the stimuli (>80% accuracy), they were assigned to treatment groups counterbalanced 
across the following variables based on the last day of training before initiation of the 
pairwise discrimination task: weight, accuracy, session length, correct response latency 
(average duration of time from trial initiation to a registered nosepoke on the stimulus) 
and reinforcer retrieval latency (average duration of time to make a head entry into the 
reward receptacle following a correct response)  
Pairwise Discrimination Task. To examine the role of M4 mAChR function on learning 
and memory processing we examined acquisition of a pairwise discrimination task. 
Following training mice were exposed to 10 consecutive daily cognition sessions in 
which two stimuli were pseudo-randomly presented on the left and right windows of the 
screen. Responding on one stimulus (S+, “fan”) resulted in delivery of a liquid reward 
followed by a 5 sec inter-trial interval (ITI); responding on the incorrect stimulus (S-, 
“marbles”) terminated the trial, extinguished the house light, and initiated the 5 sec ITI 
before the house light illuminated again to signal the next trial. “Correction trials” were 
not implemented following incorrect responses. Total sessions lasted 60 trials or a 
maximum of 60 min. For all cognition studies, effects of treatment (dose or dose group) 
were determined by a Two-Way ANOVA followed by a Dunnett’s or Tukey’s test 
comparing treatment to vehicle groups (Exp 1, 4) or comparing all groups to each other 
(Exp 3), respectively. 
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Experiment 1. Assessing role of M4 mAChRs on rate of learning and acquisition of a 
pairwise discrimination task. Following training wild-type mice were administered 
vehicle (10% Tween 80 in sterile H2O) or the M4 PAM VU0467154 (0.3, 1, 3 or 10 
mg/kg, synthesized within the Vanderbilt Center for Neuroscience Drug Discovery; 
(Bubser et al., 2014)) intraperitoneally (i.p.) 60 min prior to the start of each 
discrimination session for 10 consecutive days starting on day 1 of the pairwise 
discrimination task. Doses were based on previous studies showing cognitive enhancing 
effects or reversal of pharmacological-induced cognitive disruptions (Bubser et al., 
2014).  
To assess effects of repeated dosing of VU0467154 on plasma and brain 
concentrations, a subset of mice were administered vehicle or VU0467154 (1, 3, 10 
mg/kg) for 4 additional days after the last cognition session (14 days of dosing). 2.5 hr 
following administration on day 14 mice were lightly anesthetized with isoflurane, 
decapitated and trunk blood was collected and stored on ice in EDTA-coated blood 
collection tubes until centrifuged (10 min 3,000 RPM, 4 °C). Brains were extracted and 
flash frozen on dry ice. Plasma was collected and plasma and whole brain were stored at -
80°C until analysis. Total plasma and brain concentrations of VU0467154 were 
determined using LC-MS/MS methods as previously described (Bubser et al., 2014). 
Collection time point and procedures were identical to prior studies to compare present 
data with previously published data following acute administration (Bubser et al., 2014). 
Calculated unbound plasma and brain concentrations were determined based on plasma 
(0.022) and brain free fractions (0.014) (Bubser et al., 2014). Data are presented as mean 
+/- standard deviation (n=4-5/dose). 
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Experiment 2. Assessing effects of acute (1 day) versus repeated (10 days) dosing of 
VU0467154 on MK-801-induced hyperlocomotion. To determine if the 
pharmacodynamic effects of VU0467154 were altered by repeated dosing, we examined 
the ability of VU0467154 to attenuate MK-801-induced hyperlocomotion, a frequently 
used assay with predictive validity of antipsychotic-like activity. (Bubser et al., 2014; 
Anticevic et al., 2015; Coyle et al., 2012). Separate groups of mice were administered 
vehicle (n=23) or 10 mg/kg VU0467154 (n=12) for 9 consecutive days. On the following 
day (Day 10), half of the mice in the vehicle group were administered vehicle (n=11) and 
the other half was administered 10 mg/kg VU0467154 (acute group). The group that 
received 10 mg/kg VU0467154 for days also was administered 10 mg/kg VU0467154 on 
Day 10 (repeated dosing group). Effects of acute (1 day) versus repeated administration 
(10 days) of VU0467154 on MK-801-induced hyperactivity were examined using the 
following paradigm: Open field activity was tested using an open field system (OFA-510, 
MedAssociates, St. Albans, VT) with three 16 × 16 arrays of infrared photobeams as 
described previously (Bubser et al., 2014; Byun et al., 2014). Wild-type mice were 
habituated for 90 min in the open field before being injected with vehicle or 10 mg/kg 
VU0467154; 30 min later 0.3 mg/kg MK-801 were administered, and locomotor activity 
was recorded for an additional 120 min. Doses of VU0467154 and MK-801 were chosen 
based on previously determined full dose-response functions (Bubser et al., 2014). The 
time course of drug-induced changes in ambulation was expressed as total distance 
travelled (cm)/5 min over the entire 240-min session as well as total distance travelled in 
the 120 min following administration of MK-801. Total activity data (means±S.E.M.) 
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were analyzed by a one-way ANOVA and post hoc comparisons were made by 
Bonferroni’s test. 
 
Experiment 3. Confirming selectivity of VU0467154 for M4 mAChRs by examining rate of 
learning and acquisition of a pairwise discrimination task in wild-type and M4 KO mice. 
To confirm that the cognitive enhancing effects of VU0467154 were mediated by M4 
mAChRs separate groups M4 KO mice were administered vehicle or 3 mg/kg 
VU0467154 (dose producing largest cognitive enhancing effects in wild-type mice) prior 
to each of 10 consecutive cognition test days.  
Experiment 4. Assessing role of M4 mAChRs on acquisition versus consolidation of 
memory. To determine whether cognitive enhancing effects of VU0467154 were 
mediated by enhanced acquisition versus consolidation of memory, wild-type mice were 
trained as above and then separate groups were administered vehicle or 1 mg/kg 
VU0467154 60 minutes prior to the start or immediately upon completion of each 
discrimination session for 10 consecutive days starting on day 1 of the pairwise 
discrimination task. This dose was chosen as the lowest dose to improve cognition in 
Experiment 1 and based on a 4.7 elimination half-life following intraperitoneal dosing in 
mice, would be eliminated within 24 hr. Half of the vehicle-treated mice were dosed 
before, and the other after each session; percent accuracy between these vehicle-treated 
groups were not different and averaged together. 
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Results 
Experiment 1. Assessment of the effects of acute (1 day) versus repeated (10 days) 
dosing of VU0467154 on reversal of MK-801-induced hyperlocomotion. As shown in 
Figure 24, pretreatment with a dose of 10 mg/kg VU0467154 administered once (p<0.05) 
and after 10 days of repeated once-daily dosing significantly (p<0.01) attenuated MK-
801-induced hyperlocomotion when summed across the 120 minute period following 
MK-801 administration (F2,32=6.91, p<0.01); activity was not different between the two 
different VU0467154-treatment groups. 
Experiment 2. Assessment of the effects of repeated (10 days) dosing of VU0467154 
on rate of learning and acquisition of a pairwise discrimination task in wildtype mice. As 
shown in Figure 25A, on day 1 percent accuracy for all groups was near 50% (chance). 
For the overall data analysis, 4 of the total 59 mice tested were excluded; 2 mice that 
completed <20 trials per day and 2 mice that did not improve above 55% accuracy across 
the 10 days. Over the 10-day dosing period, there was a significant increase in percent 
accuracy (F9,450=71.48; p<0.0001), and a significant interaction between day and group 
(F36,450=1.92; p<0.01), but not a significant effect of dose (F4,50=2.52; p=0.053). 
Dunnett’s post-hoc analysis revealed that mice treated with 1 and 3 mg/kg VU0467154 
demonstrated a significant improvement in rate of learning, as shown by significantly 
higher percent accuracy on day 5 (1 mg/kg) and days 5 and 6 (3 mg/kg), compared to the 
vehicle-treated wildtype mice (all p<0.05). Daily IP administration of 0.3 and 10 mg/kg 
VU467154 did not improve rate of learning in wildtype mice compared to respective 
vehicle-treated mice, demonstrating a classic inverted-U-shaped dose-effect curve (see 
below).  To examine acquisition between treatment groups, the percent of each group that 
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acquired per test day (>80% accuracy) was plotted as a survival curve. As shown in 
Figure 25B, 50% and 80% of the mice treated with 1 and 3 mg/kg VU0467154 acquired 
this task in 5 and 6 days respectively, compared to 7 and 8 days for vehicle-treated mice.  
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Figure 24. Repeated once-daily dosing of 10 mg/kg VU0467154 attenuates MK-801-
induced hyperlocomotion on the 10
th
 day of dosing in wildtype mice. A) Distance 
travelled in cm travelled/5 min bins, and B) total distance traveled in the 120 minutes 
following MK-801 administration; n=11-12/group per treatment group; * p<0.05, ** 
p<0.01 compared to vehicle+MK-801 treatment group. All data shown as means (± 
SEM).  
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Figure 25. VU0467154 dose-dependently improves rate of acquisition of a pairwise 
discrimination task in mice when administered 60 minutes prior to each daily test 
session. A) Percent accuracy across the first 10 days of learning a PWD task. B) Percent 
of mice that reached acquisition criteria (>80% accuracy) across the 10 days of learning a 
PWD task. C) Total number of completed trials, D) session length, and E) average 
latency to respond for all correct trials, reward across 10 days of learning a PWD task; 
n=10-12 mice/group; open symbols, p<0.05 compared to vehicle-treated mice on the 
same day. All data shown as group average (± SEM). 
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Table 3. In vivo plasma and brain concentrations following repeated dosing of 
VU0467154. Arithmetic mean (± SD) of total and calculated unbound plasma and brain 
concentrations of VU0467154 in wildtype mice 2.5 hr after intraperitoneal administration 
of 1, 3 or 10 mg/kg VU0467154 once daily for 14 days; n = 4−5/ group. Kp, Kp,uu, total 
and calculated unbound brain/plasma partition coefficients. Mouse plasma and brain 
unbound fractions, 0.022 and 0.014, respectively. 
  
 
1 mg/kg 3 mg/kg 10 mg/kg 
 
total unbound total unbound total unbound 
plasma [nM] 
383.8    
(268.8) 
8.44 
(5.9) 
1239.7 
(539.0) 
27.3 
(11.9) 
3034.3 
(1350.8) 
66.8 
(29.7) 
brain [nM] 
84.3 
(0.5) 
1.2 
(0.01) 
159.1 
(62.4) 
2.2 
(0.9) 
304.8 
(145.5) 
4.2 
(2.0) 
Kp 
Kp, uu  
0.22 
0.14  
0.13 
0.08  
0.10 
0.06 
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We also examined the number of completed trials, overall session length, average 
response latency on correct trials and average reinforcer retrieval latency to provide 
measures of motor function or motivation to respond that may indirectly influence 
learning. As shown in Figure 25C, there was a significant effect of dose (F4,499=18.96, 
p<0.0001) and day (F9,499=2.70, p<0.01) on number of trials completed. As shown in 
Figure 25D, there was a significant effect of dose (F4,499=43.63, p<0.0001) and day 
(F9,499=12.34, p<0.0001) on session length such that treatment with VU0467154 
increased total session length (open symbols significantly different from vehicle, p<0.05). 
There was also a significant effect of dose (F4,498=1.88, p<0.0001) on correct response 
latency (Figure 25E), such that 10 mg/kg VU0467154 significantly increased latency. 
Similarly, there was a significant effect of dose (F4,497=7.27, p<0.0001) and day 
(F9,497=2.12, p<0.05) on reinforcer retrieval latency such that 10 mg/kg increased latency, 
while lower doses did not affect retrieval latency (data not shown). Significant effects of 
post-hoc comparisons between respective treatment group compared to vehicle-treated 
mice within each day are denoted by open symbols (p<0.05). In general, effects were 
dose-dependent and driven by the 10 mg/kg treatment group, suggesting that at the 
highest dose tested, nonselective disruptive effects on motor output or motivation may 
contribute to lack of cognitive enhancing effects; however, tolerance developed to these 
disruptive effects across the 10 days.  
This study represents the first characterization of the effects of repeated 
administration of an M4 PAM on measures of cognition. To confirm that effects on 
memory were not influenced by pharmacokinetic factors (e.g. cytochrome P450 
autoinduction or steady-state accumulation), a subset of mice from this pairwise 
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discrimination study was administered VU0467154 for an additional 4 days (total 14 days 
of dosing), followed by measurement of plasma and brain levels of VU0467154 at 2.5 hr 
(after the last dose). As shown in Table 3, repeated dosing of 1, 3, and 10 mg/kg 
VU0467154 produced 1.2, 2.2, and 4.2 nM calculated unbound brain concentrations. The 
2.5 hr post-final dosing time point was chosen to correspond with the previously reported 
time point for assessment of plasma and brain concentrations following a single 
administration of 1, 3, and 10 mg/kg VU0467154 in mice, which resulted in 1.0, 2.2, and 
5.6 nM calculated unbound brain concentrations (Bubser et al., 2014). Thus, 10 day of 
repeated dosing produced plasma/brain concentrations similar to those observed from a 
single dose of VU0467154, consistent with the once daily dosing interval (24 hr) 
encompassing ≥5 half-lives, and thereby precluding steady-state accumulation. 
Experiment 3. Assessment of the effects of repeated (10 days) dosing of 
VU0467154 on rate of learning and acquisition of a pairwise discrimination task in M4 
KO mice. To determine whether enhancement of the rate of learning a pairwise 
discrimination task by VU0467154 was mediated through potentiation of M4 mAChRs, 
we administered vehicle or 3 mg/kg VU0467154 60 minutes before test sessions for 10 
consecutive days in M4 KO mice. As shown in Figure 26A, over the 10-day period, there 
was a significant increase in percent accuracy (F9,135=16.76; p<0.0001), but no effect of 
treatment. There were no days on which VU0467154-treated mice differed from vehicle-
treated mice (all p>0.05). As shown in Figure 26B by day 10, 30% of the vehicle-treated 
mice and 60% of the VU0467154-treated mice acquired the discrimination within 10 
days. 2 of the total 19 mice that did not improve above 55% accuracy across the 10 days 
were excluded from overall data analysis. There was a significant effect of day 
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(F9,135=32.16, p<0.0001) on session length (Figure 26C) and significant effects of dose 
(F1,149=11.32, p<0.01) and day (F9,149=2.19, p<0.05) on correct response latency (Figure 
26D); both measures decreased across sessions and were not different between treatment 
groups. There were no differences in number of trials completed or reinforcer retrieval 
latency between groups.  
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Figure 26. VU0467154 does not improve rate of acquisition of a pairwise 
discrimination task in M4 KO mice when administered 60 minutes prior to each 
daily test session. A) Percent accuracy across the first 10 days of learning a PWD task. 
B) Percent of mice that acquired (>80% accuracy) across the 10 days of learning a PWD 
task. C) Average total session length,  D) average latency to respond for all correct trials 
across 10 days of learning a PWD task; n=7-10 mice/group. All data shown as group 
average (± SEM). 
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Experiment 4. Assessment of the effects of repeated (10 days) dosing of 
VU0467154 on acquisition versus consolidation of a pairwise discrimination task in 
wildtype mice. To determine whether enhancement of the rate of learning a pairwise 
discrimination task by VU0467154 was through acquisition or consolidation of memory, 
we administered 1 mg/kg VU0467154 60 minutes before or immediately after each 
session for 10 consecutive days. As shown in Figure 27A, over the 10-day period, there 
was a significant increase in percent accuracy (F9,205=26.11; p<0.0001), and a significant 
effect of dose/time of dosing (F2,205=18.08; p<0.0001). Dunnett’s post-hoc analysis 
revealed that mice treated with 1 mg/kg VU0467154 before daily sessions demonstrated a 
significant improvement in rate of learning, as shown by significantly higher percent 
accuracy on days 3-5. Mice treated with 1 mg/kg VU0467154 after each session 
demonstrated a significant improvement on day 3, compared to the vehicle-treated 
wildtype mice (all p<0.05); there were no significant differences between groups treated 
with VU0467154. As shown in Figure 27B, 50% of mice dosed with VU0467154 before 
and after daily sessions acquired the discrimination on days 3 and 4, respectively, 
compared to 6 days in the vehicle-treated group.  
There was a significant effect of dose (F2,205=13.64, p<0.0001) and day 
(F9,205=2.76, p<0.01) on correct response latency (Figure 27C) and a significant effect of 
dose (F2,204=8.83, p<0.001) and day (F9,204=3.10, p<0.05) on reinforcer retrieval latency 
(Figure 27D). Correct response latency was higher in mice treated with VU0467154 
before the session on day 3 compared to post-session VU0467154 or vehicle-treated 
groups (p<0.05). Reinforcer retrieval latency was higher on day 3 in mice administered 
VU0467154 before the session compared to vehicle (p<0.05) (not shown). However, 
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similar to data in Experiment 2 (Figure 25), significant effects on latency were driven by 
decreases across the 10-day period. There were no differences in number of trials 
completed or overall session length between groups.   
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Figure 27. VU0467154 improves rate of acquisition of a pairwise discrimination task 
in wildtype mice (A, B) when administered 60 minutes prior to (red squares) or 
immediately following (green triangles) each daily test session. A) Percent accuracy 
across the first 10 days of learning a PWD task. B) Percent of mice that acquired (>80% 
accuracy) across the 10 days of learning a PWD task. C) Average latency to respond for 
all correct trials, D) and average latency to retrieve the reinforcer after each correct trial 
across 10 days of learning a PWD task; n=8 mice/group; open symbols, p<0.05 compared 
to vehicle-treated mice on the same day. All data shown as group average (± SEM). 
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Discussion 
Selective activation of M4 mAChRs represents an important novel mechanism for 
the potential treatment of multiple symptom clusters associated with schizophrenia, 
including positive symptoms and cognitive impairments. Given the dearth of M4-
selective ligands with suitable pharmacokinetic properties for in vivo use until recently, 
all previous preclinical studies have focused on evaluations of efficacy using acute dosing 
paradigms. The present studies provide the first demonstration that there is no 
development of tolerance to the antipsychotic-like activity and cognitive enhancing 
effects of M4 PAMs after 10 days of repeated dosing.  These studies confirm and extend 
accumulating evidence supporting future development of selective M4 PAMs for the 
treatment of positive symptoms and cognitive deficits observed in various 
neuropsychiatric disorders, such as schizophrenia. 
The current validation of M4 PAM efficacy under conditions of repeated dosing 
provides a greater degree of translatability to support future clinical dosing approaches. 
Previous reports suggested a lack of cytochrome P450 induction by VU0467154 and that 
little or no accumulation at steady-state would occur from a once daily administration 
schedule. To confirm this, the brain and plasma concentrations of VU0467154 after 14 
days of chronic dosing were measured as a control and found to be comparable to the 
levels (and brain:plasma distribution ratios) observed in previously reported studies by 
our group after acute administration of VU0467154 (see Table 3 from,  Bubser et al., 
2014). These pharmacokinetic findings confirmed that the observed efficacy with 
VU0467154 after repeated administration was not due to changes in exposure levels 
resulting from drug accumulation or from potential alterations in the metabolism of 
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VU0467154 through cytochrome P450 induction after chronic dosing. 
The present findings also provide the first report of improved cognitive 
performance in a preclinical learning and memory task over multiple days through 
selective potentiation of M4 mAChRs with repeated dosing of VU0467154. These 
findings with VU0467154 build on several previously reported studies that examined the 
acute effects of M4 mAChR potentiation on cognition. In particular, the M4 PAM 
VU0152100 enhanced performance in a version of an object recognition task following a 
5 min delay (Galloway et al., 2014), and VU0467154 enhanced cue-mediated conditioned 
freezing following a 24-hr delay, two classic preclinical models of working and long-
term memory, respectively (Bubser et al., 2014). VU0467154 also blocked MK-801-
induced impairments on a contextual conditioned freezing task following a 24-hr delay 
and impairments on a pairwise discrimination task following acquisition (Bubser et al., 
2014). By assessing alterations in the acquisition of pairwise discrimination task induced 
by VU0467154 over multiple days, we controlled for several sources of variability often 
associated with acute cognition studies, including individual differences and fluctuations 
in baseline performance, or introduction of a cognitive disruptor to artificially increase 
signal window to examine cognitive enhancing effects. As shown in the dose-response 
determination (Exp 2) and follow-up study (Exp 4), VU0467154 significantly improved 
rates of learning and acquisition by 2-3 days in both experiments, demonstrating 
reproducibility of a robust improvement on memory with chronic dosing. Importantly, 
these improvements in cognitive performance were absent in the M4 KO mice, indicating 
that the effects of VU0467154 are mediated through actions at M4 mAChRs. 
An additional advantage for using operant cognition paradigms is the ability to 
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examine multiple dependent variables that can influence cognitive performance. For 
example, consistent with many cognition studies (Bentley et al., 2011), VU0467154 
engendered an “inverted-U” dose response curve such that administration of 10 mg/kg 
did not improve cognition. This dose decreased the number of trials completed and 
increased total session duration, suggesting that 10 mg/kg VU0467154 indirectly 
influenced the outcome of cognitive performance (e.g. motoric, motivational effects). It is 
important to note that the present cognitive enhancing effects occur at dose ranges 
providing calculated unbound concentrations below the in vitro EC50 (~18 nM). 
Interestingly, the dose-exposure range producing cognition-enhancing effects overlaps 
with the low end of the range in which we have previously demonstrated antipsychotic-
like effects in preclinical models of the positive symptoms of schizophrenia (Bubser et 
al., 2014). Two explanations for the differing dose ranges between these effects include 
treatment with the M4 PAM alone versus reversing pharmacological disruptions, and 
divergent circuitry (e.g. mesolimbic versus mesocortical) underlying these processes as 
well as likely differences in M4 receptor expression levels and receptor reserve that may 
influence the effects of VU0467154.  
Understanding the potential mechanism(s) through which potentiation of M4 
activity by VU0467154 improves performance in the pairwise discrimination task holds 
potential promise for advancement of novel treatment approaches for the cognitive 
impairments in schizophrenia.  Currently available typical and atypical APDs provide 
little, if any, therapeutic effects for the cognitive deficits observed in individuals with 
schizophrenia, and, in many cases, may actually further exacerbate cognitive disruptions 
(Price et al., 2014; Miyamoto et al., 2012). M4 mAChRs are expressed throughout limbic 
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and cortical brain regions, including the striatum, hippocampus, and cortex, (Levey et al., 
1991; Hersch & Levey, 1995; Rouse et al., 1999) and can function as autoreceptors in the 
striatum and midbrain (Zhang et al., 2002; Tzavara et al., 2004), as well as postsynaptic 
modulatory receptors in the striatum, neocortex, and hippocampus (Levey et al., 1991; 
Zang & Creese, 1997). For example, potentiation of M4 mAChRs can selectively 
potentiate mAChR-mediated reductions in glutamatergic, but not GABAergic, 
neurotransmission in hippocampal neurons (Shirey et al., 2008), suggesting a possible 
key role for M4 in regulating hippocampal function that may mediate the improved 
acquisition of the present learning and memory task observed with VU0467154.  
Alternatively, effects of M4 mAChR potentiation on enhancing memory, the only 
cognitive domain examined to date, may in part be mediated through mechanisms of 
consolidation versus specific memory encoding or acquisition. While enhanced 
muscarinic cholinergic function is critical for acquisition of new memory formation, 
previous preclinical and clinical studies have demonstrated that decreased cholinergic 
tone is critical for memory consolidation, particularly sleep-dependent memory 
consolidation (Gais & Born, 2004; Hasselmo & Sarter, 2011; Gais & Born, 2004). For 
example, scopolamine, a nonselective mAChR antagonist, has shown differential effects 
on memory using a conditioned freezing paradigm depending on the time of dosing 
relative to the training conditions. When administered prior to training, scopolamine 
disrupts memory retention 24 hr later (affecting acquisition of memory), yet when 
administered after the training period, facilitates memory retention, presumably through 
enhancing memory consolidation (Rasch et al., 2006; Winters et al., 2006). Declarative 
memory, one of the most disrupted cognitive domains in schizophrenia (Green et al., 
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2000), is improved following slow wave-rich sleep compared to rapid eye movement-rich 
sleep in healthy subjects (Plihal & Born, 1997). Moreover, declarative memory is 
improved by increasing slow wave activity during slow wave sleep via transcranial direct 
current stimulation in patients with schizophrenia (Goder et al., 2013). Furthermore, we 
have recently shown that, in healthy rats, VU0467154 dose-dependently increases the 
ratio of slow wave sleep to rapid eye movement sleep (Gould et al., 2016).  
In the present studies, we specifically examined potential M4-mediated effects on 
memory consolidation versus acquisition in the pairwise discrimination task by 
administering 1 mg/kg VU0467154 either one hr prior to or immediately following test 
sessions. Following this dosing paradigm, mice receiving VU0467154 prior to each 
session would have peak concentrations of VU0467154 in the brain at the initiation of the 
session (Tmax = 1 hr based on previous mouse IP PK studies). Given the moderate 
elimination half-life in this species (4.7 hr), these mice still possess pharmacologically 
relevant concentrations of VU0467154 in the brain for several hours after the session. 
Mice are nocturnal, and spend a large percentage of time sleeping during light periods. 
Since these studies were conducted during the light phase, mice presumably cycled in and 
out of sleep after each daily test session, while relevant concentrations of VU0467154 
were present in the brain. Thus, VU0467154 may be affecting memory acquisition 
(during task performance) as well as consolidation (period directly after task performance 
thought to last ~1-6 hrs). However, in mice dosed immediately after the session, 
VU0467154 only affected memory consolidation. Importantly, results observed with 
dosing after each session were not quite as robust as results observed with dosing prior to 
each session, suggesting potential effects on both memory acquisition and consolidation. 
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While not yet available, confirmation of these effects using an equipotent M4 PAM 
possessing a shorter elimination half-life, or administering an M4 selective antagonist 
immediately after test sessions, will be important for future studies. Collectively, these 
data provide compelling evidence that selective potentiation of M4 mAChRs enhances 
learning and memory, in part through memory consolidation. Ongoing studies are 
currently investigating the impact of selective potentiation of M4 mAChRs by 
VU0467154 on additional cognitive domains, including attention and executive function 
that are reported to be impaired in patients with schizophrenia. 
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CHAPTER V 
SELECTIVE POTENTIATION OF M1 MUSCARINIC ACETYLCHOLINE 
RECEPTORS AMELIORATES ELECTROPHYSIOLOGIC AND BEHAVIORAL 
DEFICITS IN A GENETIC MODEL OF NMDAR HYPOFUNCTION 
Introduction 
Multiple lines of evidence suggest that disruptions in the normal signaling of the 
N-methyl-D-aspartate subtype of the glutamate receptor (NMDAR) may underlie many of 
the symptoms associated with schizophrenia, particularly the cognitive 
impairments(Balu, 2016; Kantrowitz & Javitt, 2010; Kantrowitz & Javitt, 
2010).  Previous studies have demonstrated that acute or chronic administration of 
noncompetitive NMDAR antagonists, including phencyclidine (PCP) and ketamine, 
induce psychotic-like symptoms and cognitive impairments in animals and healthy 
individuals and exacerbate symptoms in patients with schizophrenia (see review by 
(Balu, 2016; Krystal et al., 1994)).  Recent copy number variation analysis studies have 
identified numerous de novo mutations in genes encoding the NMDAR and other proteins 
within the glutamatergic postsynaptic density associated with increased risk of 
schizophrenia (Fromer et al., 2014; Kirov et al., 2012; Purcell et al., 2014). Postmortem 
studies have also revealed reductions in the mRNA and protein expression of the NR1 
subunit of the NMDAR in the prefrontal cortex (PFC) of individuals with schizophrenia 
(Catts et al., 2016).  Moreover, studies using genetic models with deletion or knockdown 
(KD) of the GluN1 subunit of the NMDAR, either globally or constitutively in 
parvalbumin inhibitory neurons, cortical and hippocampal interneurons, or cortical 
pyramidal neurons have reported abnormalities in various physiologic measures, 
129 
 
 
 
including changes in gamma band oscillations, and impairments in social and cognitive 
performance similar to many of the symptoms observed in schizophrenia (Belforte et al., 
2010; Jadi et al., 2016; Tatard-Leitman et al., 2015; Mohn et al., 1999; Milenkovic et al., 
2014; Gregory et al., 2013). Taken together, targeting abnormalities in NMDAR function 
represents a critical strategy for the treatment of the complex symptoms associated with 
schizophrenia. 
Development of ligands that selectively target the M1 muscarinic acetylcholine 
receptor (mAChR) subtype represents an important approach for modulating NMDAR 
function and could lead to potential therapeutic interventions for schizophrenia (Jones et 
al., 2012), The M1 mAChR subtype is one of the five different mAChR subtypes, termed 
M1-M5 (Bonner et al., 1987; Bonner et al., 1988), which are G-protein-coupled receptors 
(GPCRs) activated by the neurotransmitter acetylcholine (ACh).  M1 is highly expressed 
across many forebrain regions implicated in the pathophysiology of schizophrenia, 
including the striatal complex, all layers of the cortex, and postsynaptically on the 
dendrites and cell bodies of hippocampal granule cells and pyramidal neurons (Levey et 
al., 1995; Levey et al., 1991; Marino et al., 1998; Rouse et al., 1998; Rouse et al., 1999). 
Postmortem studies have reported that M1 mAChR expression is reduced in the PFC, 
hippocampus, and other forebrain regions of a subset of patients with schizophrenia 
(Dean et al., 2002; Gibbons et al., 2013; Scarr et al., 2013).  More importantly, previous 
studies have shown that M1 is both physically and functionally coupled to NMDARs and 
activation of M1 potentiates NMDAR currents in cortical and hippocampal pyramidal 
cells, increases excitatory postsynaptic currents in PFC neurons, and enhances 
performance in several preclinical learning and memory tasks (Gould et al., 2015; 
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Ghoshal et al., 2016; Jones et al., 2012; Shirey et al., 2009; Sur et al., 2003; Jones et al., 
2008; Digby et al., 2012).  Conversely, M1 knockout (KO) mice have impaired 
performance in medial prefrontal cortex (PFC)-dependent cognitive tasks and reduced 
hippocampal long-term potentiation (LTP) (Anagnostaras et al., 2003; Gould et al., 2015; 
Bartko et al., 2011; Miyakawa et al., 2001). While clinical studies with selective M1 
ligands have been limited, studies with the M1/M4-preferring mAChR agonist 
xanomeline produced robust efficacy in reversing psychotic symptoms and behavioral 
disturbances, with some modest effects on cognitive impairments, in both schizophrenia 
and Alzheimer’s disease patient populations (Bodick et al., 1997a; Bodick et al., 1997b; 
Shekhar et al., 2008). Unfortunately, xanomeline, similar to other orthosteric mAChR 
agonists, failed to progress in clinical development due to dose-limiting adverse effects 
from nonselective activation of other mAChR subtypes (Bymaster et al., 2002).  
Over the last decade, we and others have developed subtype-selective M1 mAChR 
ligands; these compounds do not target the orthosteric binding site of acetylcholine 
(ACh) that is highly conserved across all five mAChR subtypes, but rather act at more 
topographically distinct allosteric sites (Digby et al., 2012; Jones et al., 2008; Jones et al., 
2012).  In particular, our group and others have now reported the discovery and extensive 
optimization of multiple novel chemical series of highly selective M1 positive allosteric 
modulators (PAMs) which enhance the efficacy and/or affinity of the endogenous 
neurotransmitter Ach (Bridges et al., 2010; Bridges et al., 2010; Bridges et al., 2010; 
Marlo et al., 2009; Melancon et al., 2013; Shirey et al., 2009; Ma et al., 2009; Mistry et 
al., 2013; Uslaner et al., 2013).  Earlier generation M1 PAMs served as important tool 
compounds for the in vitro characterization of the molecular and slice-based physiologic 
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activity of selective M1 potentiation, but provided limited utility for animal studies due to 
poor central penetration (Kuduk et al., 2010; Kuduk et al., 2010; Kuduk et al., 2011; 
Shirey et al., 2009; Thomsen et al., 2012).  Using several second generation M1 PAMs 
with more favorable pharmacokinetic (PK) properties for in vivo dosing,  selective 
potentiation of M1 has been reported to reverse pharmacologically induced deficits and/or 
improve normal performance on many measures of learning, memory and top-down 
prefrontal  processing in rodents and nonhuman primates (Ma et al., 2009; Gould et al., 
2015; Chambon et al., 2012; Chambon et al., 2011; Galloway et al., 2014; Uslaner et al., 
2013; Ghoshal et al., 2016; Shirey et al., 2009; Reid et al., 2011; Poslusney et al., 2013; 
Panarese et al., 2016).  For example, the M1 PAM BQCA robustly enhanced the synaptic 
excitation of pyramidal cells in the PFC and improved PFC-mediated cognitive functions, 
including performance in attentional set shift tasks (Shirey et al., 2009). More recently, 
we reported the discovery of the selective M1 PAM VU0453595 that enabled further 
characterization of the role of M1 on PFC-mediated synaptic plasticity, cognitive function 
and social interaction. Specifically, VU0453595 reversed chronic PCP-induced 
disruptions in muscarinic long term depression (mLTD) in the PFC and corresponding 
deficits in novel object and social recognition tasks (Ghoshal et al., 2016).  However, to 
date the progress in understanding the role of M1 modulation in PFC-mediated 
physiology and behavior relevant to schizophrenia has been achieved using only acute 
and chronic NMDAR antagonist challenge approaches in adult animals.  
Recent development of several genetic models of reduced NMDAR activity have 
provided important in vivo systems for studying changes in relevant cortical and limbic 
circuitry comparable to those observed in schizophrenia  (see (Balu, 2016; Ferris et al., 
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2014; Milenkovic et al., 2014; Ramsey, 2009; Belforte et al., 2010; Jadi et al., 2016; 
Tatard-Leitman et al., 2015)).  While the null mutation of grin1, the gene encoding the 
NR1 subunit of NMDARs, is lethal, a hypomorphic or partial loss-of-function mutation 
of grin1 results in an NR1 subunit knockdown (NR1 KD) mouse that is still viable, but 
displays only 10-15% of the wild-type levels of NMDARs and exhibits severe behavioral 
and physiologic impairments, many of which are consistent with those induced by acute 
and/or chronic NMDAR antagonist challenge (Ramsey, 2009).  We and others have 
reported that NR1 KD mice display increased locomotor and stereotypic behaviors that 
can be reduced with antipsychotic drugs and a novel metabotropic glutamate receptor 
subtype 5 (mGlu5) PAM, as well as severe impairments in social interactions and 
cognition (Ramsey, 2009; Gregory et al., 2013).  In the present studies, we specifically 
evaluated PFC-mediated physiologic and cognitive functions in NR1 KD mice. We first 
used slice-based extracellular field potential recordings and found deficient muscarinic 
agonist-induced LTD in layer V of the PFC in NR1 KD mice.  Using in vivo 
electrophysiological recordings in awake, freely moving NR1 KD mice, we report 
excessive pyramidal neuron firing in layer V PFC neurons.  NR1 KD mice were also 
impaired in their responses in two preclinical models of PFC-mediated learning and 
memory, the novel object recognition and cue-mediated fear conditioning tasks. 
Importantly, we report the ability of the novel and highly potent M1 PAM VU6004256 to 
reverse these selective PFC-mediated abnormalities in synaptic plasticity, in vivo 
physiology, and behavior in NR1 KD mice. 
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Methods 
Chemicals. VU6004256 (4,6-difluoro-N-(1S,2S)-2-hydroxycyclohexyl-1-((6-(1-
methyl-1H-pyrazol-4-yl)pyridine-3-yl)methyl)-1H-indole-3-carboxamide) and 
VU0453595 (Ghoshal et al., 2016; Panarese et al., 2016) were synthesized in-house and 
dissolved in DMSO for slice physiology studies or 10% Tween 80 in sterile water for in 
vivo studies. Carbachol (Sigma, St. Louis, MO) stocks were prepared in water and all 
other compound stocks were prepared in DMSO. For field recording experiments, all 
drugs were diluted in artificial cerebrospinal fluid (ACSF) (0.1% DMSO final conc.) and 
bath applied. All chemicals were obtained from Sigma (St. Louis, MO). 
 
Animal Care and Housing.   
All in vivo studies were carried out using age-matched adult male NR1 KD mice 
with a C57B1/6J and 129X1/SvJ crossed background and wild-type littermate controls 
(described previously by (Mohn et al., 1999; Milenkovic et al., 2014; Gregory et al., 
2013)). Animals were group-housed under a 12/12 h light-dark cycle (lights on at 6 AM) 
with food and water available ad libitum unless stated elsewhere. All animal experiments 
were approved by the Animal Care and Use Committees of Vanderbilt University and 
University of Toronto, and experimental procedures conformed to guidelines established 
by the National Research Council Guide for the Care and Use of Laboratory Animals. 
All efforts were made to minimize animal suffering and the number of animals used. 
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Novel Object Recognition Task 
Mice were placed in a dark blue novel object recognition arena (32 X 32 X 40 
cm) and allowed to habituate for 10 minutes.  On the following day, mice were injected 
with either vehicle (10% tween 80) or VU6004256 (3 mg/kg or 10 mg/kg, i.p.) and 
returned to their home cages for 5 minutes.  Mice were then placed in the novel object 
recognition arenas with 2 identical objects for 10 minutes.  Following the initial 
exposure, mice were placed in their home cages for 1 hour.  Upon completion of the 1 
hour period, mice were returned to the arenas and one of the familiar objects was 
replaced with a novel object.  Mice were recorded for 10 minutes and data were scored 
by 2 observers blinded to experimental conditions.  Recognition index scores were 
calculated using the following equation:  (seconds spent exploring novel object – seconds 
spent exploring familiar object)/total time exploring either object.  
 
Locomotor Activity Studies in Mice 
Spontaneous locomotor activity was assessed in 8-10 week old wild-type and NR1 KD 
mice.  Animals were placed in an open field system (OFA-510, MedAssociates, St. 
Albans, VT) with three 16 × 16 arrays of infrared photobeams as described previously 
(Byun et al., 2014). Mice were allowed to habituate in their home cage for one hour prior 
to the start of the experiment.  Following the habituation period, mice were injected with 
either vehicle (10% tween 80, i.p.) or a dose of VU6004256 (1 mg/kg or 10 mg/kg, i.p.) 
and placed directly into the open field chambers.  Spontaneous locomotor activity was 
recorded for 90 minutes.  The time course of drug-induced changes in spontaneous 
locomotor activity is expressed as distance traveled (cm) per 5 minute bin for the 90 
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minute session.  Total activity data represent the sum of all 5 minute bins for the 
recording session.  Data are represented as mean ± SEM and were analyzed using two-
way ANOVA with Bonferroni’s post hoc test. 
 
In Vivo Electrophysiology 
The method was a modified version of that described in (Walker et al., 2008).  
Mice anesthetized with isoflurane were secured on a stereotaxic apparatus and a 
craniotomy was performed at AP(+1.7 mm) ML(+0.5 mm).  The electrode bundle was 
composed of eight 25 μm Formvar-insulated stainless-steel wires for recording single 
units and two 50 μm uninsulated stainless-steel ground wires, one of which served as a 
depth reference electrode.  The bundle length was 2.5 mm, allowing for recording of 
prelimbic mPFC pyramidal cells when the array is fixed to the skull with dental acrylic.  
Mice are allowed to recover 5-7 days before entering the recording arena. All recordings 
took place between 12pm and 4pm.  A wire harness attached to a headstage containing 
unity gain amplifiers was secured to the electrode array and mice were allowed to explore 
the chamber for fifteen minutes prior to the initiation of baseline recording.  Animals 
were placed in a chamber equipped with a Faraday cage and attached to an electric 
commutator which allowed for unrestricted movement during the in vivo recording.   
Neuronal discharges were acquired by the Multichannel Acquisition Processor (MAP) 
system following preamplification (Plexon Inc, Dallas, TX). To detect spiking activity, 
signals were bandpass filtered (154 Hz to 8.8 kHz) and digitized at a rate of 40 kHz. 
After establishing a voltage threshold ≥2.5 times background noise, waveforms were 
continuously collected and principal component analysis was used to discriminate 
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putative pyramidal neurons from fast-spiking interneurons. All recording sessions lasted 
for 75 minutes.  Baseline firing rate was assessed during the final 5 minutes of the 
baseline collection period (30 minutes), and the effects of vehicle (10% tween 80, i.p.) or 
VU6004256 (10 mg/kg , i.p.) were assessed during the final 5 minutes of the drug 
treatment period (45 minutes).  Data are expressed as mean frequency during each period 
or as a percent of baseline and significance is determined using a paired t-test.  
 
Extracellular Field Potential Recordings  
8-10 week old male NR1 KD or wild-type littermate control mice were 
anesthetized with isofluorane, and the brains were removed and submerged in ice-cold 
cutting solution (in mM: 230 sucrose, 2.5 KCl, 8 MgSO4, 0.5 CaCl2, 1.25 NaH2PO4, 10 
D-glucose, 26 NaHCO3).  Coronal slices containing the prelimbic prefrontal cortex were 
cut at 400 µm using a compresstome (Precisionary Instruments, Greenville, NC).  Slices 
were transferred to a holding chamber containing NMDG-HEPES recovery solution (in 
mM: 93 NMDG, 2.5 KCl, 1.2 NaH2PO4, 30 NaHCO3, 20 HEPES, 25 D-glucose, 5 
sodium ascorbate, 2 thiourea, 3 sodium pyruvate, 10 MgSO4, 0.5 CaCl2, 12 N-acetyl-L-
cysteine, pH 7.3, <310 mOsm) for 15 minutes at 32 ºC.  Slices were then transferred to a 
room temperature holding chamber for at least 1 hour containing ACSF (in mM: 126 
NaCl, 1.25 NaH2PO4, 2.5 KCl, 10 D-glucose, 26 NaHCO3, 2 CaCl2, 1 MgSO4) 
supplemented with 600 µM sodium ascorbate for slice viability.  All buffers were 
continuously bubbled with 95% O2/5% CO2.  Subsequently, slices were transferred to a 
32 ºC submersion recording chamber where they were perfused with ACSF at a rate of 2 
mL/min.  Borosilicate glass electrodes were pulled using a Flaming/Brown micropipette 
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puller (Sutter Instruments) and had a resistance of 2-4 MΩ when filled with ACSF. 
Sampled data was analyzed offline using Clampfit 10.2 (Molecular Devices, Sunnyvale, 
CA). The slopes from three sequential sweeps were averaged.  All slopes calculated were 
normalized to the average slope calculated during the pre-drug period (percent of 
baseline).  Data were digitized using a Multiclamp 700B, Digidata 1322A, and pClamp 
10 software (Molecular Devices).  Input-output curves were generated to determine the 
stimulation intensity that produced 50-60% of the maximum response before each 
experiment, which was used as the baseline stimulation. A minimum of 10 min stable 
baseline was recorded before application of any drugs. 50 and 10 µM carbachol was 
applied for 10 min to induce saturated and threshold form of muscarinic LTD in the 
prefrontal cortex. M1 PAM VU6004256 was treated alone for 10 min immediately 
followed by co-application with carbachol. Carbachol (Sigma, St. Louis, MO) stocks 
were prepared in water and all other compound stocks were prepared in DMSO. All 
drugs were diluted in ACSF (0.1% DMSO final conc.) and bath applied. 
 
Fear Conditioning 
Contextual- and cued-mediated conditioned freezing. Studies were conducted 
using conditioning chambers in sound attenuating cubicles equipped with a stainless steel 
grid floor for shock delivery and a video camera for recording freezing behavior 
(MedAssociates, Allentown, NJ). To assess ability of NR1 KD mice to learn both 
contextual and cue-mediated associative learning, we conducted studies across a 72 h 
period, with initial training occurring on Day 1, testing of contextual conditioned freezing 
on day 2, and testing cue-mediated conditioned freezing on Day 3. Wildtype and NR1 
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KD mice were handled for three days prior to study initiation. On the conditioning day, 
mice were habituated for 1 h in an anteroom. Mice were then placed into the chamber - 
scented with 1.0 mL 10% vanilla extract and illuminated by a white house light - and 
exposed to the following events during an 8-min session: 90 s habituation followed by 
four 30 s tone presentations (85 dB, 2500 Hz) co-terminating with a shock (0.7mA, 1 s) 
with an inter-tone interval of 60 s, followed by a 90 s interval without any stimuli.  
Approximately 24 h after conditioning (Day 2), mice were placed in the anteroom for 1 h 
and then exposed to the same conditioning context (identical environment and 
conditioning chamber including tactile, light, and odor cues). Freezing behavior, defined 
as motionless posture, excluding respiratory movements, was measured in the absence of 
any tone or shock stimuli for 8 min. After this 8 min test mice were returned to their 
homecage. Approximately 48 h after conditioning (Day 3), mice were returned to the 
anteroom and habituated under infrared light for 1 h. The test room and chamber were 
also illuminated by an infrared light only. The context of the chamber was altered with 
the addition of a white plexiglass floor on top of the shock grid, a black teepee to alter the 
shape/size of the chamber, and a 0.5 mL 10% Eucalyptus oil odor cue. Mice were 
exposed to the identical testing paradigm as on the conditioning day (e.g. presentation of 
the 4 tones) but without the shock stimuli. Again, freezing behavior was measured in the 
absence of any shock stimuli for 8 min. Data are presented as means ± S.E.M. and 
analyzed by one-way ANOVA followed by Bonferroni’s test. 
 
Cue-Dependent Fear Conditioning. Studies were conducted using conditioning 
chambers in sound attenuating cubicles equipped with a stainless steel grid floor for 
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shock delivery and a video camera for recording freezing behavior as previously 
described (MedAssociates, Allentown NJ, see (Bubser et al., 2014)). Wild-type and NR1 
KD mice, 8-10 weeks old, were handled for 3 days prior to conditioning and injected 
with saline for 1 day prior to commencement of the study. On the conditioning day, mice 
were habituated for 1 h in an anteroom adjacent to the test room. Mice were pretreated 
with vehicle (10% Tween 80 in sterile water i.p.) or a dose of VU6004256 (10 mg/kg i.p.) 
5 min prior to conditioning. Mice were then placed into the chamber, scented with 1.0 
mL of 10% vanilla extract and illuminated by a white house light, and exposed to the 
following events during an 8 min session: 90 s habituation followed by four 30 s tone 
presentations (85 dB, 2500 Hz) coterminating with a shock (0.7 mA, 1 s) with an 
intertrial interval of 60 s, followed by a 90-s interval without stimuli. Approximately 24 h 
after conditioning, mice were returned to the anteroom where they were habituated under 
infrared light for 60 min. The test room and chamber were also illuminated by an infrared 
light only. The context of the chamber was altered with the addition of a white plexiglass 
floor on top of the shock grid, a black teepee to alter the shape/size of the chamber, and a 
0.5 mL 10% Eucalyptus oil odor cue. Mice were exposed to the identical testing 
paradigm as on the conditioning day but without the shock stimuli. Freezing behavior 
was measured in the absence of any shock stimuli for 8 min. Data are presented as means 
± SEM and analyzed by one-way ANOVA followed by Bonferroni’s test. 
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Results 
 
VU6004256 is a highly potent M1 Positive Allosteric Modulator with optimized 
pharmacokinetic properties relative to the previously reported M1 PAM 
VU0453595.  
As shown in Figure 28, the structure of the novel M1 PAM 4,6-difluoro-N-
(1S,2S)-2-hydroxycyclohexyl-1-((6-(1-methyl-1H-pyrazol-4-yl)pyridine-3-yl)methyl)-
1H-indole-3-carboxamide 2 (VU6004256) is compared side-by-side with previously 
published M1 PAM VU0453595, 1 (Ghoshal et al., 2016; Lindsley et al., 2014; Tarr et al., 
2012). VU6004256 is a potent potentiator of mouse M1 (EC50 = 155 nM, 88% ACh Max) 
and is ~20-fold more potent than VU0453595.   In addition, VU6004256 displays mouse 
brain:plasma partitioning (Kp) coefficient of 4.84 and an unbound brain:plasma 
coefficient (Kp,uu) of 2.6.   In addition to selectivity for M1 (M2-5 EC50s >30 µM), 
VU6004256 also displayed no off-target pharmacology at over 68 GPCRs, ion channels 
and transporters in an ancillary pharmacology radioligand binding panel (% inhibition @ 
10 µM <50%).   Therefore, VU6004256 represents a more potent and centrally penetrant 
M1 PAM compared to VU0453595 to explore efficacy in NR1 KD mice as a genetic 
model of NMDAR hypofunction. 
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Figure 28. Structure, potency and pharmacokinetic properties of the novel M1 PAM 
4,6-difluoro-N-(1S,2S)-2-hydroxycyclohexyl-1-((6-(1-methyl-1H-pyrazol-4-
yl)pyridine-3-yl)methyl)-1H-indole-3-carboxamide (VU6004256) (right) in 
comparison with the previously published M1 PAM VU0453595 (Left). 
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Deficits in Carbachol-Induced LTD Can Be Rescued by VU6004256.  
Bath application of carbachol (50 µM) induced a robust muscarinic LTD response 
in layer V mPFC of wild-type mouse tissue (68.5% ± 7.0 of baseline; Figure 29A).  This 
effect was dramatically blunted in NR1 KD mouse tissue (88.3% ± 5.1 of baseline; 
Figure 29B), but bath application of VU6004256 (1 µM) during the carbachol application 
resulted in normalization of the muscarinic LTD response (Figure 29C) to levels 
comparable to wild-type mouse tissue (65.3% ± 1.6, H = 10.41, p < 0.01; Figure 29D). 
 
VU6004256 Attenuates Excessive Pyramidal Cell Firing in the Prefrontal Cortex of 
NR1 KD Mice.  
In vivo electrophysiology recordings from the prelimbic cortex of awake, 
behaving mice revealed a significant increase in firing rate of pyramidal neurons in NR1 
KD mice (1.44 Hz ± 0.079) compared to wild-type littermate controls (1.090 Hz ± 
0.0603)(t141 = 3.544, p < 0.0005; see Figure 30B). Mice received either vehicle or 10 
mg/kg VU6004256 following 30 minutes of baseline recording (Figure 30A).  Pyramidal 
cell firing rate was reduced in the NR1 KD animals following VU6004256 administration 
(85.3% ± 4.1, t69 = 2.09, df = 69, p < 0.05; Figure 30F), with no observed effect of 
vehicle dosing (105.8% ± 9.4; Figure 30F). Vehicle or VU6004256 administration did 
not affect firing rate in wild-type animals (101.8% ± 5.1 and 88.7% ± 7.7, respectively; 
Figure 30C). Comparison of raw firing rates using a paired t-test revealed a strong post-
dose decrease in NR1 KD mice following VU6004256 administration (t37= 3.76, p < 
0.001; Figure 31H) but no effect in wild-type animals (Figure 30E).  
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Figure 29. Muscarinic LTD is absent in NR1 KD animals but can be rescued by the 
M1 PAM VU6004256. (A) CCh application (50 µM) induced LTD in layer V mPFC in 
WT mice (red circles, shaded gray area). (B) CCh-induced LTD is absent in NR1 KD 
animals, but treatment with VU6004256 (1 µM) before and during CCh application 
resulted in significant induction of LTD (blue circles, gray shaded area). (D) Graphical 
representation comparing minutes 55-60 from panels A-C. (**p = 0.0055, ANOVA, 
Kruskal-Wallis followed by Dunn’s post hoc test). 
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Figure 30. Comparison of WT and NR1 KD mouse pyramidal neuron firing rate in 
mPFC in awake, freely moving mice. (A) Recording paradigm with depiction of when 
firing rate averages were assessed (black boxes). (B) NR1 KD mice exhibit significantly 
increased firing rate compared to WT littermate controls. (C-E) VU6004256 had no 
effect on pyramidal cell firing rate WT littermate controls. (F-H) VU6004256 
significantly reduced pyramidal cell firing rate in NR1 KD mice. Data in panels C and F 
represent changes in frequency compared to the baseline recording period prior to drug 
administration.  (B, C and F) t-test, *p < 0.05. (D, E, G, and H) Paired t-test, ***p < 
0.001. B: n=71-72 cells, C-H: n=33-41 cells. 
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VU6004256 Administration Improves Performance in Novel Object Recognition.  
NR1 KD mice showed a marked, but statistically insignificant reduction in 
recognition index compared to their WT littermate controls (-0.0085 ± 0.0156 vs. 0.1150 
± 0.0563, respectively, Figure 31).  Pretreatment with VU6004256 at either 3 mg/kg 
(0.1475 ± 0.0381) or 10 mg/kg (0.1662 ± 0.0401) significantly improved recognition 
index in NR1 KD mice (Fdose(1,44) = 14.64, p < 0.05; Fgenotype(2,44) = 11.43, p < 0.05; 
Finteraction(2,44) = 0.056, n.s.), while the top dose of 10 mg/kg (0.3125 ± 0.0552) also 
improved performance in WT littermate controls.  
 
NR1 KD mice display robust learning and memory impairments.  
Initial studies sought to characterize the ability of wild-type and NR1 KD mice to 
acquire contextual- (hippocampal-dependent) and cue-mediated (PFC/amygdala-
dependent) fear conditioning responses. Findings measuring the effect of genotype on 
this response are reported in Figure 32A and B. Wild-type mice were able to acquire both 
contextual- and cue-mediated associative learning tasks (74.9 ± 6.0 and 17.4% ± 2.9, 
respectively). NR1 KD mice showed a lack of freezing in both paradigms (4.6% ± 1.8 
and 1.5% ± 0.3, respectively) that was significantly lower than that of wild-type controls 
(context: t24 = 9.70, p < 0.0001; cue: t23 = 4.86). To specifically determine if potentiation 
of M1 mAChRs would normalize PFC-mediated cognitive impairments, the effects of 
VU6004256 on cue-mediated fear conditioning were examined in wild-type and NR1 KD 
animals. NR1 KD mice displayed severe deficits in cue-mediated fear conditioning 
compared to their wild-type littermate controls (1.2% ± 0.7 and 41.9% ± 7.0, 
respectively; Figure 33). Pretreatment with 10 mg/kg VU6004256 5 minutes before being 
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placed in the chamber on the training day significantly improved performance on the test 
day in NR1 KD mice (12.3% ± 6.2, t14 = 1.762, p < 0.05). 
To assess associative learning and behavioral flexibility using a translational 
touchscreen pairwise discrimination and reversal task, mice were trained to respond to 
one of two stimuli presented on the computer touchscreen. Responding on one stimulus 
(S+) resulted in reward delivery, whereas responding on the alternate stimuli (S-) 
terminated the trial.  On the day following acquisition of the discrimination (>80% 
accuracy for 2 consecutive days), the rule for reinforcement would be reversed such that 
the previously non-reinforced stimulus is now reinforced and vice-versa. As seen in 
Figure 34, NR1 KD mice failed to show improvements in percent accuracy across the 
first 15 days of training. In contrast, WT mice showed increases in accuracy within 
several sessions (left) and 80% of the WT mice acquired the discrimination within 2 
weeks (right) whereas not a single NR1 KD mouse reached 80% accuracy. 
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Figure 31. The novel object recognition deficit of NR1 KD mice is reversed by M1 
PAM administration. NR1 KD animals showed no preference for the novel object when 
treated with vehicle.   Pretreatment with VU6004256 resulted in dose-dependent 
increases in recognition index. Acute treatment with 10 mg/kg VU6004256 in WT 
animals resulted in an increase in recognition index.  (n=8-10/treatment group, * p < 
0.05, 2-way ANOVA followed by Bonferroni’s post hoc test).  
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Figure 32.  Comparison of NR1 KD and WT littermate control mice in context and 
cue-mediated fear conditioning.  Left, NR1 KD mice displayed a significant reduction 
in time spent freezing compared to WT littermate controls. Right, Similar results were 
observed in the cue-mediated fear conditioning paradigm. (Unpaired t-test, ***p < 
0.0001).  
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Figure 33. Cue-mediated conditioned freezing in WT and NR1 KD mice. 
Pretreatment with VU6004256 on training day significantly improved performance on 
test day in NR1 KD, but not WT mice. (n = 8-10/group, t-test, *p < 0.05). 
  
150 
 
 
 
1 2 3 4 5
4 0
6 0
8 0
1 0 0
D a y s
%
 A
c
c
u
r
a
c
y
W T
N R 1  K D
D a y s
P
e
r
c
e
n
t 
A
c
q
u
is
it
io
n
0 5 1 0 1 5
0
2 0
4 0
6 0
8 0
1 0 0 W T
N R 1  K D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Training WT and NR1 KD mice in a model of associative learning and 
behavioral flexibility reveals cognitive deficits. NR1 KD mice do not learn the visual 
pairwise discrimination. In contrast, WT littermates acquire the pairwise discrimination 
task within 1 week of the initiation of training; n=12/group. 
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VU6004256 Reverses Excessive Locomotor Activity in NR1 KD Mice.  
NR1 KD mice exhibit excessive spontaneous locomotor activity compared to their 
WT littermate controls (Fgenotype(5, 39) = 31.35, p < 0.0001; see Figure 35B).  Pretreatment 
with VU6004256 at 10 mg/kg produced a significant reduction in spontaneous locomotor 
activity that persisted for the duration of measurement (Fdose(5,612) = 331.9, p < 0.001; 
Ftime(17,612) = 6.101, p < 0.001, Finteraction(85,612) = 0.46, n.s.; Figure 35A). No reduction in 
locomotor activity was observed at 1 mg/kg in NR1 KD mice.  Additionally, pretreatment 
with VU6004256 at all doses did not alter spontaneous locomotor activity in WT 
littermate controls. Spontaneous locomotor activity was also measured in response to an 
additional M1 PAM, VU0453595, with a distinct chemical scaffold (Figure 36).  While 
NR1 mice exhibited a robust increase in spontaneous locomotor activity compared to WT 
littermate controls (Fdose(9,2400) = 246.7, p < 0.001; Ftime(23,2400) = 16.19, p < 0.001, 
Finteraction(207,2400) = 0.97, n.s.), VU0453595 was unable to significantly alter this response, 
though there was a strong downward trend at the 1 mg/kg dose (Figure 36B).  
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Figure 35. VU6004256 reduces excessive locomotor activity in NR1 KD mice. NR1 
KD mice showed excessive locomotor activity when compared to WT littermate controls. 
Pretreatment with 1 mg/kg VU6004256 had no effect on locomotor activity in either WT 
or NR1 KD animals.  Pretreatment with 10 mg/kg VU6004256 did not affect WT 
animals, but significantly reduced locomotor activity in NR1 KD mice. (n =7-9/treatment 
group, *p < 0.05, ANOVA followed by Bonferroni’s post hoc test).  
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Figure 36. VU0453595 does not reduce hyperlocomotor activity in NR1 KD mice. 
Vehicle-treated NR1 KD mice showed excessive locomotor activity when compared to 
WT littermate controls. Pretreatment with VU0453595 (0.3-10 mg/kg) did not 
significantly affect locomotor response in NR1 KD or WT mice.  (n =9-14/treatment 
group).  
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Discussion 
 
As a close downstream signaling partner of the NMDAR, potentiation of the M1 
mAChR subtype represents an important indirect mechanism for the potential 
normalization of aberrant NMDAR signaling thought to underscore many of the 
symptoms observed in schizophrenia.  In the present studies, we provide the first 
evidence of selective physiological dysfunction within the PFC and PFC-related 
cognitive deficits in a genetic model of global, constitutive knock down of the NR1 
subunit of the NMDAR.   More importantly, selective potentiation of M1 using the 
optimized and highly potent M1 PAM VU6004256 resulted in a restoration of these 
deficits in PFC-mediated synaptic plasticity, pyramidal cell firing, and corresponding 
measures of learning and memory.   
Discovery of highly selective and potent M1 PAMs allows for the investigation of 
antipsychotic-like effects that has been previously reported in preclinical and clinical 
studies with the M1/M4 preferring ligand, xanomeline.(Stanhope et al., 2001; Bodick et 
al., 1997a; Bodick et al., 1997b; Shekhar et al., 2008) While dose-dependent reversal of 
psychostimulant-induced increases in locomotor activity has been observed previously 
with the M1 selective ligands, as demonstrated by the M1 allosteric agonist TBPB and the 
M1 PAM BQCA, much of the antipsychotic-like efficacy of xanomeline was attributed to 
M4 activation.(Jones et al., 2008; Ma et al., 2009) In the current studies, we observed a 
significant reduction in elevated spontaneous locomotor activity of NR1 KD mice with a 
selective M1 PAM in a genetic model of NMDAR hypofunction that is consistent with 
acute psychostimulant challenge models, which furthers the hypothesis that M1 
modulation in cortical and limbic regions may contribute to antipsychotic-like effects 
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observed with xanomeline.  Interestingly, these effects are only observed with the more 
potent M1 PAM, VU6004256 (EC50=155 nM), and not with VU0453595 (EC50=3.22 
µM), suggesting VU6004256 may have efficacy in other behavioral models that less 
potent M1 ligands do not.  These findings provide valuable insight into the importance of 
developing more potent M1 ligands to assess additional aspects of M1-related 
antipsychotic-like efficacy.  
Traditionally, acute or repeated dosing with a use-dependent open channel 
blocker of NMDAR is employed to produce NMDAR hypofunction in rodents that 
mimics neurochemical and behavioral changes observed in patients with 
schizophrenia.(Bubenikova-Valesova et al., 2008; Jentsch & Roth, 1999) There is a 
potential liability when evaluating M1 PAMs in these models since M1 is a closely 
associated signaling partner of NMDARs and selective activation of M1 in cortical and 
hippocampal regions results in the downstream potentiation of NMDAR currents, which 
could exacerbate the effects of the NMDAR antagonist.(Marino et al., 1998) Because of 
the critical impact of NMDAR signaling in the modulation of normal cognition and 
neural circuitry hypothesized to be dysregulated in schizophrenia (Tsai & Coyle, 2002; 
Marino et al., 1998), ligands like the M1 PAM VU6004256 that selectively potentiate the 
response of ACh at M1 mAChRs may ameliorate many of the psychotic and cognitive 
impairments of schizophrenia through enhancement of NMDAR neurotransmission. 
Moreover, selective potentiation of M1 by VU6004256 provides indirect modulation of 
NMDAR function, which may produce therapeutic effects without the potential high risk 
of excitotoxicity connected with direct agonist activity at the NMDAR. Importantly, 
these data provide the first evidence supporting antipsychotic-like effects with an M1 
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PAM in a genetic model of NMDAR hypofunction that does not rely on pharmacologic 
manipulation to induce behavioral disruptions.  
Previous reports indicate a crucial role for mAChRs in regulating synaptic 
plasticity in the PFC and suggest that deficits in cholinergic signaling may contribute to 
the electrophysiological and behavioral phenotypes associated with dysfunctional PFC 
plasticity. For example, non-selective activation of mAChRs is sufficient to convert 
transient depression into long-lasting LTD in the PFC following a sub-threshold LTD 
protocol in rats (Lopes-Aguiar et al., 2013). Importantly, acute co-application of an 
NMDAR antagonist blocked this response, suggesting an integral role of glutamatergic 
activation in muscarinic-mediated cortical LTD. The effects of mAChRs on this form of 
plasticity in the PFC were further characterized in studies utilizing M1 knockout mice and 
the M1 PAM VU0453595, revealing that muscarinic LTD is dependent on M1 activation 
and can be potentiated by an M1 PAM. Interestingly, synaptic depression was not 
observed following repeated NMDAR administration during early adolescent 
development, strengthening the importance of intact NMDA-M1 receptor signaling in 
cortical synaptic plasticity.(Ghoshal et al., 2016) 
Here we report the first electrophysiological analysis of spontaneous pyramidal 
cell activity in the layer V PFC of awake, free-moving NR1 KD mice in comparison with 
their wild-type littermate controls.  Our findings revealed substantial information-
processing deficits (Jackson et al., 2004) at the single-neuron level as denoted by a 25% 
increase in the firing rates in the NR1 KD mice. This disinhibition of PFC pyramidal cell 
firing in the NR1 KD mice is consistent with previous studies performed in rodents after 
acute administration of MK-801 or PCP (Jackson et al., 2004). At present, the underlying 
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mechanism(s) for this disinhibition of PFC activity in the NR1 KD mice remains 
unknown. However, based on NMDAR antagonist studies, one possible explanation may 
involve increased PFC activation resulting from disinhibition of hippocampal-PFC inputs 
(Jodo, 2013; Jodo et al., 2005; Kamiyama et al., 2011; Thomases et al., 2014), resulting 
in reduced LTD and enhanced LTP mechanisms. (Thomases et al., 2014; Kamiyama et 
al., 2011)  This interpretation is further supported by the observation that the novel M1 
PAM VU6004256 decreased the firing rates in the NR1 KD mice. Alternatively, 
activation of M1 is known to increase excitability in GABAergic interneurons of the PFC 
(Yi et al., 2014) through an NMDAR-independent mechanism; thus, another possible 
explanation for the effects of VU6004256 on pyramidal cell firing rates in NR1 KD mice 
may by through increased activity of GABAergic interneurons in the PFC, resulting in 
sustained reductions in PFC excitation. The ongoing development of cell type-specific 
NMDAR knockdown/knockout mice allows for more intricate examination of the role of 
NMDARs on local and projection neurons in the PFC and will be utilized by our group 
and others to elucidate the role of NMDAR hypofunction in the PFC. In future studies, it 
will also be important to further understand the relative contributions of M1 modulation to 
both NMDAR-dependent and -independent mechanisms of PFC circuitry disrupted in the 
mice with global NR1 KD.   
Genetic models of NMDAR hypofunction exhibit profound cognitive deficits as 
measured in radial arm maze performance, social and object recognition, and spatial and 
non-spatial memory tasks. (Belforte et al., 2010; Dzirasa et al., 2009; Rampon et al., 
2000) Consistent with these findings, we observed robust deficits in context- and cue-
mediated fear conditioning in NR1 KD mice, similar to the deficits encountered in NR2C 
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knockout mice.(Hillman et al., 2011) M1 PAM administration improved deficits of NR1 
KD mice in novel object recognition and cue-mediated fear conditioning, both of which 
are thought to heavily rely on intact PFC signaling. These data, taken together with recent 
reports that M1 PAMs are efficacious in similar behavioral tasks performed in a 
pharmacologic model of NMDAR hypofunction (Ghoshal et al., 2016), suggest that M1 
potentiation may have broad utility across several animal models of schizophrenia. 
 Collectively, the current studies provide important novel insights into the role of 
M1 modulation of PFC-mediated physiologic and cognitive functions under conditions of 
chronic NMDAR hypofunction. These findings also confirm and extend accumulating 
evidence for the broader therapeutic utility for M1 PAMs in the treatment of affective and, 
more importantly, cognitive impairments observed in schizophrenia.  
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CHAPTER VI 
 
DISCUSSION 
 
 
In this work, we have demonstrated a broad therapeutic potential for the use of M1 
and M4 PAMs as novel antipsychotic agents for the use in treating the positive symptoms, 
negative symptoms, and cognitive deficits observed in schizophrenia. In particular, we 
have shown the ability of an M4 PAM to dose-dependently reverse psychostimulant-
induced changes in locomotor activity, produced by either amphetamine or MK-801 
administration. Importantly, these effects were absent in mice lacking functional M4 
receptors, suggesting the observed efficacy was due to activation of M4 receptors in WT 
animals. In the case of amphetamine-induced changes in behavior, we were able to 
attribute the observed efficacy of an M4 PAM to reductions in amphetamine-induced 
changes in dopamine release in the NAS and CP of rats.  In addition, these changes in 
mesolimbic and mesostriatal circuitry were accompanied by overall reductions in CBV 
and regional connectivity in the retrosplenial and motor cortices, hippocampus and 
thalamus. These studies, taken together with a growing body of research discussed 
previously, suggest that M4 PAMs reduce dopaminergic signaling and have a range of 
effects in rodent models predictive of antipsychotic-like activity. Importantly, these 
findings support a role for M4 in the antipsychotic-like efficacy observed with the M1/M4-
preferring ligand, xanomeline, and point to modulation of other brain circuits and 
neurotransmitter systems implicated in the cognitive deficits and negative symptoms 
observed in schizophrenia. 
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To address this question, further studies were carried out to determine the ability of 
an M4 PAM to reverse NMDAR antagonist-induced changes in electrophysiological and 
behavioral deficits that are more closely associated with brain regions involved in the 
cognitive deficits and negative symptoms observed in schizophrenia. In these studies, we 
showed that an M4 PAM could reverse 5-HT-evoked changes in glutamate release, as 
measured by sEPSC frequency in a slice-based electrophysiology paradigm, in layer V 
mPFC. The response to 5-HT has been attributed to activation of presynaptic 5-HT2A 
receptors located presynaptically on glutamatergic thalamocortical terminals in the mPFC.  
Upon activation of these 5-HT2A receptors, there is a dramatic increase in the frequency 
of spontaneous excitatory postsynaptic currents (EPSCs) measured in layer V pyramidal 
cells of the mPFC (Aghajanian & Marek, 1997; Aghajanian & Marek, 1999; Marek et al., 
2001; Marek et al., 2000). Previous studies have demonstrated that atypical 
antipsychotics, including clozapine and olanzapine, inhibit this effect and reduce 
spontaneous EPSCs in the mPFC by direct antagonist activity at 5-HT2A receptors on 
thalamocortical terminals. Additionally, others have demonstrated that the selective 
mGlu2 PAM BINA and mGlu2/3 agonists also blocked increases in the frequency of 
sEPSCs in layer V pyramidal cells of the PFC induced by activation of 5-HT2A receptors 
on these presynaptic glutamatergic thalamocortical terminals in the PFC (Benneyworth et 
al., 2007). To confirm a role for M4 in this circuit, a series of optogenetic experiments 
were performed, in which optically-evoked EPSCs were measured in pyramidal cells of 
the mPFC following viral-mediated gene transfer of CHR2 in MD thalamic neurons. 
These studies confirmed a role for M4 modulation of this circuit, with decreases in CV 
analysis suggesting a presynaptic mechanism of action. Subsequent studies evaluating the 
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presence of M4 transcript on MD thalamic projection neurons to layer V mPFC in rats, 
confirmed the presence of M4 receptors in this circuit and validated the functional data 
observed in the slice electrophysiology experiments. The schematic depicted in Figure 37 
shows the hypothesized expression of M4 receptors in thalamocortical circuitry. 
 
 
 
 
Figure 37. Model of M4 mAChR expression in thalamocortical circuit.  
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To determine if ex vivo modulation of the PFC by M4 PAMs translated into 
changes in cognitive performance, we first needed to confirm activity of the M4 PAM in 
vivo. Based on our findings in whole cell electrophysiology we hypothesized MK-801 
administration in vivo would result in dramatic changes in mPFC electrophysiological 
properties. As expected, MK-801 administration resulted in a significant increase in 
pyramidal cell firing rate in layer V mPFC pyramidal neurons, and pretreatment with an 
M4 PAM was able to significantly block this response.  These data suggest that M4 PAMs 
are efficacious in modulating electrophysiological responses to psychostimulants in vivo, 
thus cognitive and behavioral tasks that are sensitive to disruptions in cortical circuitry 
via psychostimulants or hallucinogens may be rescued by M4 PAM administration. To 
test this hypothesis we first performed behavioral assessment of the effect of M4 PAM 
treatment on (±) DOI-induced head twitch response in mice. Interestingly, the M4 PAM 
was as efficacious as the mGlu2 PAM BINA at reversing the induction of head twitches, 
suggesting there was sufficient acetylcholine present for the PAM to function, and that 
there is sufficient M4 expression in the cortex to elicit a change in behavior in response to 
M4 PAM treatment. We then assessed the performance of WT mice in an operant-based 
spatial alternation task, a more complex behavioral assay that is thought to more heavily 
rely on normal function of PFC circuitry. Administration of an NMDAR antagonist 
resulted in severe deficits in performance, but pretreatment with an M4 PAM was able to 
significantly reverse this response, resulting in performance well above chance 
responding. These data would suggest that M4 PAMs are capable of modulating PFC 
circuitry that is implicated in the cognitive deficits observed in patients with 
schizophrenia. 
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To date, the effects of M4 PAMs have been primarily evaluated in acute behavioral 
and physiological experiments, with little work performed to test the consequences of 
repeated dosing on behavior responses. To determine the role of M4 in cognition, and to 
understand the effects of prolonged treatment, we examined the effects of repeated 
dosing with the M4 PAM VU0467154 on learning a touchscreen-based visual pairwise 
discrimination task. First, we observed no difference is plasma or brain concentrations of 
drug following 10 days of repeated dosing, when compared to a single dose, suggesting 
there are no changes in absorption, distribution, metabolism, or excretion in response to 
repeated dosing. As expected, this translated to no loss of efficacy in reversing NMDAR 
antagonist-induced changes in locomotor activity. These studies are of great importance, 
as a loss of efficacy with repeated administration would preclude the use of M4 PAMs in 
a clinical setting. Of equal importance, repeated administration of VU0467154 resulted in 
a significant increase in the rate of acquisition of the pairwise discrimination task.  This 
was observed when VU0467154 was administered before and after the training session, 
suggesting effects on cognition may in part be through consolidation of memory. 
Together these data further support a role for M4 mAChRs in learning and memory and in 
the potential treatment of multiple symptom clusters associated with schizophrenia. 
Finally, in Chapter V we evaluated the effects of the novel and highly potent M1 
PAM VU6004256 in ameliorating selective PFC-mediated physiologic and cognitive 
abnormalities in a genetic mouse model of NMDAR hypofunction.  Using slice-based 
extracellular field potential recordings, deficits in muscarinic agonist-induced LTD in 
layer V of the PFC in the NR1 KD mice were normalized with bath application of 
VU6004256. Systemic administration of VU6004256 also reduced excessive pyramidal 
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neuron firing in layer V PFC neurons in awake, freely moving NR1 KD mice. Moreover, 
selective potentiation of M1 by VU6004256 reversed the performance impairments of 
NR1 KD mice observed in two preclinical models of PFC-mediated learning, specifically 
the novel object recognition and cue-mediated fear conditioning tasks. VU6004256 also 
produced a robust, dose-dependent reduction in the hyperlocomotor activity of NR1 KD 
mice. These novel findings provide further support for M1 PAMs as a novel therapeutic 
approach for the PFC-mediated impairments in schizophrenia. 
 Taken together, these findings support a role for both M1 and M4 in the observed 
efficacy in preclinical and clinical studies with xanomeline, and should provide sufficient 
evidence for further development of selective muscarinic ligands for use as potential 
antipsychotic agents. Importantly, our findings suggest selective potentiators for either 
M1 or M4 can have beneficial effects when administered in animal models that are used to 
assess antipsychotic-like efficacy or cognitive enhancement. Previous hypotheses 
(Grunze et al., 1996)efficacy on measures of cognition were attributed to M1 potentiation.  
Here, we show that while M4 potentiation does indeed result in attenuation of positive-
like symptoms, there is growing evidence to support the cognitive enhancing properties.  
This is observed in psychostimulant and hallucinogen-induced deficit models, as well as 
when the M4 PAM is administered alone in WT animals (Bubser et al., 2014; Gould et 
al., 2016). Our data suggest one mechanism for this observed efficacy is through 
modulation of PFC circuitry that is known to be involved in higher cognitive processes.  
Interestingly, M4 PAMs also reverse MK-801-induced hyperlocomotion, which does not 
result in elevated dopamine release in the mesolimbic and mesostriatal pathways, 
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suggesting that changes in locomotion in this assay may be the result of M4 activation in 
other circuits.  
Conversely, the cognitive enhancing effects with xanomeline have been 
previously attributed to activation of M1 receptors.  Here, we do show that M1 PAMs are 
capable of modulating PFC circuitry that is known to be heavily involved in cognition, as 
measured by changes in ex vivo and in vivo electrophysiology studies. This resulted in 
changes in performance in PFC-mediated behavioral tasks, namely cue-mediated CF and 
novel object recognition.  This is consistent with previous reports that evaluated the 
effects of an M1 PAM in a sub-chronic NMDAR antagonist paradigm of NMDAR 
hypofunction (Ghoshal et al., 2016). These findings are also in accordance with previous 
findings from our lab, which reported an enhancement in the rate of learning pairwise 
discrimination in a top-down cognitive assay in response to daily administration of an M1 
PAM (Gould et al., 2015).  Our most recent findings with a more optimized M1 PAM, 
VU6004256, show the ability of potentiating M1 receptors to have an antipsychotic-like 
profile, as was seen in locomotor reduction in NR1 KD mice. These findings do not 
support a strict adherence to the idea that M4 receptors are only involved in attenuating 
the positive-like symptoms and M1 receptors are only involved in improving cognition. 
Rather, these studies raise the possibility that potentiators of either M1 or M4, or both, 
could be exciting mechanisms to explore for the treatment of all three symptom domains 
observed in schizophrenia. 
 There have been huge advances in the development of selective, potent, and 
bioavailable muscarinic agents in the last decade. As reported here, VU6004256 is many-
fold more potent and selective than other previously reported M1 PAMs, and possesses 
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pharmacokinetic properties that make it amenable to in vivo dosing. Likewise, 
VU0467154 represents a highly potent and selective M4 PAM with excellent drug 
metabolism and pharmacokinetic properties that have been extensively evaluated in acute 
and chronic dosing paradigms. This raises, for the first time, the interesting possibility of 
combining doses of selective M1 and M4 PAMs for evaluation in complex behavior 
studies. Future studies should evaluate the effects of varying doses of each and perform 
isobologram analysis to predict efficacy based on the concept of dose equivalence. This 
will become important, as behaviorally ineffective doses of either M1 or M4 PAM may 
have profound effects when combined with each other. By performing studies of this 
nature, it will be possible to determine the relative contribution of M1 and M4 to the 
observed clinical efficacy of xanomeline, but also opens up the possibility of using lower 
doses of each, and could limit the potential for off-target activation of other receptors in 
the CNS and periphery.  
 Similar studies will need to be performed in conjunction with treatment with 
traditional antipsychotic medications, such as haloperidol, clozapine, and olanzapine. As 
mentioned several times previously in this work, current antipsychotics are fairly 
effective at controlling the positive symptoms associated with schizophrenia, but do little 
to curb the cognitive deficits and negative symptoms. As such, removing a patient from 
treatment that stably controls psychotic episodes may be untenable, or even considered 
unethical. This would limit the patient population to those that are being treated shortly 
after their first psychotic break. While there is evidence to suggest a muscarinic 
potentiator could be efficacious in this population, it restricts the scope of treatment to a 
small group of patients, and may not be predictive of efficacy in later stages of the 
167 
 
 
 
disorder. To address this, clinical trials need to be designed with combination therapy in 
mind. 
 However, there are several potential complexities when performing studies of this 
nature. First, many of the currently available antipsychotics have significant activity at 
some of, or all, of the mAChRs. For example, the prototypical antipsychotic drug, 
clozapine, has nanomolar affinity for all five cloned muscarinic receptors (Bolden et al., 
1992), where it has been reported to be a potent antagonist of M1 (Sur et al., 2003; 
Weiner et al., 2004; Zorn et al., 1994) and M2/3/5 mAChRs (Bymaster et al., 1996; Michal 
et al., 1999). Contradicting reports have suggested clozapine is a partial agonist at M1/2/4 
mAChRs (Fritze & Elliger, 1995; Olianas et al., 1997; Zeng et al., 1997; Zorn et al., 
1994). Adding to the complexity further, the primary metabolite of clozapine in rodent 
and human, N-desmethylclozapine, also has significant activity at mAChRs, specifically 
as a potent agonist at M1 receptors (Aravagiri & Marder, 2001; Baldessarini et al., 1993; 
Balu et al., 2012; Sur et al., 2003; Weigmann et al., 1999; Weiner et al., 2004). In fact, N-
desmethylclozapine has been shown to increase cortical acetylcholine and dopamine 
release in vivo via stimulation of M1 muscarinic receptors, suggesting co-administration 
of an M1 PAM could be a very efficient way to further increase dopamine levels in the 
cortex, leading to enhanced cognitive performance (Li et al., 2005). These types of 
interactions between compounds could obviously greatly impact studies that utilize co-
administration of muscarinic potentiators, leading to changes in observed efficacy with 
either the antipsychotic or muscarinic ligands alone.  
For example, there is a recent report by (Choy et al., 2016) that evaluated the 
efficacy of the M1 PAM, BQCA, in combination with currently available typical and 
168 
 
 
 
atypical antipsychotics in rodent models of NMDAR hypofunction. In these studies, 
BQCA was administered alone or in combination with haloperidol, clozapine, or 
aripiprazole, and the ability to reverse MK-801-induced deficits in sensorimotor gating 
and spatial memory function, as measured by PPI and Y-maze.  While administration of 
BQCA alone had no effects in either model, there were differing levels of efficacy in 
reversing the MK-801-induced deficits in PPI when combined with a sub-effective dose 
of each of the three antipsychotics. Interestingly, this observed efficacy did not translate 
to reversals with all three antipsychotics in the Y-maze task, where BQCA in 
combination with haloperidol could not reverse the deficits. These findings are very 
interesting given the reported M1 receptor agonist activity of atypical, but not typical, 
antipsychotics. This study highlights the importance of thoroughly investigating the 
mAChR activity of currently approved antipsychotics, and the need to carefully design 
experiments that will utilize a co-administration design. 
Also, it is important to note the possibility of adverse side effects developing with 
co-administration studies. For example, the recent characterization of a highly selective 
M1 PAM, Compound 38 (PF-06767832), showed that despite lacking activity at M2-5, 
there were still gastrointestinal and cardiovascular side effects observed (Davoren et al., 
2016). These effects were not observed in rodent models, but when advanced into safety 
toxicology tests in dogs, adverse events such as diarrhea, emesis, and convulsions were 
observed. Interestingly, the plasma concentration when these adverse events were 
observed was approaching 1 µM, well above the reported EC50 of 60 nM. In fact, these 
plasma values, along with calculated unbound brain concentrations of approximately 330 
nM, are at or slightly below the in vitro agonist EC50. This suggests that M1 activation, 
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either through agonist or PAM activity, contributes to the cholinergic liabilities that were 
previously attributed to activation of the M2 and M3 receptors, and that combination 
therapy with an antipsychotic that has known M1 agonist activity could be 
contraindicated.  
 In the reports described in this work, we took advantage of a genetic model of 
NMDAR hypofunction that utilizes a constitutive knockdown of the NR1 subunit of the 
NMDA receptor.  This leads to greatly reduced expression of functional NMDARs in key 
brain regions that are known to be involved with the symptoms of schizophrenia, namely 
the PFC, hippocampus, and striatum (Mohn et al., 1999). This is important to the 
understanding of the role of NMDAR function in psychiatric illnesses, such as 
schizophrenia, for several reasons. First, constitutive genetic knockdown of NMDARs 
from birth, and throughout neurodevelopment, better mimics the global glutamatergic 
hypofunction that is thought to be present in schizophrenia. As discussed in Chapter I, 
changes in glutamatergic signaling are evident in patients with schizophrenia, and 
changes in NMDAR expression and function around the time of adolescence are thought 
to contribute to the development of the disease (Olney & Farber, 1995; Tsai & Coyle, 
2002). While there are recent developments in the creation of NR2A-D knockout and cell-
type selective NR1 knockout mice that lack normal glutamatergic signaling from birth, 
these models have been primarily useful for delineating the role of NMDARs in specific 
circuits or brain regions, and their behavioral deficits are not as well aligned with those 
observed following NMDAR antagonist administration (Billingslea et al., 2014; Forrest 
et al., 1994; Halene et al., 2009; Hillman et al., 2011; Tatard-Leitman et al., 2015; von 
Engelhardt et al., 2008; Zhao et al., 2005). Additionally, global NR1 KD mice represent a 
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novel approach to evaluate the effects of life long NMDAR hypofunction without the use 
of acute or repeated dosing with an NMDAR antagonist. As discussed in Chapter V, one 
approach to treating the electrophysiological and behavioral deficits induced by NMDAR 
hypofunction is to potentiate NMDAR function. Direct stimulation of NMDARs has been 
shown to lead to excitotoxicity and seizure liability, however, there has been some 
success in clinical trials administering the co-agonist glycine (Heresco-Levy et al., 1996; 
Javitt et al., 1994; Leiderman et al., 1996). Our studies point to a novel mechanism of 
NMDAR potentiation through activation of M1 mAChRs. These studies would not be 
possible without the use of genetic tools, like the NR1 KD mice, since pharmacologic 
hypofunction models traditionally use non-competitive, use-dependent antagonists that 
would not allow for NMDAR potentiation. 
 It is important to mention the potential disconnect between animal models of 
schizophrenia, such as NMDAR antagonist administration or genetic models of NMDAR 
hypofunction, and what is actually observed in patients with schizophrenia. It has been 
repeatedly demonstrated that NMDAR antagonist administration in humans and rodents 
leads to enhanced glutamatergic activity and increased firing rate of cortical neurons, 
primarily through  decreases in activity of GABAergic interneurons (Anticevic et al., 
2015; Homayoun & Moghaddam, 2007). This fits with data suggesting that GABAergic 
interneurons are 10-fold more sensitive to NMDAR antagonists than pyramidal neurons, 
presumably through increased NMDAR-dependent signaling and membrane properties 
that result in more open NMDA channels (Grunze et al., 1996). While this state can 
recapitulate many of the behavioral symptoms observed in schizophrenia, it is in stark 
contrast to the vast majority of clinical reports that routinely find hypofrontality, rather 
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than hyperfrontality, in patients with schizophrenia (Andreasen et al., 1997; Andreasen et 
al., 1992; Buchsbaum et al., 1990; Hazlett et al., 2000; Ragland et al., 2007; Tamminga et 
al., 1992; Volz et al., 1999). One potential explanation for this involves a time-dependent 
neurobiological evolution of the disease, in which excessive signaling in the cortical 
regions leads to changes in network connectivity over time (Krystal & Anticevic, 2015). 
It is counterintuitive to believe that constitutive, prolonged NMDAR hypofunction, 
resulting in excessive glutamate release in key circuits of the brain early in life and 
through adolescence, would result in a static cellular and behavioral phenotype during all 
stages of adulthood. Put another way, it is likely that prolonged increases in cellular 
excitability leads to progressive changes in circuitry, resulting in changes in behavior 
over time. In support of this, there are reports indicating a progressive loss of dendritic 
spine density in NR1 KD mice compared to WT littermate controls (Ramsey et al., 2011), 
and though unpublished, our group has observed progressive changes in locomotor 
activity and pyramidal cell firing rate that coincide with the age of the animal. 
Additionally, recent clinical studies by (Anticevic et al., 2015) have demonstrated that 
acute treatment with the NMDAR antagonist ketamine in healthy humans can induce a 
state of mPFC disinhibition, or hyperconnectivity, that is also observed in early course 
schizophrenic patients. Moreover, this hyperconnectivity observed in early course 
patients dissipates over time, and is not observed in patients that have chronic 
schizophrenia. With this in mind, it is important to entertain the idea that schizophrenia 
may be a progressive disease with an ever-evolving phenotype, and the animal models 
chosen may imitate different stages of the disease.  
172 
 
 
 
 If schizophrenia is, in fact, a progressive disease, it is crucial that we make strides 
towards understanding the changes in circuitry over time to better inform the type of 
therapy needed.  For example, administration of an M4 PAM in early stages of the disease 
may produce an antipsychotic-like phenotype and elicit some degree of cognitive 
enhancement through modulation of PFC circuitry. Alternatively, a patient that has 
chronic schizophrenia with a reduction in glutamatergic signaling in the PFC may 
experience adverse consequences if an M4 PAM was administered. Of course, this is an 
over simplified scenario, and M4 PAM treatment could be efficacious in both through a 
different mechanism, such as modulating sleep/wake architecture. Regardless, treating 
schizophrenia as a progressive disease should alter the design of clinical trials for novel 
antipsychotics in favor of patient stratification. This should decrease the rate of clinical 
candidate failure in human trials, and should better serve patients with schizophrenia by 
more effectively addressing the symptoms that are present at their stage of the disease.  
Perhaps most excitingly, this model would suggest that early intervention with a 
targeted pharmacotherapeutic that reduces cortical excitation, such as an M4 PAM, could 
prevent some of the neuroplastic changes that are thought to occur as a result of the 
disease. In this sense, early treatment with an M4 PAM could actually be disease-altering 
and neuroprotective. One mechanism for this preventative action could be through direct 
modulation of glutamate levels in the PFC, in much the same way mGlu2/3 activators or 5-
HT2A antagonists elicit this response (Marek et al., 2000; Moghaddam & Adams, 1998). 
It will be important to perform preclinical studies in animal models of hyperfrontality or 
disinhibition to test this hypothesis. For example, based on the work described above, 
repeated administration of an M4 PAM should be tolerated well and allow for chronic 
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dosing to occur in NR1 KD mice. As stated previously, these mice undergo a progressive 
loss in dendritic spine density, resulting in altered glutamatergic function that is 
consistent with clinical literature (Garey et al., 1998; Sweet et al., 2009). Since we have 
shown that acute administration of an M4 PAM results in altered glutamatergic signaling 
in these animals, it is fair to postulate that chronic treatment could prevent spine loss if 
the decrease in density was associated with hyperglutamatergic signaling. Studies like 
these will allow for the investigation of the effects of M4 PAMs in models of early-course 
schizophrenia and may predict the disease-altering properties of muscarinic ligands and 
other novel mechanisms that modulate cortical signaling. 
In sum, we have demonstrated both the antipsychotic-like effects and cognitive 
enhancing properties of M1 and M4 PAMs, through modulation of dopaminergic or 
glutamatergic circuitry, or both. Additionally, we have shown efficacy in a broad range of 
assays utilizing pharmacological and genetic approaches to model the complex symptoms 
of schizophrenia. Taken together, the findings reported in this dissertation provide strong 
support for the development of selective M1 and M4 PAMs for the treatment of 
schizophrenia.  
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APPENDIX A 
EFFECTS OF VU0467154 ON AMPHETAMINE- OR MK-801-INDUCED 
DEFICITS IN 5CSRT TASK 
Methods 
Five Choice Serial Reaction Time (5CSRT) task. 
 This method is based on previous studies by (Amitai & Markou, 2009; Shannon 
et al., 2007) using a within subject design in male adult Sprague-Dawley rats. Rats were 
food-restricted to approximately 85% of their free-feeding weights by food presented 
during experimental sessions and supplemental feeding after the experimental sessions. 
The apparatus consisted of operant conditioning  chambers  located  within  sound  and  
light-attenuating  enclosures  (model  ENV-009,  MED Associates Inc., St Albans, 
Vermont, USA). Each chamber was equipped with a white house light centered near the 
top of the front panel and a tone generator near the top on the right-hand side of the front 
panel. Five nosepoke apertures were located 2.5 cm above the chamber floor with 1.5 cm 
between nosepoke aperture with a 28 V direct current and 100 mA stimulus light within 
each nosepoke apertures. A pellet dispenser was centered on the opposite wall and 
delivered 45-mg dustless precision pellets (Bioserv, Frenchtown, New Jersey, USA). 
Operation of the house and stimulus lights, pellet dispenser, tone generator, and recording 
of data were controlled by a computer using Med-State Notation software (version 2; 
MED Associates). Rats were trained to discriminate a brief visual stimulus presented 
randomly in one of the five nosepoke apertures. Under the final schedule contingencies, 
each session began with a 1-min acclimatization period during which the chamber was 
dark and responding had no scheduled consequences. The beginning of each trial was 
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signaled by the illumination of the house light. A response on any nosepoke aperture after 
the onset of the house light, but before the presentation of a stimulus light immediately 
terminated the house light and initiated a 5-s intertrial interval (ITI) during which the 
chamber was dark and responding had no scheduled consequences. Responses during the 
prestimulus interval were termed anticipatory responses. In the absence of an anticipatory 
response, after an average of 6.5 s (5.0–8.0 s) following the onset of the house light, a 
stimulus light was illuminated above one of the five nosepoke apertures in random order. 
During training sessions, the stimulus light remained illuminated for a maximum of 2 s. 
During test sessions, the stimulus light remained illuminated for a maximum of either 0.2, 
1.0, or 2.0 s, in randomized order and the two durations were presented an equal number 
of times. A response on the nosepoke aperture below which the stimulus is presented 
within 5 s of the onset of the stimulus (‘response window’) immediately terminated the 
trial, and resulted in the presentation of a food pellet, 0.2 s presentation of a tone, and 
initiated a 5-s ITI. An incorrect response during the response window immediately 
terminated the trial and initiated a 5-s ITI. Responses during the ITI were counted but 
have no scheduled consequences; the next trial began immediately after the end of the 5-s 
ITI. Sessions were conducted 4 days per week and each session duration was 30 min or 
until 100 trials had been completed, whichever occurred first each session. Data was 
analyzed for the following parameters: 1) Accuracy: the number of correct responses 
divided by the sum of correct and incorrect responses( [# correct responses/(# correct 
responses + # incorrect responses)] × 100); 2) Percent Correct Responses (total # correct 
responses/total # of trials) × 100); 3) Percent Incorrect Responses (total # incorrect 
responses/total # of trials) × 100); 4) Percent Omissions (total # omissions/total # of 
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trials) × 100);  5)  Premature  or  anticipatory  responses  (total  #  of  responses  
performed  during  the  ITI,  before presentation of the light stimulus); 6) perseverative 
responses, further responses into the apertures after the performance of a correct 
response, but before reward retrieval from the magazine/initiation of a new trial resulting 
in a timeout and no food reward. Data was analyzed using a one-way analysis of variance 
and if significant (p<0.05), all dose groups were compared to the vehicle group using a 
Dunnett’s test. A difference will be considered significant when p≤ 0.05. 
 
Results 
 
 Rats were trained to baseline performance values over the course of ~30 days, 
which was considered 2 consecutive days above 70% correct when tested at a 2 s 
stimulus interval.  All studies were conducted using a within subject design. On testing 
day, rats received one of 3 dosing schedules: vehicle/vehicle (10% tween 80, i.p., 60 min 
pretreatment/sterile water, s.c., 30 min pretreatment), vehicle/AMPH (10% tween 80, i.p., 
60 min pretreatment/0.732 mg/kg AMPH, s.c., 30 min pretreatment), or 
VU0467154/AMPH (1, 3, or 5.6 mg/kg, i.p., 60 min pretreatment/0.732 mg/kg AMPH, 
s.c., 30 min pretreatment).  In the same cohort of animals, following a significant 
washout period, rats received one of 3 dosing schedules: vehicle/vehicle (10% tween 80, 
i.p., 60 min pretreatment/sterile water, s.c., 30 min pretreatment), vehicle/MK-801 (10% 
tween 80, i.p., 60 min pretreatment/0.1 mg/kg MK-801, s.c., 30 min pretreatment), or 
VU0467154/MK-801 (0.56, 1, 3, or 5.6 mg/kg, i.p., 60 min pretreatment/0.1 mg/kg MK-
801, s.c., 30 min pretreatment).  Vehicle treated animals responded at levels consistent 
with 2 s stimulus presentation on training days, with testing responses at ~70% (Figure 
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38). When the stimulus presentation interval was decreased, however, there was a 
significant decrease in % correct responding and an increase in % omissions.  AMPH 
administration alone resulted in a significant decrease in % correct responding across all 
stimulus presentation times (Figures 38-40).  Pretreatment with VU0467154 was able to 
attenuate the response to AMPH and MK-801 responses at select doses and stimulus 
presentation intervals.  While these data are promising, the lack of consistency across 
dose and presentation interval makes interpreting the data difficult.  Potential problems 
with the study design may include the dose of psychostimulant used to induce disruptions 
in performance, pretreatment times with VU0467154, or the advanced age of the rats (> 1 
year old).  Also worth noting, these rats had a complex drug history including previous 
dosing with a range of psychostimulants, muscarinic agonists and modulators, and 
metabotropic glutamate receptor ligands.  
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Figure 38. Effects of an M4 PAM on amphetamine-induced disruptions in 5CSRT 
task performance at 0.2 s stimulus presentation interval. 
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Figure 39. Effects of an M4 PAM on amphetamine-induced disruptions in 5CSRT 
task performance at 1.0 s stimulus presentation interval. 
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Figure 40. Effects of an M4 PAM on amphetamine-induced disruptions in 5CSRT 
task performance at 2.0 s stimulus presentation interval. 
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Figure 41. Effects of an M4 PAM on MK-801-induced disruptions in 5CSRT task 
performance at 0.2 s stimulus presentation interval.  
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Figure 42. Effects of an M4 PAM on MK-801-induced disruptions in 5CSRT task 
performance at 1.0 s stimulus presentation interval.  
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Figure 43. Effects of an M4 PAM on MK-801-induced disruptions in 5CSRT task 
performance at 2.0 s stimulus presentation interval.  
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APPENDIX B 
EFFECTS OF VU0467154 ON MK-801-INDUCED HYPERLOCOMOTOR 
ACTIVITY WITH ALTERED DOSING SCHEDULE  
Methods 
Locomotor Activity Studies in Rats 
Open field activity was tested using a SmartFrame Open Field System (Kinder 
Scientific, San Diego, CA) with a 16 × 16 array of infrared photobeams located 2.5 cm 
above the floor of the chamber as previously described (Jones et al., 2008). To determine 
the effects of VU0467154 on reversing MK-801-induced hyperlocomotion, rats were 
habituated in the open field for 30 min, followed by administration of vehicle (0.9% 
saline) or MK-801 (0.18 mg/kg, IP). After an additional 30 min, (10% Tween 80 in 
sterile water) or VU0467154 (30 mg/kg, IP) was injected, and locomotor activity was 
recorded for another 120 min. The time course of drug-induced changes in ambulation is 
expressed as mean number of beam breaks per 5 min bin over the 120 min session. Ttime 
course data (means ± SEM) was analyzed by two-way ANOVA and post 
hoc comparisons were made by Dunnett’s test using GraphPad Prism. 
Results 
This study was performed to assess the ability of an M4 PAM to reverse MK801-
induced hyperlocomotor activity when administered following the onset of MK-801 
response.  Traditionally, our group, and others, pretreats rodents with a compound that 
has potential antipsychotic-like activity based on the pharmacokinetics of the compound.  
The blockade of psychostimulant-induced hyperlocomotor response is then calculated 
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based on a vehicle treated control.  In this experiment, rats were administered MK-801 
(0.18 mg/kg) 30 minutes prior to VU0467154, to measure the ability of the compound to 
reverse the locomotor response induced by MK-801. Consistent with previously reports, 
MK-801 induced a robust increase in locomotor activity within 15 mins of administration 
(Figure 44).  However, unlike previously published pretreatment paradigms, VU0467154 
administration following the onset of MK-801 response was not able to significantly 
reduce locomotor activity. This study highlights the necessity to dose a potential 
antipsychotic-like compound in accordance with the known pharmacokinetics properties 
of the compound.  
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Figure 44. Effects of an M4 PAM on MK-801-induced hyperlocomotion when 
administered 30 minutes following Mk-801. MK-801 induced a robust increase in 
locomotor activity within 15 mins of administration.  However, unlike previously 
published pretreatment paradigms, VU0467154 administration following the onset of 
MK-801 response was not able to significantly reduce locomotor activity (ANOVA 
followed by Bonferroni’s post hoc test). 
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APPENDIX C 
 
IN VIVO MICRODIALYSIS IN WT AND NR1 KD MICE 
 
Methods 
 Mice (n = 8-9 per genotype) were anesthetized with isoflurane and placed in a 
stereotaxic frame (Kopf Instruments, Tujunga, CA). A guide cannula (CMA7, 
Harvard Apparatus, USA) was placed above the medial prefrontal cortex (+2.0 AP, ± 
0.7 ML from Bregma and -1.0 DV from dura) and secured to the skull with glass 
ionomer cement (Instech Laboratories). Following a 5-7 day recovery period, 
animals were placed in individual activity chambers and a microdialysis probe 
(CMA7 microdialysis, USA) with an active length of 2 mm was inserted into the 
guide cannula. The probe was then perfused at a rate of 1.0 μL/min with artificial 
cerebral spinal fluid (149 mM NaCl, 2.8 mM KCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 
pH 7.2. After a 2-hour equilibration period dialysate samples were collected every 
ten minutes (10 μL fractions) for a total of 4 hours. Benzoylation Reaction.  
Calibration standard or dialysate samples (5 μL) were added to 2.5 μL of 100 mM 
sodium borate buffer 2.5 μL of benzoyl chloride (2% in acetonitrile ). The mixture 
was vortexed, and 2.5 μL of internal standard was added before LC-MS analysis. 
HPLC-MS Analysis. Dialysate sample components, including glutamate and 
acetylchoine, were separated on a Waters BEH C18 column (1 mm × 100 mm, 1.7 
μm, 13 nm pore size, maintained at  using 27 °C, using.a Waters nanoAcquity HPLC 
system (Milford, MA). Following sample injection (9 μL), analytes were separated at 
a flow rate of 100 μL/min, by gradient elution (mobile phase A: 10 mM ammonium 
188 
 
 
 
formate and 0.15% (v/v) formic acid in water; mobile phase B [acetonitrile]. 
Analytes were then quantitated using a Waters/Micromass Quattro Ultima triple 
quadrupole mass spectrometer (for a more detailed description see (Song et al., 
2012)). Basal levels of extracellular glutamate and acetylcholine were compared 
between genotypes using a student’s t-test. 
Results  
Basal levels of extracellular glutamate and acetylcholine in WT and NR1 KD mice 
 Preliminary in vivo microdialysis analysis of extracellular glutamate and 
acetylcholine levels were measured in mPFC of NR1 KD and WT mice.  NR1 KD mice 
appear to have increased basal glutamate and acetylcholine levels compared to littermate 
controls, though there is a large amount of variability between animals that prevents 
statistical significance at this point.  This is likely due to differences in expression levels 
of the NR1 subunit in the knockdown animals.  This variability has been documented by 
our group, and others, and is most obvious when monitoring behavioral responses, such 
as basal locomotor activity or performance in CF. There is also potential for variability in 
the derivatization of microdialysis samples prior to analysis using HPLC/MS. Finally, the 
use of an antioxidant mixture containing a cholinesterase inhibitor in the collection wells 
would aid in the stability of the sample and allow for a greater degree of consistency 
between samples. 
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Figure 45. Preliminary in vivo microdialysis analysis of extracellular glutamate and 
acetylcholine levels in mPFC of NR1 KD and WT mice.  NR1 KD mice have a trend 
towards increased basal glutamate and acetylcholine levels compared to littermate 
controls. n = 8-9 animals, student’s t-test, n.s.). 
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APPENDIX D 
 
PROGRESSIVE RATIO STUDIES IN WILDTYPE AND M4 KO MICE 
Methods 
To assess the reinforcing strength of the liquid reinforcer between wild-type and M4 KO 
mice, we trained a separate cohort of wild-type and M4 KO mice to respond on a 
progressive ratio schedule. Mice (age 9-12 weeks at training; n=11-12/genotype) were 
maintained at 85% their free-feeding weight and first trained to respond via a nosepoke in 
operant chambers (Med Associates) with 3 nosepoke holes on one wall and a reward 
receptacle on the opposite wall to allow reinforcement delivery from a dipper. Mice were 
initially trained such that a single response in the middle nosepoke hole when a light was 
illuminated would be reinforced via delivery of 0.2 mls of 33% diluted Ensure (fixed 
ratio 1 schedule of reinforcement). The dipper would remain elevated until the mouse 
entered the reward receptacle and for 5 seconds thereafter. Sessions lasted 1 hour or until 
completion of 100 trials. The fixed ratio (FR) was increased to 10 responses over the 
course of subsequent sessions. When mice completed greater than 50 trials under a FR10 
schedule for a minimum of three days, the reinforcement schedule was switched to a 
progressive ratio. The number of responses necessary for reinforcement delivery 
increased following each completed ratio based on the equation described by (Richardson 
& Roberts, 1996) ratio= [5e^injection number x 0.2)]-5. The first 10 ratios in the series 
were 1, 2, 4, 6, 9, 12, 15, 20, 25, 32. Following each completed ratio, the stimulus light 
was extinguished for 5 sec (ITI). Sessions lasted for 2 hours or until a 20-min period 
elapsed during which a ratio was not completed; the last ratio completed was termed the 
break point and served as the dependent measure to assess reinforcing strength between 
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genotypes. Responding was initially maintained by 33% diluted Ensure and then a 
concentration-response curve was determined (water, 10%, 33% 100% Ensure) in 
random order. Each concentration was available for a minimum of 5 days and a 3-day 
stable average was determined such that the number of reinforcers delivered did not 
deviate from the mean by more than 2. If stability was not achieved within 10 sessions, a 
5-day average was calculated. Following each determination, the reinforcer concentration 
was returned to 33% for 2-3 days to ensure that baseline responding was similar prior to a 
new concentration determination. The primary dependent variable was the number of 
ratios completed at each dose.  
Results  
A two-way non-repeated measures ANOVA examined effects of concentration 
and genotype followed by Bonferonni post-hoc comparisons, p<0.05. There was a main 
effect of genotype (F1,84=24.49, p<0.0001) and dose (F3,84=77.84, p<0.0001) and a 
significant interaction (F3,84=3.74, p<0.05) (Figure 46). Number of reinforcers and 
completed ratios increased in a concentration-dependent manner in both genotypes. M4 
KO mice received a higher number of reinforcers than wild-type mice under vehicle 
(water; p<0.01), 10 (p<0.01) and 33 % (p<0.05) Ensure. 
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Figure 46. Assessing relative reinforcing strength of the liquid reinforcer in wild-
type and M4 KO mice under progressive ratio schedule of reinforcement.  
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